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1 Summary 
Microglia are the resident immune cells of the central nervous system (CNS) and play 
an important role in innate immune defense as well as tissue homeostasis. Chronic 
microglial reactivity, microgliosis, is a general hallmark of inflammatory and 
degenerative diseases that affect the CNS, including the retina. There is increasing 
evidence that chronic microgliosis is more than just a bystander effect, but rather 
actively contributes to progression of degeneration through processes such as toxic 
nitric oxide (NO) production and even phagocytosis of stressed but viable 
photoreceptors. Therefore immunmodulation of microglia presents a possible 
therapeutic strategy for retinal degenerations. Notably, the expression of the 
mitochondrial translocator protein 18 (κDa) (TSPO) is highly elevated in reactive 
microglia as seen in several neuroinflammatory diseases such as Alzheimer’s 
disease, Parkinson’s disease and multiple sclerosis. Therefore it is used as a gliosis 
biomarker in the brain. Moreover TSPO ligands show potent effects in resolving 
neuroinflammatory brain disorders. However, TSPO expression in the eye had not 
been investigated before. Further, it was unknown whether TSPO ligands’ potent 
immunomodulatory effects could be used to treat retinal degenerations. 
To fill this gap, the study aimed to analyze whether TSPO is also a potential 
biomarker for degenerative processes in the retina. Moreover the thesis attempted to 
determine whether a specific TSPO ligand, XBD173, might modulate microglial 
reactivity and is a potent therapeutic, to treat retinal degenerative diseases. 
The findings revealed that TSPO is strongly upregulated in microglial cells of 
retinoschisin-deficient (RS1-/y) mice, a model of inherited retinal degeneration and in 
a murine light damage model. A co-localization of TSPO and microglia was 
furthermore detectable in human retinal sections, indicating a potential role for TSPO 
as a biomarker for retinal degenerations. In vitro assays showed that the TSPO 
ligand XBD173 effectively inhibited features of microglial activation such as 
morphological transformation into reactive phagocytes and enhanced expression of 
pro-inflammatory cytokines. XBD173 also reduced microglial migration and 
proliferation and reduced their neurotoxic potential on photoreceptor cells. In two 
independent mouse models of light-induced retinal degeneration, the treatment with 
XBD173 reduced accumulation of amoeboid, reactive microglia in the outer retina 
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and attenuated degenerative processes, indicated by a nearly preserved 
photoreceptor layer.  
A further question addressed in this thesis was whether minocycline, an antibiotic 
with additional anti-inflammatory properties is able to reduce microglial neurotoxicity 
and to protect the retina from degeneration.  
Minocycline administration dampened microglial pro-inflammatory gene expression, 
NO production and neurotoxicity on photoreceptors. Interestingly, in addition to its 
immunomodulatory effect, minocycline also increased the viability of photoreceptors 
in a direct manner. In the light damage model, minocycline administration counter-
acted microglial activation and blocked retinal degeneration. 
Taken together these results identified TSPO as a biomarker for microglial reactivity 
and as therapeutic target in the retina. Targeting TSPO with XBD173 was able to 
reverse microglial reactivity and could prevent degenerative processes in the retina. 
In addition, the study showed that the antibiotic minocycline effectively counter-
regulates microgliosis and light-induced retinal degeneration. Considering that 
microgliosis is a major contributing factor for retinal degenerative disorders, this 
thesis supports the concept of a microglia-directed therapy to treat retinal 
degeneration. 
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2 Zusammenfassung 
Mikrogliazellen sind die Gewebsmakrophagen des zentralen Nervensystems (ZNS). 
Sie spielen eine wichtige Rolle bei der Immunabwehr sowie der Aufrechterhaltung 
der Gewebshomöostase. Chronische Mikrogliaaktivierung, Mikrogliose, gilt als 
generelles Kennzeichen von degenerativen und entzündlichen Erkrankungen des 
ZNS, inklusive der Retina. Eine zunehmende Anzahl von Studien belegt, dass 
persistierende Mikrogliareaktivität nicht nur eine Folgeerscheinung degenerativer 
Erkrankungen, sondern aktiv am Voranschreiten solcher Prozesse beteiligt sein 
kann, beispielsweise durch Produktion reaktiver Sauerstoffspezies oder sogar 
Phagozytose gestresster, aber lebender Photorezeptoren. Mikroglia-gerichtete 
Therapien könnten daher ein Behandlungskonzept für retinale Degenerationen 
darstellen. Bei neurodegenerativen Erkrankungen wie Alzheimer, Parkinson oder 
Multipler Sklerose wurde festgestellt, dass reaktive Mikrogliazellen eine erhöhte 
Expression des mitochondrialen Translokatorproteins (18κDa) (TSPO) aufweisen. 
Deshalb wird TSPO als Gliosemarker im Gehirn verwendet. Spezifische TSPO-
Liganden zeigten außerdem Wirksamkeit bei der Behandlung von 
neuroinflammatorischen Erkrankungen des ZNS. Ob TSPO auch im Auge exprimiert 
wird und ob TSPO-Liganden möglicherweise zur Therapie von retinalen 
Degenerationen geeignet sind, ist bisher noch nicht untersucht worden. 
Neben der Überprüfung, ob TSPO auch als Biomarker für degenerative 
Veränderungen der Netzhaut verwendet werden kann, wurde in dieser Arbeit 
untersucht, inwiefern der spezifische TSPO-Ligand, XBD173, Mikroglia Reaktivität 
modulieren kann und sich zur Therapie von retinalen Degenerationen eignet.  
Sowohl Untersuchungen an Retinoschisin-defizienten Mäusen, einem Modell für 
erbliche Netzhautdegeneration, als auch in einem Licht-Schadensmodell zeigten eine 
Hochregulation von TSPO in Mikrogliazellen. Eine Kolokalisation von TSPO und 
Mikrogliazellen war außerdem in humanen Retinapräparaten erkennbar und 
verdeutlicht die potentielle Eignung als Biomarker für retinale Erkrankungen. In vitro 
Analysen zeigten, dass XBD173 Zeichen von Mikrogliareaktivität wie erhöhte 
Expression inflammatorischer Marker, Migration, Proliferation und die 
morphologische Transition zu reaktiven Phagozyten reduziert sowie das 
neurotoxische Potential von Mikrogliazellen verringert. In zwei unabhängigen 
murinen Modellen für Licht-induzierte Degeneration, reduzierte die Behandlung mit 
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XBD173 die Akkumulation amoeboider, reaktiver Mikrogliazellen in der äußeren 
Netzhaut und schützte die Retina vor degenerativen Prozessen, erkennbar durch 
den Erhalt der Photorezeptorschicht. 
Ein weiteres Ziel dieser Arbeit war zu untersuchen, ob Minocyclin, ein Antibiotikum 
mit zusätzlichen anti-inflammatorischen Eigenschaften, Mikroglia Reaktivität 
modulieren und die Retina vor degenerativen Prozessen schützen kann. 
Stimulation von Mikrogliazellen mit Minocycline verringerte die Expression von 
Entzündungsmarkern, die Produktion von toxischem Stickstoffmonoxid und die 
Neurotoxizität von Mikrogliazellen gegenüber Photorezeptoren. Interessanterweise 
war zusätzlich zu der immunmodulativen Wirkung war auch ein direkter protektiver 
Effekt auf Photorezeptoren festzustellen. Behandlung mit Minocyclin bei Licht-
induzierter Degeneration wirkte pro-inflammatorischer Mikroglia-Aktivierung entgegen 
und schützte die Retina vor Degeneration. 
Die Ergebnisse zeigen, dass sich TSPO als Biomarker für Mikroglia-Reaktivität und 
therapeutisches Target bei retinalen Degenerationen eignet. TSPO gerichtete 
Therapie mit XBD173 reduzierte Mikroglia-Reaktivität und verhinderte degenerative 
Prozesse in der Retina. Zusätzlich zeigt die vorliegende Arbeit, dass das Antibiotikum 
Minocyclin, Mikrogliose entgegenwirkt und die Retina vor Licht-induzierter 
Degeneration schützt. Unter der Annahme, dass chronische Mikrogliose maßgeblich 
den Verlauf von degenerativen Prozessen beeinflussen kann, stellen Mikroglia-
gerichtete Therapieansätze ein erfolgsversprechendes Konzept zur Behandlung von 
retinalen Degenerationen dar. 
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3 Introduction 
3.1 Structure and function of the retina 
The gross morphological structure of the human eye consists of three different layers 
(shown as sagittal section of the adult human eye Fig. 1, A). The external layer 
consists of the sclera and the cornea. The intermediate layer is generally further 
divided into an anterior part, which includes iris and ciliary body and a posterior part, 
the choroid. The retina belonging to the CNS is designated as inner layer. The 
chambers that occur between these layers are the anterior chamber (between iris 
and cornea) and the vitreous humor (between lens and retina). Both are filled with 
differently viscous fluids (Kolb, 2005). 
 
Figure 1: Schematic overview of the mammalian eye and its retinal structure. (A) Cross section of the 
human eye. The retina is located at the posterior part of the eye and is loosely stocked to the retinal pigment 
epithelium (RPE) (B) Cross section of the murine eye. (C) H&E stained murine retinal cross section showing the 
different retinal layers. (D) Schematic overview of the different retinal layers, including respective cell types. (GCL) 
ganglion cell layer, (IPL) inner plexiform layer, (INL) inner nuclear layer, (OPL) outer plexiform layer, (ONL) outer 
nuclear layer, (IS) inner segments, (OS) outer segments (A-C) modified from (Veleri et al., 2015) D modified from 
(Kimbrel and Lanza, 2015) 
During embryogenesis, the retina derives from the neural tube (Lamb et al., 2007). 
As sensory part of the eye, the retina absorbs light and converts it into electrical 
signals that are transferred to the brain and are decoded to gain visual information. 
The retina consists of different neuronal cell types that roughly divide the retina into 
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three cellular layers, the ganglion cell layer (GCL), the inner nuclear layer (INL) and 
the outer nuclear layer (ONL) which are separated from each other by two synaptic 
layers, the inner plexiform layer (IPL) and the outer plexiform layer (OPL)) (Fig. 1 C, 
D). The retinal pigment epithelium (RPE) lies juxtaposed to the apical side of the 
photoreceptors and is essential to support the retina (Sung and Chuang, 2010). 
Beside the absorption of light the RPE phagocytoses sheded membrane discs of the 
photoreceptors that are damaged due to photo-oxidative stress. This is a daily 
occurring process that leads to a complete membrane disc renewal in about 10-15 
days. Furthermore the RPE is co-responsible for the recycling of rhodopsin after 
bleaching, a process called visual cycle and supports the retina with nutrients (Travis 
et al., 2007). Additionally the RPE is part of the blood-retina barrier (BRB) and 
controls the transport of molecules between choroidal blood flow and retina 
(Campbell and Humphries, 2012, Strauss, 2005, Young, 1967).  
After passing the different retinal layers light is absorbed by the photoreceptors that 
are located at the outer side of the retina. In the human retina, photoreceptors can be 
divided into two subtypes: rods (~120 million cells), which are responsible for dim 
light vision and cones (~6 million cells), which mediate color vision under brighter 
light conditions (Bommas-Ebert et al., 2006). Dependent of its spectral sensitivity 
three cone types with different opsins can be distinguished in primates: L- (long, 
564nm), M- (medium, 533 nm) and S- (short, 437nm) wavelength cones (Bowmaker 
and Dartnall, 1980). In the human retina, a certain spot called fovea (~1,5 mm2) 
consists only of cones and has the highest visual acuity. The area (~3 mm2) around 
the fovea, recognizable by its yellow screening pigments (zeaxanthin and lutein), is 
named macula. (Veleri et al., 2015, Morrow et al., 1998, Balashov and Bernstein, 
1998). The absorption of a photon by the chromophore 11-cis retinal within the 
photoreceptors, leads to isomerization to all-trans retinal and initiates the process of 
phototransduction, which is a cascade of biochemical events resulting in closure of 
ion channels, photoreceptor hyperpolarization and signal transmission to second 
order neurons, such as bipolar, horizontal and amacrine cells that form the inner 
nuclear layer (INL) (Travis et al., 2007, Sung and Chuang, 2010, Yau and Hardie, 
2009). Neurons of the INL are interconnected to each other, which allows reciprocal 
excitation or inhibition and serves as contrast intensification (Bommas-Ebert et al., 
2006). After processing of the signal by the different cell types of the INL, the signal is 
forwarded to the ganglion cells, whose axons form the optic nerve and transmit the 
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converted light signals to the brain (Sung and Chuang, 2010). Furthermore three glial 
cell types are found in the retina: Müller cells, microglia and astrocytes (Bringmann et 
al., 2006). Microglia are the immune cells of the eye which are under homeostatic 
conditions located in the plexiform layers (Kettenmann et al., 2011). Müller cells span 
the entire retina and are important for the maintenance of retinal homeostasis 
(Bringmann et al., 2006).  
Although the murine eye is structurally very similar to the human eye, some 
differences remain: the lens of the mouse eye is much bigger in proportion to the rest 
of the eye (Fig. 1, B) (Veleri et al., 2015). Furthermore mice, as nocturnal animals, 
rely predominantly on rod-mediated vision and in contrast to humans possess only 
two different types of cones, M- and S-cones (dichromatic vision) and no macula or 
fovea (Morrow et al., 1998).  
 
3.2 Inherited retinal degenerative diseases  
Loss of visual function means a severe loss of life quality for the affected individuals. 
Major causes for blindness are neurodegenerative retinal diseases that lead to 
dysfunction or death of photoreceptors (Veleri et al., 2015). In general, retinal 
degenerations can be divided into monogenic or multifactorial (complex) disorders 
(Berger et al., 2010). A relatively common form of monogenic retinal degeneration 
affecting 1 in 4000 individuals, is retinitis pigmentosa (RP) (Ferrari et al., 2011). 
Within the group of multifactorial retinopathies, age-related macular degeneration 
(AMD) is the leading cause of blindness in elderly populations in developed countries 
(The Eye Diseases Prevalence Research Group, 2004) (Coleman et al., 2008). 
Genetic susceptibility factors such as variants in complement factor H (CFH) and 
age-related maculopathy susceptibility 2 (ARMS2) genes, risk factors such as 
smoking, diet and higher age are associated with the development of this late-onset 
disease (Swaroop et al., 2009, Cooke Bailey et al., 2013, Jager et al., 2008). 
Improvement of molecular techniques such as next generation sequencing and large 
scale genotyping allowed the identification of many disease-causing genes. 
Nowadays more than 250 causal genes are known for this heterogeneous group of 
retinal diseases (RetNet:https://sph.uth.edu/retnet/). Despite this knowledge, there is 
a need to develop novel therapeutic strategies for retinal degenerations.  
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Because of limitations to study disease mechanisms in patients, mouse models 
provide a valuable tool to analyze disease pathology and to validate novel 
therapeutic strategies (Veleri et al., 2015). Despite the fact that the mouse eye is not 
completely identical to the human eye, mouse models allow to study important 
features of retinal degeneration such as immune activation or photoreceptor 
apoptosis. Several genetic as well as experimental models are available including 
those that mimick the damaging features of bright light. These models vary basically 
in the onset and severity of degeneration and discriminate underlying causes such as 
defects in cilia or RPE function, phototransduction and synaptic transmission (Veleri 
et al., 2015, Wenzel et al., 2005, Morrow et al., 1998). A common feature of retinal 
degenerative diseases, which is also detectable in most mouse models, is microglial 
activation. There is now ample evidence that chronic microglial activation is more 
than a bystander effect of such pathologies, but rather actively contributes to 
progression of retinal degeneration (Karlstetter et al., 2015, Chen and Xu, 2015, 
Gupta et al., 2003). For instance, it was reported that reactive microglial cells are 
able to produce cytotoxic oxygen radicals such as NO and may even phagocytose 
stressed, but viable photoreceptors (Zhao et al., 2015, Yang et al., 2007a). For the 
therapeutic intervention studies in this thesis, we have chosen the acute white light-
induced degeneration paradigm, which models both disease characteristics, the fast 
degeneration of photoreceptors and activation of microglial cells (Zhang et al., 2004) 
(Joly et al., 2009, Ng and Streilein, 2001).  
 
3.2.1 Light damage as retinal degeneration model  
Light-induced retinal degeneration represents an inducible model to study 
mechanisms of neuronal cell death and to test immune-directed treatment strategies 
simultaneously. Besides that, light is also a promoting factor in human retinal 
degenerations and is therefore not just an artificial stimulus (Cruickshanks et al., 
1993, Swaroop et al., 2009, Wenzel et al., 2005). The advantage over genetically 
modified mouse strains is that the start of degeneration can be well defined. It has a 
relatively synchronized wave of cell death and progresses relatively fast. These 
features allow to better analyze biochemical processes leading to photoreceptor 
degeneration and proper timing of intervention approaches (Grimm and Reme, 
2013). Different light exposure settings can be distinguished: short-term exposure to 
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bright white light, long-term exposure to low levels of white light and exposure to 
monochromatic light of a specific wavelength (Grimm and Reme, 2013). The 
damaging potential of light critically depends on its wavelength. Short wavelength 
blue light has a higher damaging potential than long-wavelength green light. This is 
due to a process called photo-reversal, the regeneration of rhodopsin from bleaching 
intermediates that results in a higher absorption of photons in a certain time span 
(Grimm et al., 2001). In addition, there are also indications that the different light-
damage setups vary in mechanisms of cell death, and caspases involved in cell 
death induction are differentially expressed (Wenzel et al., 2005). Responsible for the 
induction of light-induced degeneration is the excessive and ongoing bleaching of 
rhodopsin. This leads to the production and accumulation of retinoid metabolites and 
other toxic byproducts that initiate a cascade of death signals, subsequently resulting 
in photoreceptor cell death (Wenzel et al., 2005). Crucial for this process is a 
functional visual cycle as RPE 65 deficiency, an enzyme involved in the rhodopsin 
recycling process, protects from light-induced degeneration (Grimm et al., 2000). 
Furthermore, the RPE65 Leu450Met variation, in which leucine is substituted by 
methionine, slows down the visual cycle and thereby decreases the light damage 
susceptibility (Wenzel et al., 2001b). Other factors that can influence light damage 
susceptibility are increased levels of corticosteroids, which suppress AP-1-induced 
cell death and circadian dependent effects (Wenzel et al., 2001a, Organisciak et al., 
2000).  
 
3.3 Microglia 
3.3.1 Microglial reactivity markers  
Microglia cells represent the resident immune cells of the CNS, including the retina 
(Kettenmann et al., 2011). They were first described by the Spanish histopathologist 
Pio Del Rio Hortega back in the 1920s. The invention of the silver carbonate staining 
procedures enabled Hortega, to identify and distinguish microglia from neurons, 
astrocytes and oligodendendroglia by morphological criteria (Rio-Hortega, 1939, 
Perez-Cerda et al., 2015). Nowadays, several macrophage-related surface and 
intracellular markers are known and used to study the role of microglia in health and 
disease. These markers include F4/80 (ȕ-glucan receptor dectin-1), CD68 
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(macrosialin), CD11b/CD18 (also called complement factor 3 (CR3), Mac1) and 
ionized calcium-binding adapter molecule 1 (iba1), which is currently the most 
reliable and widely used marker in humans and mice (Hume et al., 1983, Xu et al., 
2007, Ito et al., 1998, Karlstetter et al., 2015). Other known markers are CD16, 
CD169 (siglec-1), CD 206 and MHC II. A few of these markers were shown to 
increase with microglial reactivity. This was observed for iba1 and CD11b. As 
microglial reactivity is often associated with neurodegeneration, the identification of 
activity markers is important as it complements the known morphological criteria of 
ramified versus amoeboid cell shape. Unfortunately, none of the introduced markers 
is exclusively expressed on microglia so that resident microglia can be hardly 
separated from CNS-recruited monocytes (Kettenmann et al., 2011). Another method 
to specifically label microglia is the use of genetically modified animals that express 
enhanced green fluorescent protein (EGFP) under the control of a 
microglia/macrophage specific gene promoter factor such as CX3CR1 (fraktalkine 
receptor) (Xu et al., 2007, Kezic and McMenamin, 2008).  
 
3.3.2 Origin and self-renewal of microglia cells 
The origin and renewal of microglial cells has been discussed controversially over the 
last twenty years. Adoptive transfer experiments with bone marrow (BM) cells from 
EGFP+ transgenic donors transferred into full body-irradiated adult wild-type mice, 
initially indicated that microglial cells originate and renew from BM precursors, 
because EGFP+ BM cells were detectable in the retina of wildtype recipients a few 
weeks after transfer (Xu et al., 2007, Kezic and McMenamin, 2008). But criticism was 
raised that whole body irradiation and the transfusion of BM do not reflect normal 
physiological conditions, because they may lead to the breakdown of the blood-brain-
barrier (BBB) and the blood-retina-barrier (BRB) and bring progenitors into the 
circulation which would normally rest in the BM (Li et al., 2004, Ajami et al., 2007). In 
contrast to adoptive transfer studies, parabiosis experiments, in which the blood-flow 
of wildtype and GFP+ transgenic mice were connected, showed that cells from the 
circulation are not recruited to the retina, neither in healthy nor in disease conditions 
(Ajami et al., 2007). This and other findings strongly suggest that microglial cells are 
not recruited from the circulation under physiological conditions and that observed 
microglial replacement in older studies was very likely caused by the experimental 
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procedure of irradiation and bone marrow transplantation (Mildner et al., 2007, 
Ransohoff, 2007, Kierdorf et al., 2013b, Alliot et al., 1999). Furthermore, different fate 
mapping approaches independently reveal that microglia cells are ontogenetically 
distinguishable from hematopoietic cells and derive from the yolk-sac during early 
embryonic development (Ginhoux et al., 2010, Schulz et al., 2012, Kierdorf et al., 
2013a).  
 
3.3.3 Microglial function in the developing and adult retina 
During retinal development, before the complex structure of the retina is fully 
differentiated, a burst of developmental apoptosis can be observed in neurons 
located in the GCL and in the IPL (Hume et al., 1983). The phenomenon of 
developmental apoptosis is detectable in the entire CNS and different studies proof 
that microglia cells actively contribute to that process (Bessis et al., 2007). Microglia 
cells seem to orchestrate apoptosis by the production of several molecules, like 
tumor necrosis factor-� (TNF-�), nerve growth factor (NGF) and nitric oxide (NO). 
However, they are also important for phagocytosis of occurring cellular debris (Sedel 
et al., 2004, Frade and Barde, 1998, Chao et al., 1992, Hume et al., 1983). Although 
the underlying reasons of developmental apoptosis are not completely understood, 
the chronology showing developmental apoptosis preceding synaptogenesis, 
indicates a possible correlation between both processes (Bessis et al., 2007). This is 
further sustained by studies that propose microglia cell involvement in 
synaptogenesis. The deletion of the microglial specific protein KARAP/DAP 12 as 
well as the blockage of complement receptor 3 CR3/C3 signaling negatively 
influenced synaptic function and the process of synaptic pruning and also reduced 
the connectivity between neurons (Roumier et al., 2004, Schafer et al., 2012). These 
studies implicate that microglia can control neuronal function by orchestrating 
synaptogenesis and apoptosis, starting early during retinal development. 
In the healthy adult retina microglia cells are mainly located in the plexiform layers, 
where they build up a not overlapping meshwork that spans the entire retina (Lee et 
al., 2008). Under physiological conditions microglia have a ramified morphology with 
a small somata and wide ranging, fine processes (Figure 2, A). Normal microglial 
appearance is often denoted as “resting state”, but their processes are highly motile 
and permanently scan their microenvironment to clear it from metabolic products or 
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tissue debris and to detect pathological changes. They also directly contact other 
cells such as astrocytes, neurons and blood vessels. Furthermore, microglial 
protrusions undergo a permanent reconstruction process. The permanent monitoring 
and the expression of several surface receptors, such as purino-and fractalkine 
receptors, receptors for complement factors, immunoglobulins, adhesion molecules 
and chemokines enable microglia to sense and react quickly to potential danger 
signals (Nimmerjahn et al., 2005, Karlstetter et al., 2015, Langmann, 2007, 
Kettenmann et al., 2011). Such activation goes along with an extensive change in 
morphology, gene expression and function (Figure 2, B) (Kettenmann et al., 2011). 
 
 
Figure 2: Microglial retinal location and appearance during health and disease. (A) In the healthy retina Iba1 
positive ramified microglial cells are located in the plexiform layers. (B) After exposure to bright white light 
microglial cells migrate to the degenerating outer retina and the amoeboid shape points towards a much more 
activated state. (ONL) outer nuclear layer, (OPL) outer plexiform layer, (INL) inner nuclear layer, (IPL) inner 
plexiform layer, (GCL) ganglion cell layer. 
 
In general reactive microglia cells have a more amoeboid shape, with less branches 
and thicker processes. But there are many different intermediate forms described, 
ranging from highly ramified to more or less round cells completely lacking processes 
(Figure 3) (Karperien et al., 2013). In addition to these morphological changes, 
microglia cells can become motile and migrate into damaged areas following 
chemotactic signals from neurons, astrocytes and endothelial cells. 
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Figure 3: Microglial morphological plasticity. Under homeostatic conditions microglial cells have a small cell 
body and scan their environment with their long-branched protrusions. Microglia are able to sense subtle 
degenerative changes and respond quickly. Activation of microglial goes a long with a morphological 
transformation from a ramified to a much more amoeboid shape. Drawings modified from Karperien et al. 2013. 
 
The phenotypical changes are accompanied by several functional changes. 
Enhanced phagocytic activity is observed, release of several neurotropic factors, 
chemokines or molecules like NO, upregulation of intracellular cytokines, expression 
of several surface markers, which are important for cell-cell interaction and enhanced 
proliferation (Hanisch and Kettenmann, 2007, Kettenmann et al., 2011).  
Microglial cells are located in a highly specialized tissue, where immune reactions 
including chronic activation and recruitment of other immune cells such as T-cells 
would have detrimental effects. So there are many control mechanisms available to 
surveil microglial reactivity. These mechanisms constitute to the immune privilege of 
the eye and the CNS to prevent overwhelming and damaging immune reactions 
(Carson et al., 2006, Zhou and Caspi, 2010). Several retinal cell types are essentially 
involved in the control of microglial reactivity either by direct interaction or by the 
production of different soluble factors. For instance, healthy neurons express CD200 
(OX2), a membrane glycoprotein that represents an inhibitory signal for microglia. 
CD200 deficiency or the missing interaction of CD200 and its receptor leads to an 
activation of microglial cells and promotes the susceptibility to autoimmune and 
degenerative pathologies of the CNS in animal models (Hoek et al., 2000, Wang et 
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al., 2007, Chitnis et al., 2007, Dick, 2003). Fractalkine (CX3CL1) is a further 
regulatory molecule produced by neurons and endothelial cells. In the CNS only 
microglia cells express the respective receptor for fractalkine and its deficiency can 
increase microglial neurotoxicity in models for Parkinson’s disease, amyotrophic 
lateral sclerosis (ALS) and Alzheimer’s disease (Cardona et al., 2006, Cook et al., 
2001, Fuhrmann et al., 2010). In addition to these regulatory molecules, healthy 
neurons have a sugar-coated exterior surface, designated as glycocalyx which is 
covered with sialic acids caps. Sialic acids can be recognized by microglial siglec 
receptors. This interaction signals the healthy state of neurons and suppresses 
microglial activation (Karlstetter and Langmann, 2014, Linnartz and Neumann, 2013). 
The retinal pigment epithelium (RPE) is also involved in modulation of microglial 
reactivity. The RPE is source of several cytokines in the eye including transforming 
growth factor-ȕ (TGF-ȕ) (Tanihara et al., 1993). Microarray analysis of murine 
primary microglia pre-stimulated with INF-Ȗ and TNF-α and then with TGF-ȕ 
revealed, that TGF-ȕ can downregulate the expression of pro-inflammatory genes 
involved in chemotaxis, migration, apoptosis and host response to infection 
(Paglinawan et al., 2003). Thus, microglial reactivity is a complex process that is fine-
tuned by the quality of the activating stimulus and the interaction with other retinal 
cells. 
 
3.3.4 Microglia in the aging retina 
In the entire CNS, including the retina, aging-related changes in microglial cells can 
be observed in healthy conditions and in responses to injury. Comparative studies 
between young and aged healthy mice revealed that microglia undergo phenotypic 
changes with increasing age. Resting microglia from aged mice compared to young 
ones appear smaller and stretched out fewer branched protrusions that were less 
motile (Damani et al., 2011). Furthermore the number and density of microglial cells 
increase with age. Of note is that the mosaic like arrangement of microglia in the 
retina became more irregular and the territory monitored by a single cells is smaller 
(Tremblay et al., 2012). Microglia cells which are in the young and healthy retina 
confied to the plexiform layers are also detected in the outer part in aged retinas 
(Wong, 2013, Ma et al., 2009).  
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The phenotypic changes occur along with altered microglial functions. Markers such 
as MHCII and pro-inflammatory cytokines like IL-6, TNFα- and IL-1ȕ are upregulated 
with age, whereas cytokines associated with attenuation of microglial cells such as 
IL-4, IL-10 and TGF-ȕ are generally downregulated. A further aging effect is that 
receptor interactions involved in suppression of microglial reactivity, such as CD200-
CD200r and CX3CL1-CX3CR1 interactions, are significantly weaker with age (Matt 
and Johnson, 2016). These age-related changes promote inadequate microglial 
behavior also in response to injuries. Investigations in a laser -induced retinal injury 
model revealed that process motility as well as migration capacity was slowed down 
in aged microglia. Although the capability to respond to pathological stimuli was 
reduced, once activated the cells failed to transform back into a “resting” state 
(Damani et al., 2011). Since aging is a risk factor and microglia can contribute to 
degenerative diseases of the CNS, age-dependent microglial alterations like 
reduction of neuroprotective function, increase of neurotoxicity and inadequate 
responses to injury, are possible drivers for pathological processes (Flanary et al., 
2007). 
 
3.3.5 Microglia reactivity in retinal degenerative diseases 
Several studies revealed an association between enhanced microglial reactivity and 
neurodegeneration. It is still discussed whether microglial reactivity is just the 
consequence of pathological alterations or if microglia cells are actively involved in 
the progression of degenerative diseases (Figure 4) (Karlstetter et al., 2015, Masuda 
and Prinz, 2016, Zhao et al., 2015, Giulian, 1999). An increasing number of studies 
indicate that microglial activation is an early event and precedes or accompanies 
degeneration of photoreceptors in various retinal degeneration models (Zhang et al., 
2004, Zeiss and Johnson, 2004, Gehrig et al., 2007, Ebert et al., 2009, Zhao et al., 
2015). For instance, an association between microglial proliferation and ongoing 
degenerative processes was detectable in the Pde6brd1 mice, an inherited model of 
retinal degeneration (Zeiss and Johnson, 2004). Also in the RS1h knockout mouse 
that shows several features of X-linked juvenile retinoschisis (XLRS), microarray 
analysis revealed an upregulation of microglial-related genes starting at postnatal 
day p11, before any occurrence of photoreceptor apoptosis (Gehrig et al., 2007, 
Ebert et al., 2009). 
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Figure 4: Schematic representation of microglial action during retinal degenerations. (A) Under 
homeostatic conditions ramified microglia mainly populate the plexiform layers and keep up tissue maintenance 
by phagocytoses of cell debris, secretion of neurotrophic factors and scan their environment in regard of 
pathological alterations. (B) Several factors signaling damage or abnormal function are sensed by microglia and 
lead to their activation. (C) Microglia and in case of breakdown of the blood-retina barrier, recruited blood-derived 
precursors migrate to the lesion sites, where they transform into amoeboid reactive phagocytes. These effector 
cells may be protective or detrimental depending on their immunological phenotype and the local cytokine milieu. 
RPE, retinal pigment epithelium; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; 
IPL, inner plexiform layer; GCL, ganglion cell layer (modified from (Karlstetter et al., 2010a) 
 
Furthermore analysis of human retinal sections from patients with AMD, late-onset 
retinal degeneration (L-ORD) or retinitis pigmentosa (RP) revealed an accumulation 
of amoeboid shaped microglia in regions of ongoing photoreceptor death. Of note is 
that these microglia cells contained rhodopsin-positive cytoplasmatic inclusions, 
indicating that they phagocytosed photoreceptor cell debris and are possibly also 
involved in cell death of adjacent cells by production of neurotoxic factors (Gupta et 
al., 2003). Despite the fact that microglia cells basically exert several functions to 
keep-up tissue homeostasis and support neurons e.g. by production of different 
neurotrophic factors, many different studies revealed that microglia cells that lose 
their autoregulatory capacity can actively participate in the initiation and perturbation 
of retinal degenerative diseases. (Harada et al., 2002, Karlstetter et al., 2015). In line 
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with this, in vitro studies that compared the neurotoxic potential of activated versus 
non-activated supernatant of microglia and Müller cells, revealed that activated 
microglia cells induce much more photoreceptor cell death than conditioned medium 
from non-activated microglia or Müller cells. These findings suggest that soluble 
factors produced by reactive microglia such as NO, pro-inflammatory cytokines, 
complement factors or proteinases may contribute to induction of cell death during 
degenerative processes (Roque et al., 1999).  
Which factors are involved in microglial activation is an open field of research. It was 
reported that stimulation with Toll-like receptor (TLR) ligands disturb the ability of 
microglial cells to distinguish between dead and alive, resulting in phagocytosis of 
viable neurons (Brown and Neher, 2014). The phagocytosis of stressed, but still 
viable neurons is designated as “phagoptosis” or primary phagocytosis. Phagoptosis 
generally mediates turnover of different cells like neutrophils or erythrocytes and is 
one form of cell death; however experiments in models of brain inflammation indicate 
that this process also contributes to neuron loss during degeneration. An important 
factor for phagoptosis induction seems to be the expression of ‘eat me’ signals, like 
the reversible expression of phosphatidylserine (PS) or the loss of ‘don’t eat me’ 
signals, as blocking of phagocytic signaling in microglia prevents neuron loss without 
inhibiting inflammation (Brown and Neher, 2012). In line with that, Zhao et al. showed 
that microglial phagocytosis of living photoreceptors is also involved in cell death in 
the CX3CR1 GFP/+/rd10 retinal degeneration model that mimics features of retinitis 
pigmentosa. Depletion of microglial cells as well as blockage of microglial 
phagocytosis in the same model attenuated photoreceptor degeneration, suggesting 
reactive microglia as key players of cell death during degeneration (Zhao et al., 
2015).  
 
3.4 Modulation of microglial cells as a therapeutic strategy 
The observation that microglia cells can be actively involved in retinal degeneration 
brings them into focus as a potential therapeutic target. Although causative genetic 
defects and contributing factors can vary tremendously, different pathologies share 
the common feature of innate immune activation. Microglial reactivity and 
inflammation is a general hallmark of neurodegenerative diseases. Therefore, 
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modulation of microglial cells could be a good therapeutic strategy to diminish 
degenerative processes in different diseases. Several compounds including natural 
occurring substances, synthetic pharmaceuticals as well as endogenous factors are 
investigated with regard to their immune modulatory competence.  
 
3.4.1 Endogenous factors: AMWAP, micro RNAs and Interferon-β 
After activation, microglia must be able to return back into a normal ramified scanning 
state. As loss of auto-regulatory function can have detrimental effects, microglia 
possess endogenous control mechanisms. Activated microglia/macrophe whey acidic 
protein (AMWAP) is produced by microglial cells and acts in a paracrine fashion. 
Overexpression of AMWAP as well as treatment of microglia cells with recombinant 
AMWAP reduced reactivity and limited their neurotoxic potential. Thus, AMWAP is an 
efficient endogenous counter-regulator of pro-inflammatory activity and a possibly 
therapeutic modulator of microglial reactivity (Karlstetter et al., 2010b, Aslanidis et al., 
2015).  
Further endogenous molecules that are able to modulate microglial cells are 
MicoRNAs (miRNAs). miRNAs are small non-coding RNA molecules that are 
involved in the regulation of diverse physiological processes including functions of 
the immune system. Different miRNAs were identified to control microglial reactivity, 
proposing epigenetic regulation by miRNAs as a potential therapeutic application 
(Cardoso et al., 2016). For example, overexpression of the microglial specific miR-
124 in a model of experimental autoimmune encephalomyelitis (EAE) promoted the 
formation of a resting microglial phenotype, suppressed microglial activation and 
clearly ameliorated disease symptoms (Ponomarev et al., 2011).  
Interferon-ȕ (IFN-ȕ) is a body own cytokine, but is also therapeutically used for the 
treatment of multiple sclerosis (MS) (Waubant et al., 2003, Kasper and Reder, 2014, 
Teige et al., 2003). Data from our research group recently revealed an important role 
for INF-ȕ in a laser-induced mouse model of choroidal neovascularization (CNV), 
which mimics several features of age-related macular degeneration (AMD). Complete 
absence of IFNAR or specific deletion in microglia enhanced lesion size and 
microglial reactivity, whereas treatment with INF- ȕ reduced CNV and microgliosis 
(Lückoff et al., 2016). 
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3.4.2 Natural compounds: Luteolin, Curcumin, Crocin and DHA 
Different naturally occurring substances can modulate microglial reactivity and 
reduce their neurotoxic potential. Luteolin is a plant derived flavone that displays anti-
oxidative and anti-inflammatory capacity in micromolar concentrations (Seelinger et 
al., 2008). In vitro studies with LPS-pre-activated BV-2 microglial cells revealed that 
Luteolin can reduce pro-inflammatory and pro-apoptotic gene expression as well as 
production of NO; whereas markers associated with enhanced phagocytosis, 
ramification, chemotaxis and anti-oxidative pathways were clearly upregulated, 
resulting in less neurotoxicity on photoreceptor cells (Dirscherl et al., 2010).  
Similar findings were reported for Curcumin, a spice often found in curry powder 
(Oyagbemi et al., 2009). Transcriptome analysis of resting and activated microglia 
showed that treatment with curcumin potently downregulates transcripts that are 
associated with microglial activation. Furthermore, supernatant from curcumin 
challenged microglia were less toxic to photoreceptors cells compared to controls 
(Karlstetter et al., 2011).  
A further plant-derived compound with microglial modulative capacity is crocin, a 
carotenoid that can be found in stigmas of safran or fruits of gardenia. Crocin was 
shown to reduce LPS, interferon-Ȗ and amyloid-ȕ induced microglial NO production 
and cell death ex vivo in hippocampal slice cultures as well as in vivo in light induced 
retinal degeneration and even improved retinal function measured by 
electroretinograms (ERG)(Nam et al., 2010, Yamauchi et al., 2011).  
Another naturally occurring substance that also influences microglial reactivity is 
docosahexaenoic acid (DHA), which can be found in fish oil and some seeds. DHA is 
derived from an essential polyunsaturated fatty acid (PUFA) that must be obtained 
from dietary sources. DHA is an important structural fatty acid in brain and retina and 
is responsible for its integrity and functionality (Singh, 2005). Levels of DHA were 
shown to decrease during different forms of retinal degeneration, including 
retinoschisin deficient mice, a model of inherited retinal degeneration (Schaefer et al., 
1995, Ebert et al., 2009). Dietary intervention with DHA alone or combined with 
curcumin reduced microgliosis and enhanced photoreceptor survival in retinoschisin 
deficient mice as well as in a model of neuronal lipofuscinosis (NCL) (Ebert et al., 
2009, Mirza et al., 2013). 
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3.4.3 Minocycline  
Minocycline is a semisynthetic tetracycline which is in use against a wide range of 
infectious diseases caused by gram-positive and gram-negative bacteria for at least 
30 years. The ability to bind bacterial 30s ribosomal subunit results in blockage of 
protein synthesis and is mainly responsible for minocycline’s anti-biotic effect. Beside 
the bacteriostatic action minocycline exerts several other biological activities, 
including anti-inflammatory and anti-apoptotic effects, neuroprotective capacity as 
well as inhibition of proteolysis, angiogenesis and tumor metastasis. In various 
disease models reaching from inflammatory diseases (dermatitis, atherosclerosis), 
autoimmune disorders (inflammatory bowel disease, rheumathoid arthritis) and 
neurodegenerative disorders (Parkinson’s disease, Alzheimer’s disease, Multiple 
sclerosis, amyotrophic lateral sclerosis, spinal cord injury, Huntington’s disease and 
Ischemic injury) beneficial effects were observed. Accountable for the broad 
application possibilities is at least partially the rapid absorption, long half-life, good 
bioavailability and lipophilic properties that allow overcoming of the blood-brain 
barrier (Garrido-Mesa et al., 2013, Du et al., 2001, Wu et al., 2002b, Biscaro et al., 
2012, Brundula et al., 2002, Nikodemova et al., 2010, Wang et al., 2003, Wu et al., 
2002a).  
In the eye several studies reported minocycline to act immune modulatory and 
neuroprotective. Glaucoma is a disease caused by degeneration of retinal ganglion 
cell axons. In DBA/2J mice, a chronic glaucoma model, microglial activation and 
migration into the optic nerve head are thought to be involved in disease progression. 
Treatment with minocycline was able to calm down microglial reactivity and to 
improve axonal integrity and transport. However, minocycline failed to reduce Müller 
cell and astrocyte gliosis as well as high intraocular pressure (IOP) (Bosco et al., 
2008). Furthermore, administration of minocycline successfully preserved outer 
retinal structure and improved retinal function in a model of green light-induced 
degeneration that mimics features of dry AMD. Of note is that protection was 
accompanied by a reduced number of CD11b+ cells in the outer retina (Zhang et al., 
2004). Additionally, different studies independently revealed that minocycline was 
able to reduce microgliosis and preserved retinal structure and function in different 
models for retinitis pigmentosa. For instance, Yang et al reported that minocycline 
treatment reduced iNOS expression in the retina and the authors suggested that 
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minocycline’s neuroprotective effect could be at least partially mediated by blockage 
of microglial NO production (Yang et al., 2007a). Peng et al identified microglial 
activation to be an early event in the rd 10 model of RP and suggests minocycline to 
act neuroprotective through an anti-inflammatory and anti-apoptotic mechanism. 
Interestingly they also observed that microglia, dysregulated by Cx3cr1 deficiency, 
results in enhanced degeneration in rd 10 mice, suggesting microglial cells to be 
critically involved in disease progression (Peng et al., 2014). In contrast, others also 
proposed a microglia independent mechanism (Hughes et al., 2004). Of not is also 
minocycline’s beneficial effect in the treatment of diabetic retinopathy. Diabetic 
retinopathy is characterized by intra-retinal vascular leakage and neuronal 
degeneration and there is increasing evidence that inflammatory processes including 
activation of microglial cells are involved. In a streptozotocin (STZ) induced model of 
diabetic retinopathy minocycline administration successfully suppressed the 
production of cytotoxins produced by reactive microglial cells and reduced neuronal 
apoptosis (Krady et al., 2005). In line with that, minocycline has already been tested 
in a phase I/II clinical trial for the treatment of diabetic macular edema (DME). In 
patients treatment with minocycline improved visual function and decreased vascular 
leakage, although retinal thickness was reported to decrease (Cukras et al., 2012) 
It is still not fully clear which mechanisms are mainly responsible for the observed 
immune modulatory and neuroprotective capacity of minocycline. Proposed 
mechanisms include the modulation of microglial reactivity (Wang et al., 2005, Henry 
et al., 2008, Zhang et al., 2004), mitochondrial stabilization, interference with caspase 
dependent and independent cell death pathways (Chen et al., 2000, Wang et al., 
2003, Wang et al., 2004), inhibition of p38 MAPKinase phosphorylation (Matsui et al., 
2010, Hua et al., 2005), blockage of matrix metalloproteases (MMP) activity 
(Brundula et al., 2002, Park et al., 2011, Koistinaho et al., 2005, Xiao et al., 2012) 
and anti-oxidative as well as direct radical scavenging activity (Kraus et al., 2005) 
 (Plane et al., 2010).   
 
3.4.4 Translocator protein (18κDa) (TSPO) and its ligands 
Translocator protein (18κDa) (TSPO) until 2006 also known as peripheral-type 
benzodiazepine receptor (PBR) is a transmembrane protein in the outer 
mitochondrial membrane (Papadopoulos et al., 2006, Anholt et al., 1986). TSPO is 
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an evolutionary well conserved gene and its expression is detectable in different 
organs like kidney, heart, testis, ovary and brain but highest expression levels were 
found in steroid-synthesizing tissue such as adrenal glands (Gavish et al., 1999). 
Within the brain TSPO is expressed in reactive astrocytes (Kuhlmann and Guilarte, 
2000, Maeda et al., 2007) and in microglial cells (Casellas et al., 2002, Gavish et al., 
1999, Park et al., 1996). In addition, detection has also been reported for some 
neuronal cell types for example in neurons of the olfactory bulb (Anholt et al., 1984), 
in neuro- and glioblastoma cell lines (Decaudin et al., 2002), rat dorsal root sensory 
neurons (Karchewski et al., 2004) and in cultures of rat cortical astrocytes 
(Jayakumar et al., 2002). 
Both older hydropathy profile analysis (Joseph-Liauzun et al., 1998) as well as 
recently published nuclear-magnetic resonance (NMR) analysis (Jaremko et al., 
2014) show that TSPO has a five transmembrane α-helix structure (Figure 5, A). 
 
Figure 5: TSPO structure and mitochondrial localization. (A) Structure of TSPO in the outer mitochondrial 
membrane (side view) showing the five a-helix transmembrane structure (TM1–5). IMS, intermembrane space. 
(B) TSPO is localized in the outer mitochondrial membrane where it forms a complex with the voltage-dependent 
anion channel (VDAC) and the adenine nucleotide transporter (ANT). TSPO mediates the transition of cholesterol 
from the inner to the outer mitochondrial membrane. Cholesterin-monooxygenase P450 scc converts cholesterol 
into pregnenolone, a precursor for several neurosteroids. A is modified from (Selvaraj and Stocco, 2015), B is 
modified from (Rupprecht et al., 2010), Cholesterol structure modified from (Palmer, 2004) 
 
Protein interaction studies proposed that TSPO forms a complex with other proteins 
of the inner and outer mitochondrial membrane such as the voltage-dependent anion 
channel (VDAC) and the adenine nucleotide transporter (ANT) (Garnier et al., 1994, 
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Veenman et al., 2008). TSPO, as part of this complex reaching from the inner to the 
outer mitochondrial membrane, is thought to mediate the transport of lipophilic 
substances such as cholesterol across the intermembrane space (McEnery et al., 
1992, Papadopoulos et al., 2006). At the inner mitochondrial membrane the 
cholesterol side-chain cleaving enzyme cytochrome P450 (P450 scc) converts 
cholesterol to pregnenolone, a precursor for several neurosteroids (Figure 5, B) 
(Veenman et al., 2007, Papadopoulos et al., 2007). TSPO is thought to be involved in 
this crucial a rate-limiting step in steroidogenesis (Lacapere and Papadopoulos, 
2003, Papadopoulos et al., 2006, Papadopoulos et al., 2007). In line with this role, 
TSPO ligands were reported to stimulate production of steroid hormones and 
neurosteroids in steroidogenic cells and isolated mitochondria (Mukhin et al., 1989, 
Papadopoulos et al., 1990). Additionally, knocking out TSPO or blocking TSPO with 
antisense oligodeoxynucleotides (ODNs) suppresses steroid production in Leydig 
tumor cells (Papadopoulos et al., 1997a, Hauet et al., 2005). Other described 
functions for TSPO include mitochondrial respiration (Hirsch et al., 1989, Gavish et 
al., 1999), formation of the mitochondrial permeability transition pore (MPTP) 
(Zamzami and Kroemer, 2001), cell proliferation (Corsi et al., 2008) and apoptosis 
(Veenman et al., 2008). Investigations with new established CRISPR/Cas9-mediated 
TSPO knock-out steroidogenic MA-10 Leydig cells, furthermore propose a role for 
TSPO in regulation of mitochondrial energy metabolism by modulation of fatty acid 
oxidation (FAO) (Tu et al., 2016). Of note is that many of the functions were detected 
in experiments using TSPO ligands.  
Two separate studies have however shown that a global TSPO knockout is not lethal 
as was previosly thought, with the absence of TSPO having no impact on 
steroidogenesis. This raised a lot of doubt and controversy to the functions ascribed 
to TSPO (Papadopoulos et al., 1997b, Tu et al., 2014a, Banati et al., 2014). 
Stimulation of TSPO-knockout in MA-10 mouse Leydig tumor cells with TSPO ligand 
PK11195 also revealed that enhancement of steroid production is TSPO independent 
(Tu et al., 2014b). Leading to further speculation that some of the observed effects of 
TSPO ligands on steroidogenesis are just side effects and not TSPO specific 
(Selvaraj and Stocco, 2015). There is also conflicting evidence on the role of TSPO 
as regulator of the mitochondrial permeability transition pore (MPTP), a function 
associated with cell death induction. More recently published data propose that the 
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complex of TSPO, VDAC and ANT is not involved in this process (Baines et al., 
2007, Kokoszka et al., 2004, Selvaraj and Stocco, 2015). 
Independent of the discussion about TSPO function several studies show a strong 
upregulation of TSPO during different neuropathologies (Rupprecht et al., 2010). In 
humans, TSPO upregulation is observed in neurological disorders like Alzheimer’s 
disease (Edison et al., 2008, Yasuno et al., 2008), Multiple sclerosis (Banati et al., 
2000, Versijpt et al., 2005), Parkinson’s disease (Gerhard et al., 2006) Amyotrophic 
lateral sclerosis (Turner et al., 2004), dementia (Cagnin et al., 2004), and stroke 
(Gerhard et al., 2005). This is why TSPO serves as a biomarker for brain damage 
and neurodegeneration. Radio labeled TSPO-ligands are used to detect TSPO 
expression by positon emission tomography (PET) or single photon emission 
computed tomography (SPECT), allowing to localize damaged areas or active 
disease processes (Vivash and O'Brien, 2016, Chauveau et al., 2008, Chen and 
Guilarte, 2008). However, human studies with healthy volunteers revealed variations 
in the binding affinity of TSPO ligands, so that results of TSPO density analysis have 
to be interpreted carefully (Owen et al., 2011b). 
Besides their use as diagnostic tools to visualize TSPO expression, TSPO ligands 
have been shown to be potent in resolving neuroinflammation and 
neurodegeneration in various disease models (Rupprecht et al., 2010). Endogenous 
ligands for TSPO include cholesterol (Li et al., 2001), porphyrins (Verma et al., 1987), 
diazem-binding inhibitor (DBI) and its proteolytic products: octadecaneuropeptide 
(ODN) and triakontatetraneuropeptide (TTN) (Costa and Guidotti, 1991, Mocchetti 
and Santi, 1991). The production of DBI-derived ligands is upregulated in response 
to peripheral nerve injury, suggesting a role for TSPO and its endogenous ligands in 
nerve regeneration (Lacor et al., 1999). In the retina, DBI-derived ligands produced 
by astrocytes and Müller cells, were shown to negatively regulate microglial reactivity, 
by suppression of reactive-oxygen species (ROS) production, TNF-α expression and 
blockage of microglial proliferation. This suggests DBI-TSPO signaling in the retina to 
be important for macroglia-microglial interaction and essential for returning activated 
microglial into a quiescent state after an inflammatory response (Wang et al., 2014). 
Synthetic TSPO ligands were primarily developed as neuroimaging agents. 
Nevertheless classical TSPO ligands such as PK11195 or Ro-5 4864 as well as more 
recently developed ligands have been reported to exert anti-inflammatory (Ryu et al., 
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2005) , neuroprotective (Bordet et al., 2007, Veiga et al., 2005), immune suppressive 
(Daugherty et al., 2013), regenerative (Girard et al., 2012) and anti-anxiety activity 
(Rupprecht et al., 2009, Rupprecht et al., 2010). For example, treatment with PK 
11195 reduced pro-inflammatory cytokine production, microglial reactivity and 
neuronal death in a model of quinolinic acid-induced brain lesion (Ryu et al., 2005). 
Similarly administration of Ro-5 4864 prevented neuron loss in two independent 
models of brain damage (Veiga et al., 2005, Soustiel et al., 2008). Another TSPO 
ligand, Etifoxine was shown to be protective in an experimental murine model for 
multiple sclerosis (MS). Etifoxine improved recovery from MS symptoms was 
accompanied by clearly reduced immune cell infiltration in the spinal cord and 
improved oligodendroglial regeneration (Daugherty et al., 2013). In an experimental 
model for amytrophic lateral sclerosis (ALS), characterized by death of cortical and 
spinal cord motor neurons, treatment with the TSPO ligand olesoxime (TRO 19622) 
reduced neuronal cell death and promoted regeneration (Bordet et al., 2007). 
Furthermore in psychiatric disorders, the TSPO ligand, XBD173 (AC-5216, 
Emapunil), diminished experimentally induced panic attacks in rodents and exerted 
antipanic capacity in human volunteers (Rupprecht et al., 2009). 
However, how the different TSPO ligands exert neuroprotection and other beneficial 
effects remains largely unresolved. Possible mechanisms include the modulation of 
microglial cells, hence glial cells upregulate TSPO in response to pathological 
alterations and TSPO ligands were shown to reduce microgliosis (Rupprecht et al., 
2010). In addition, beneficial effects of TSPO ligands have been associated with 
changes in neurosteroid production (Giatti et al., 2009, Barron et al., 2013, Selvaraj 
and Stocco, 2015). However, considering recent findings which challenge TSPO’s 
role in steroidogenesis further approaches are needed to elucidate the exact function 
of TSPO and how TSPO ligands work to mediate therapeutic effects. 
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3.5 Aims of the thesis 
There is increasing evidence that microglial reactivity actively contributes to the 
development and perturbation of retinal degenerations. Observations in different 
brain pathologies revealed furthermore an upregulation of TSPO in activated 
microglial cells. Moreover ligands for TSPO were effective in resolving degenerative 
CNS pathologies. Thus, attenuation of chronic microglial activation via TSPO ligands 
might represent a promising approach to diminish degenerative processes in the 
retina.  
Therefore the study aimed to elucidate the role of TSPO as potential biomarker for 
retinal microgliosis and possible therapeutic target for the modulation of microglial 
cells. A comprehensive in vitro approach, testing key microglial functions, was 
performed to determine the capacity of TSPO ligand, XBD173 to interfere with 
microglial reactivity and resultant neurotoxicity in vitro. A further question addressed 
in this thesis was whether XBD173 might modulate microglial reactivity in vivo and 
thereby reduce light induced retinal degeneration. 
A further goal of the thesis was to determine whether minocycline, an antibiotic with 
additional anti-inflammatory properties is able to reduce microglial neurotoxicity and 
to protect the retina from degeneration. Therefore a model of bright white light-
induced retinal degeneration, mimicking features of inherited degenerations such as 
microgliosis and death of photoreceptors, was used to assess the immunomodulatory 
and neuroprotective effects of minocycline during retinal degeneration. 
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4 Results 
4.1 Translocator protein (18 kDa) (TSPO) is expressed in 
reactive retinal microglia and modulates microglial 
inflammation and phagocytosis 
Marcus Karlstetter, Caroline Nothdurfter, Alexander Aslanidis, Katharina Moeller, 
Felicitas Horn, Rebecca Scholz, Harald Neumann, Bernhard H F Weber, Rainer 
Rupprecht* and Thomas Langmann* 
Background: The translocator protein (18 kDa) (TSPO) is a mitochondrial protein 
expressed on reactive glial cells and a biomarker for gliosis in the brain. TSPO 
ligands have been shown to reduce neuroinflammation in several mouse models of 
neurodegeneration. Here, we analyzed TSPO expression in mouse and human 
retinal microglia and studied the effects of the TSPO ligand XBD173 on microglial 
functions. 
Methods: TSPO protein analyses were performed in retinoschisin-deficient mouse 
retinas and human retinas. Lipopolysaccharide (LPS)-challenged BV-2 microglial 
cells were treated with XBD173 and TSPO shRNAs in vitro and pro-inflammatory 
markers were determined by qRT-PCR. The migration potential of microglia was 
determined with wound healing assays and the proliferation was studied with 
Fluorescence Activated Cell Sorting (FACS) analysis. Microglial neurotoxicity was 
estimated by nitrite measurement and quantification of caspase 3/7 levels in 661 W 
photoreceptors cultured in the presence of microglia-conditioned medium. The effects 
of XBD173 on filopodia formation and phagocytosis were analyzed in BV-2 cells and 
human induced pluripotent stem (iPS) cell-derived microglia (iPSdM). The 
morphology of microglia was quantified in mouse retinal explants treated with 
XBD173. 
Results: TSPO was strongly up-regulated in microglial cells of the dystrophic mouse 
retina and also co-localized with microglia in human retinas. Constitutive TSPO 
expression was high in the early postnatal Day 3 mouse retina and declined to low 
levels in the adult tissue. TSPO mRNA and protein were also strongly induced in 
LPS-challenged BV-2 microglia while the TSPO ligand XBD173 efficiently 
suppressed transcription of the pro-inflammatory marker genes chemokine (C-C 
motif) ligand 2 (CCL2), interleukin 6 (IL6) and inducible nitric oxide (NO)-synthase 
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(iNOS). Moreover, treatment with XBD173 significantly reduced the migratory 
capacity and proliferation of microglia, their level of NO secretion and their neurotoxic 
activity on 661 W photoreceptor cells. Furthermore, XBD173 treatment of murine and 
human microglial cells promoted the formation of filopodia and increased their 
phagocytic capacity to ingest latex beads or photoreceptor debris. Finally, treatment 
with XBD173 reversed the amoeboid alerted phenotype of microglial cells in 
explanted organotypic mouse retinal cultures after challenge with LPS. 
Conclusions: These findings suggest that TSPO is highly expressed in reactive 
retinal microglia and a promising target to control microglial reactivity during retinal 
degeneration. 
 
Own contribution to publication I: 
To exclude that TSPO is significantly expressed in Müller cells or retinal neurons, I 
established, performed and analyzed glial fibrillary acid protein (GFAP)/TSPO and 
microtubule-associated protein 2 (MAP2)/TSPO co-stainings in wildtype as well as in 
Rs1h -/y mice (Fig.1. J-M). To determine the effect of XBD173 on microglial 
proliferation I established, performed and analyzed CFSE-based flow cytometry 
analysis (Fig. 4 C) and created the respective images  
Contribution of co-authors to publication I: 
Marcus Karlstetter conceptualized parts of the project, finalized images, managed 
collaborations and carried out qRT-PCR analysis and neurotoxicity assays (Fig. 3 A-
H). Caroline Nothdurfter carried out pregnenolone ELISA (Fig. 7 A). Alexander 
Aslanidis carried out immunohistochemistry (Fig. 1 A-I), quantitative real-time PCR 
and Western blot (Fig. 2 A-E) analyses of TSPO expression in the retina and 
performed migration assays (Fig. 4 A, B). Alexander Aslanidis and Felicitas Horn 
performed morphological analyses and phagocytosis assays with BV-2 microglial 
cells and iPSdM cells (Fig. 5 A-H, Fig. 6 A-D). Katharina Moeller performed 
aminoglutethimide phagocytosis assays (Fig. 7 B) and optimized and carried out 
retinal explant experiments (Fig. 8 A-E). Prof. Harald Neumann provided iPSdM cells. 
Prof. Bernhard Weber provided valuable suggestions and critically read the 
manuscript. Prof. Rainer Rupprecht supplied the synthetic TSPO ligand XBD173 and 
provided valuable suggestions. Prof. Thomas Langmann, as principal investigator, 
coordinated the project and wrote the manuscript. 
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4.2 Targeting translocator protein (18 kDa) (TSPO) 
dampens pro-inflammatory microglia reactivity in the 
retina and protects from degeneration 
Rebecca Scholz, Albert Caramoy, Mohajeet B. Bhuckory, Khalid Rashid, Mei Chen, 
Heping Xu, Christian Grimm and Thomas Langmann* 
Background: Reactive microglia are commonly seen in retinal degenerative 
diseases, and neurotoxic microglia responses can contribute to photoreceptor cell 
death. We and others have previously shown that translocator protein (18 kDa) 
(TSPO) is highly induced in retinal degenerations and that the selective TSPO ligand 
XBD173 (AC-5216, emapunil) exerts strong anti-inflammatory effects on microglia in 
vitro and ex vivo. Here, we investigated whether targeting TSPO with XBD173 has 
immuno-modulatory and neuroprotective functions in two mouse models of acute 
retinal degeneration using bright white light exposure. 
Methods: BALB/cJ and Cx3cr1GFP/+ mice received intraperitoneal injections of 10 
mg/kg XBD173 or vehicle for five consecutive days, starting 1 day prior to exposure 
to either 15,000 lux white light for 1 h or 50,000 lux focal light for 10 min, respectively. 
The effects of XBD173 treatment on microglia and Müller cell reactivity were 
analyzed by immuno-stainings of retinal sections and flat mounts, fluorescence-
activated cell sorting (FACS) analysis, and mRNA expression of microglia markers 
using quantitative real-time PCR (qRT-PCR). Optical coherence tomography (OCT), 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stainings, and 
morphometric analyses were used to quantify the extent of retinal degeneration and 
photoreceptor apoptosis. 
Results: Four days after the mice were challenged with bright white light, a large 
number of amoeboid-shaped alerted microglia appeared in the degenerating outer 
retina, which was nearly completely prevented by treatment with XBD173. This 
treatment also down-regulated the expression of TSPO protein in microglia but did 
not change the TSPO levels in the retinal pigment epithelium (RPE). RT-PCR 
analysis showed that the microglia/macrophage markers Cd68 and activated 
microglia/macrophage whey acidic protein (Amwap) as well as the pro-inflammatory 
genes Ccl2 and Il6 were reduced after XBD173 treatment. Light-induced 
degeneration of the outer retina was nearly fully blocked by XBD173 treatment. We 
further confirmed these findings in an independent mouse model of focal light 
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damage. Retinas of animals receiving XBD173 therapy displayed significantly more 
ramified non-reactive microglia and more viable arrestin-positive cone photoreceptors 
than vehicle controls. 
Conclusions: Targeting TSPO with XBD173 effectively counter-regulates 
microgliosis and ameliorates light-induced retinal damage, highlighting a new 
pharmacological concept for the treatment of retinal degenerations. 
 
Own contribution to publication II: 
I designed, performed and analyzed all experiments, except of focal light damage 
analysis (Fig 6 A-J), created all images and helped to finalize the manuscript draft. I 
independently handled the revision phase of this project. I presented posters and oral 
presentations on several national and international meetings during my PhD. 
Contribution of co-authors to publication II: 
Albert Caramoy helped with OCT analyses. Mohajeet B. Bhuckory and Mei Chen 
carried out focal light exposure experiments coordinated by Prof. Heping Xu. Prof. 
Heping Xu and Prof. Christian Grimm provided valuable suggestions and critically 
read the manuscript. Khalid Rashid critically read the manuscript. Prof. Thomas 
Langmann, as principal investigator, coordinated the project and wrote the 
manuscript. 
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4.3 Minocycline counter-regulates pro-inflammatory 
microglia responses in the retina and protects from 
degeneration 
Rebecca Scholz, Markus Sobotka, Albert Caramoy, Thomas Stempfl, Christoph 
Moehle and Thomas Langmann* 
Background: Microglia reactivity is a hallmark of retinal degenerations and 
overwhelming microglial responses contribute to photoreceptor death. Minocycline, a 
semi-synthetic tetracycline analog, has potent anti-inflammatory and neuroprotective 
effects. Here, we investigated how minocycline affects microglia in vitro and studied 
its immuno-modulatory properties in a mouse model of acute retinal degeneration 
using bright white light exposure. 
Methods: LPS-treated BV-β microglia were stimulated with 50 μg/ml minocycline for 
6 or 24 h, respectively. Pro-inflammatory gene transcription was determined by real-
time RT-PCR and nitric oxide (NO) secretion was assessed using the Griess reagent. 
Caspase 3/7 levels were determined in 661W photoreceptors cultured with microglia-
conditioned medium in the absence or presence of minocycline supplementation. 
BALB/cJ mice received daily intraperitoneal injections of 45 mg/kg minocycline, 
starting 1 day before exposure to 15.000 lux white light for 1 hour. The effect of 
minocycline treatment on microglial reactivity was analyzed by immunohistochemical 
stainings of retinal sections and flat-mounts, and messenger RNA (mRNA) 
expression of microglia markers was determined using real-time RT-PCR and RNA-
sequencing. Optical coherence tomography (OCT) and terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) stainings were used to measure the 
extent of retinal degeneration and photoreceptor apoptosis. 
Results: Stimulation of LPS-activated BV-2 microglia with minocycline significantly 
diminished the transcription of the pro-inflammatory markers CCL2, IL6, and 
inducible nitric oxide synthase (iNOS). Minocycline also reduced the production of 
NO and dampened microglial neurotoxicity on 661W photoreceptors. Furthermore, 
minocycline had direct protective effects on 661W photoreceptors by decreasing 
caspase 3/7 activity. In mice challenged with white light, injections of minocycline 
strongly decreased the number of amoeboid alerted microglia in the outer retina and 
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down-regulated the expression of the microglial activation marker translocator protein 
(18 kDa) (TSPO), CD68, and activated microglia/macrophage whey acidic protein 
(AMWAP) already 1 day after light exposure. Furthermore, RNA-seq analyses 
revealed the potential of minocycline to globally counter-regulate pro-inflammatory 
gene transcription in the light-damaged retina. The severe thinning of the outer retina 
and the strong induction of photoreceptor apoptosis induced by light challenge were 
nearly completely prevented by minocycline treatment as indicated by a preserved 
retinal structure and a low number of apoptotic cells. 
Conclusions: Minocycline potently counter-regulates microgliosis and light-induced 
retinal damage, indicating a promising concept for the treatment of retinal 
pathologies. 
Own contribution to publication III: 
To determine the neurotoxic potential of differentially stimulated microglia and on 
661W photoreceptors I designed, performed and analyzed caspase 3/7 activity 
measurements (Fig 2 B). I performed immunohistochemical stainings (microglial 
markers: iba1, tspo) in retinal sections and flat-mounts to analyze the effect of 
minocycline treatment on microglial reactivity four days after light exposure. 
Furthermore I specified activation of Müller cells by staining of glial fibrillary protein 
(GFAP) (Fig. 3 A-L). To determine whether microglial activation is an early event after 
light exposure and precedes photoreceptor apoptosis, microglial morphology and 
location were analyzed by immunostainings of retinal sections (Fig 5 A-C) as early as 
one day after light exposure. I additionally carried out time kinetic experiments to 
analyze mRNA expression levels of microglia associated markers (Fig 5 D-I). To 
analyze structural changes of the retina, I immunostained retinal sections with DAPI 
(Fig 7 H-J). I analyzed the amount of apoptotic cells by TUNEL-labeling (Fig 7 K-M) 
and performed RNA analyses to determine the level of caspase 8 mRNA which is 
involved in programmed cell death (Fig. 7 N). To analyze how fast microglia cells 
react to light stimuli, I performed immunostainings and mRNA analysis four hours 
after light exposure (Fig S1 A-F). I created all images and wrote the manuscript draft. 
I independently handled the revision phase of this project 
Contribution of co-authors to publication III: 
Under my supervision, Markus Sobotka carried out qRT-PCR analysis in BV-2 
microglial cells (Fig. 1A-F) and retinas (Fig 4 A-F) and performed nitric oxide (NO) 
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measurements (Fig. 2A). Supported by Albert Caramoy and me, Markus Sobotka 
carried out and analyzed OCT analyses (Fig. 7 A-G). Thomas Stempfl and Christoph 
Moehle performed RNA sequencing and wrote the respecting part of the manuscript 
(Fig. 6 A-C). Prof. Thomas Langmann, as principal investigator, obtained funding, 
supervised the project, created the RNA sequencing image and tables (Fig 6 A-C, 
S2, S3) and corrected the manuscript. 
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5 Discussion 
5.1 TSPO-reactivity marker and target for therapy 
Microglial activation is a general hallmark of neurodegenerative diseases. There is 
increasing evidence that loss of auto-regulatory capacity of microglia cells, resulting 
in chronic activation, contributes to neuronal cell death in the CNS including the 
retina (Karlstetter et al., 2015). From brain pathologies it is known that activated 
microglia express enhanced levels of TSPO (Rupprecht et al., 2010). However, 
knowledge about TSPO expression in retinal microglia was missing. Therefore, in the 
current study, we aimed at elucidating the role of TSPO as a possible reactivity 
marker for microglia in the retina and hypothesized that TSPO could be a target for 
neuroprotective therapy in this tissue. 
 
5.1.1 TSPO as a microglial reactivity marker in retinal degeneration 
From different neuropathies affecting the brain or the peripheral nervous system 
(PNS), it is well known that TSPO is upregulated in reactive microglial cells and 
sometimes in astrocytes and that this mitochondrial protein is a suitable biomarker to 
detect and localize neuro-inflammatory events using radio-labeled TSPO ligands 
(Vowinckel et al., 1997, Cagnin et al., 2004, Turner et al., 2004, Gerhard et al., 2005, 
Gerhard et al., 2006, Maeda et al., 2007, Miyoshi et al., 2009). Here, we showed for 
the first time that human and mouse retinal microglia cells express TSPO. Microglial 
TSPO was upregulated in the degenerating retinoschisin-deficient as well light-
damaged retina. TSPO expression in both models overlapped with the peak of 
microglial reactivity. This implicates that TSPO could also be a suitable biomarker for 
detecting gliosis in retinal diseases. Our work was subsequently confirmed by Wang 
et al. investigating the expression of TSPO in different models of retinal inflammation 
and injury (LPS- induced inflammation/ NMDA-induced excitotoxicity, subretinal 
hemorrhage and optic nerve crush) (Wang et al., 2014). Microglial TSPO expression 
was also observed in myosin VI deficient mice with a phenotype reflecting some 
similarities of age-related macular degeneration, further highlighting TSPO as a 
biomarker of retinal degeneration (Schubert et al., 2015). Studies from other groups 
as well as our own data therefore raise hope for using TSPO ligands in the future as 
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in vivo imaging tools to monitor microgliosis during retinal degenerations. However 
there are several limitations. For instance, one widely used TSPO ligand 11C-
PK11195 has been reported to possess relatively low brain permeability and to bind 
unspecifically to plasma proteins. This results in low specificity of PET images, 
making the detection of minor alterations during neuroinflammation difficult (Vivash 
and O'Brien, 2016, Owen and Matthews, 2011). Moreover, it was noticed that there 
exists genetic variation in the binding affinity of TSPO ligands and some patients 
even completely lack tracer binding. Responsible for this is a single nucleotide 
polymorphism (rs6971) in exon 4 of the TSPO gene causing an alanine147-to-
threonine substitution (Owen et al., 2011a, Owen et al., 2012, Fujita et al., 2008). It is 
therefore necessary to test whether this polymorphism is present in patients to 
correctly interpret TSPO-binding studies. 
Considering a different role of TSPO expressing cells like microglia or astrocytes 
during degeneration, difficulties in data interpretation of TSPO ligand binding studies 
may occur (Vivash and O'Brien, 2016, Lavisse et al., 2012). In the eye we and others 
detected TSPO expression in different cell types such as microglia cells, astrocytes 
and cells of the retinal pigment epithelium (RPE) (Scholz et al., 2015a, Wang et al., 
2014). We have shown that TSPO is constitutively expressed in the RPE whereas 
microglia show a low basal expression but strong upregulation during degenerative 
changes. Hence, due to the unspecific nature of TSPO ligands used for in vivo 
imaging and low resolution of PET images, subtle changes in the relatively low 
number of retinal microglial cells might be hard to distinguish from the high 
background signal resulting from strongly expressing TSPO cells such as the RPE. 
Therefore to circumvent this problem and construe in vivo imaging pictures more 
accurately, the development of cell type specific radio-ligands would be very helpful. 
 
5.1.2 Understanding TSPO induction in microglial cells 
TSPO is upregulated in response to highly diverse stimuli such as neuronal 
degeneration (Edison et al., 2008), mechanic induced injury (Karchewski et al., 2004) 
, recovery responses from injury (Lacor et al., 1999), autoimmune processes 
(Daugherty et al., 2013, Vowinckel et al., 1997), challenge to external stressors like 
light (Scholz et al., 2015a, Scholz et al., 2015b), hereditary alterations or bacterial 
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compounds (Karlstetter et al., 2014). Due to the complexity of diseases and models 
reflecting microglial TSPO upregulation, it is hard to decipher the factors and 
pathways involved in microglial TSPO regulation. We and others found TSPO 
upregulation in microglial cells after stimulation with TLR4 ligand LPS (Karlstetter et 
al., 2014, Wang et al., 2014). Therefore damage-associated molecular patterns 
recognized by TLR4 and subsequent downstream signaling are good candidates for 
microglial TSPO induction. Indeed, pharmacological blockage of TLR 4 by LPS-RS in 
a rat model of neuropathic pain prevented TSPO upregulation and neuropathic pain 
(Wei et al., 2013). Since microglial cells express several immuno-regulatory surface 
receptors in addition to TLRs, it seems unlikely that TSPO regulation solely depends 
on TLR signaling.  
 
5.1.3 Transcriptional regulation of TSPO 
TSPO protein expression was investigated in different cells under both homeostatic 
and disease conditions, highest TSPO expression levels were detectable in steroid 
synthesizing tissue (Gavish et al., 1999). But there is only scarce information about 
the transcriptional regulation of TSPO in different cell types. Studies using cells with 
high (MA-10 mouse tumor Leydig cells) and low (NIH-3T3 mouse fibroblasts) basal 
TSPO expression level revealed that protein kinase c epsilon (PKC ε) is crucially 
involved in the control of TSPO on transcriptional level. PKC ε was proposed to 
regulate TSPO expression via a mitogen-activated protein kinase (MAPK) (Raf-1-
/MEK1/2-ERK1/2) signal transduction pathway, acting at least partially through Stat3 
and c-Jun transcription factors (Batarseh et al., 2010, Batarseh and Papadopoulos, 
2010). But it was shown that PKC ε is not expressed in microglia cells (Slepko et al., 
1999). Further investigations will be needed to elucidate microglia-specific regulation 
of TSPO transcription in health and disease. 
 
5.1.4 Immune modulation and neuroprotection by TSPO ligand 
XBD173 
We initially showed that XBD173 could reverse LPS induced microglial reactivity and 
dampen its neurotoxic potential on photoreceptors in vitro. Based on these findings 
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we tested XBD173 in two independent murine models of light-induced retinal 
degeneration. This TSPO directed therapy revealed reduced numbers and less 
amoeboid shaped, reactive microglial cells in the outer retina and preserved the 
retinal structure (Scholz et al., 2015a). 
Our findings are in agreement with studies using other TSPO ligands in pathologies 
of the brain or the peripheral nervous system that revealed neuroprotective effects 
accompanied by a reduction of immune cell reactivity (Daugherty et al., 2013, Barron 
et al., 2013, Girard et al., 2008, Ryu et al., 2005). For instance, treatment of 
experimental autoimmune encephalomyelitis (EAE) with Etifoxine attenuated disease 
severity, improved symptomatic recovery and reduced immune cell infiltration 
(Daugherty et al., 2013). The same ligand also promoted axonal regeneration in a 
model of traumatic nerve injury (Girard et al., 2012). Comparable to our findings that 
showed less GFAP expression in Müller cells and less microglial reactivity in mice 
treated with XBD173, administration of TSPO ligand, Ro5-4864 in Alzheimer’s 
disease reduced both GFAP and Iba1 immunoreactivity and attenuated 
neuropathological alterations as well as behavioral deficits (Barron et al., 2013).  
Although modulation of microglia is very likely involved in XBD17γ’s neuroprotective 
effect, TSPO function and the exact mechanism of action are still uncertain. In our in 
vitro study, treatment of LPS-activated BV-2 microglia with XBD173 dampened pro-
inflammatory marker gene expression of CCL2, IL6 and iNOS, whereas TSPO 
knockdown with two different shRNAs abrogated the suppressing effects. Transcripts 
of the same markers were also reduced in retinas of XBD173- treated mice four days 
after light challenge. In line with suppressed iNOS transcripts, XBD173 also 
suppressed microglial toxic NO production. Moreover microglial conditioned medium 
from XBD173 stimulated cells was less neurotoxic on 661W photoreceptors 
compared to controls. Indeed, elevated levels of NO are detectable in retinal 
degeneration and depending on the amount and duration, supposed to contribute to 
the disease process (Hoey et al., 1997, Yang et al., 2007a). Therefore suppression of 
pro-inflammatory signaling is very likely involved in this TSPO-directed therapy 
approach. Supporting this hypothesis, studies using the TSPO agonist PK11195 also 
revealed suppression of pro-inflammatory gene transcription. For instance, 
stimulation of human LPS-activated microglial cells with PK11195 reduced gene 
expression of cyclooxygenase-2 (COX-2) and tumor necrosis factor-a (TNF-a) (Choi 
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et al., 2002). In line with that, administration of the same compound also decreased 
mRNA levels of the pro-inflammatory cytokines IL1ȕ, IL6, TNFα and iNOS as well as 
microglial reactivity in quinolinic acid induced brain degeneration (Ryu et al., 2005).  
As mentioned previously, XBD173 dampened CCL2 gene expression in vitro and in 
vivo, which could be important for the observed neuroprotective effect. Studies 
investigating the role of CCL2/CCR2 signaling in models of AMD suggest an 
important role of this cytokine in degenerative processes, as knockout of these factor 
or pharmacological blockage prevents inflammatory microglia and monocyte 
recruitment and photoreceptor degeneration (Sennlaub et al., 2013, Raoul et al., 
2010). 
Our in vitro studies further showed XBD17γ’s capacity to suppress microglial 
migration and proliferation, suggesting TSPO to be involved in the control of these 
functions. In line with this, TTN, a DBI-derived endogenous TSPO ligand, produced 
by Müller cells and astrocytes, significantly reduced microglial proliferation in the 
retina (Wang et al., 2014). Indeed high TSPO expression is positively correlated to 
enhanced proliferative capacity in human breast cancer cell lines (Hardwick et al., 
1999). The same is also true for TSPO overexpressing glioma cells, which show 
enhanced proliferation, transmigration and motility (Rechichi et al., 2008). As 
enhanced proliferation is a sign of microglial reactivity, the ability of the synthetic 
ligand XBD173 as well as the endogenous ligand TTN to ameliorate these responses 
further proves their potency in limiting pro-inflammatory responses in microglia 
(Wang et al., 2014). 
Phagocytosis is generally enhanced during pathological conditions, however, 
phagocytosis itself is not a sign of pro-inflammatory activation, as high phagocytic 
capacity is also important to maintain physiological conditions (Sierra et al., 2013). In 
the current study, XBD173 stimulation of human iPSdM and murine BV2 microglial 
cells resulted in increased phagocytosis of both latex beads and apoptotic 
photoreceptor debris. XBD173 administration furthermore promoted the formation of 
filopodia in the human and the murine cell culture system as well as in retinal 
explants. It is not yet clear how XBD173 mediates these effects. However, since pro-
inflammatory substances such as LPS induce an increase in Ca2+ ions in microglia 
cells leading to concomitant actin organization, it is plausible that XBD173 could 
influence filopodia formation and the ramified morphology by changing Ca2+ levels 
Discussion 
 
41 
 
(Bader et al., 1994). Indeed, the TSPO ligand PK11195 reduced LPS-induced 
increase of intracellular Ca2+ in human microglial cells (Choi et al., 2002). 
TSPO is supposed to control a rate limiting step in steroidogenesis (Papadopoulos et 
al., 2006, Papadopoulos et al., 2007, Rupprecht et al., 2010) and we detected 
elevated levels of the neurosteroid precursor pregnenolon after XBD173 stimulation 
in microglial supernatant. Furthermore, blocking the rate limiting enzymatic 
conversion of cholesterol to pregnenolone by aminoglutethimide (AMG) reduced the 
phagocytic capacity of microglial cells suggesting a role for pregnenolone derived 
steroids in control of microglial functions. Interestingly, Giatti et al. observed that 
TSPO ligand, Ro5 4864 effectively reduced the severity of diabetic neuropathy 
through a local increase of neurosteroids (Giatti et al., 2009). Furthermore, 
progesterone and its metabolite allopregnanolone, both derived from pregnenolone, 
downregulated pro-apoptotic genes (caspase 3, bax, bad) and enhanced expression 
of anti-apoptotic bcl-2 in a model of traumatic brain injury, ultimately resulting in 
neuroprotection (Djebaili et al., 2005, Djebaili et al., 2004, Yao et al., 2005). 
Moreover, progesterone was recently tested in the rd1 mouse model of retinitis 
pigmentosa. Progesterone was able to decrease gliosis, the amount of cell death, 
increased ONL thickness and also improved retinal function detectable by an 
improved ERG b wave amplitude (Sanchez-Vallejo et al., 2015). These data allow 
speculations that neuroprotection by intervention with TSPO ligands to be possibly 
mediated by influencing neurosteroid production.  
Retinal TSPO expression was not limited to microglial cells and TSPO was also 
detectable in astrocytes and the RPE. Furthermore, XBD173 treatment did not 
change TSPO expression in these cells as it was seen in microglia. This indicates 
potential different functions for TSPO in astrocytes and RPE than microglia. 
Moreover, it raises the question whether the protective effect of XBD173 is 
exclusively mediated by modulation of microglial cells. Analyses of human RPE cells 
revealed a correlation between aging and mitochondrial dysfunction, resulting in 
increased susceptibility of RPE cells to oxidative stress (He et al., 2010). 
Interestingly, mitochondrial damage in RPE cells, possibly resulting in dysfunction, 
was recently associated with the development of AMD (Terluk et al., 2015). Therefore 
it has to be examined whether XBD17γ’s neuroprotection could also be mediated by 
influencing mitochondrial function in RPE cells. 
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5.1.5 TSPO - future challenges and perspectives 
As light damage is an inducible, fast progressive model and caused by one specific 
trigger, it would be interesting to test XBD17γ’s efficiency to suppress 
neurodegeneration also in a slow degeneration model of inherited retinal dystrophy. 
Since some retinopathies like AMD also comprise an uncontrolled growth of blood 
vessels, it would be interesting to test combinatorial therapeutic strategies targeting 
both microglial cells and newly formed blood vessels. 
Creation of cell type specific TSPO knock out mice, lacking TSPO in microglial or 
RPE cells would allow studying the cell type specific role of TSPO. Furthermore 
these conditional knockout mice would enable to investigate which cell type is 
essentially responsible for the before described neuroprotective effect in light induced 
degeneration. Considering high constitutive expression of TSPO in RPE, it would 
moreover be very interesting to study if and how XBD173 stimulation affects RPE 
cells. 
Insights from new established complete TSPO knockout mice, that were against 
expectations viable, bring old understanding of TSPO as a cholesterol transporter 
and theories of mechanism of action of different TSPO ligands to stagger. Future 
efforts should aim at elucidating the exact role of TSPO under physiological and 
pathological conditions and in different cell types (Tu et al., 2014a, Banati et al., 
2014). More recently published literature proposes a role for TSPO in oxidative stress 
response and fatty acid oxidation (Tu et al., 2016, Batoko et al., 2015b, Batoko et al., 
2015a). How these functions are influenced by TSPO ligands and contribute to the 
detected immunomodulatory and neuroprotective effects has to be figured out. 
 
5.2 Minocycline in retinal degeneration 
Minocycline is an approved antibiotic for the use against gram positive and negative 
bacteria. Several studies revealed further properties including anti-inflammatory and 
anti-apoptotic activities and inhibited proteolysis, angiogenesis and tumor metastasis 
(Garrido-Mesa et al., 2013, Domercq and Matute, 2004). Our investigations aimed at 
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elucidating how minocycline modulates microglia cells and if minocycline can protect 
from white light-induced degeneration. Of note is that light is also a promoting factor 
in human retinal degenerations and is therefore more than an artificial stimulus 
(Cruickshanks et al., 1993, Swaroop et al., 2009, Wenzel et al., 2005). 
 
5.2.1 Immune modulation and retinal degeneration rescue by 
Minocycline 
Our minocycline intervention study revealed that minocycline counter-regulated the 
early pro-inflammatory microglial response and protected the retina from light 
induced photoreceptor death. This neuroprotective effect was in good agreement 
with other models of retinal degeneration such as glaucoma, retinitis pigmentosa or 
diabetic retinopathy (Bosco et al., 2008, Yang et al., 2007a, Krady et al., 2005). We 
have analyzed microglia and noticed less amoeboid cells in the outer retina and 
lower expression of TSPO, AMWAP and CD68 in the Minocycline treatment group. 
This indicates that Minocycline counter-regulates retinal microglial reactivity. In 
agreement, minocycline treatment in a model of diabetic retinopathy also repressed 
pro-inflammatory mediators and cytotoxins, which are known to be released from 
reactive microglia (Krady et al., 2005). Similarly, Minocycline specifically increased 
the number of ramified microglia in a DBA/2J mouse glaucoma model. The reduction 
of microglia activation was coupled to improved retinal ganglion cell (RGC) function 
(Bosco et al., 2008). Peng and colleagues also showed that inhibition of microglial 
activation with Minocycline reduced photoreceptor apoptosis in the murine rd 10 
model of retinitis pigmentosa (Peng et al., 2014). 
We also analyzed potential mechanisms how minocycline could mediate immune 
modulation and neuroprotection. The analyses with BV-2 microglia and the light 
damage model revealed efficient suppression of key microglial activation pathways 
(CCL2, IL6, iNOS) by minocycline. Similar to our findings, pro-inflammatory 
molecules like IL6, IL1ȕ and TNF-α, TLR 2, Cox1, Cox 2 and iNOS were suppressed 
by minocycline stimulation of BV-2 microglia (Henry et al., 2008, Wang et al., 2005, 
Peng et al., 2014). Reduced transcripts of pro-inflammatory markers (IL-1ȕ, TNF-α) 
were furthermore detected in minocycline treated mice that mimic diabetic 
retinopathy and retinitis pigmentosa (Krady et al., 2005, Peng et al., 2014). Thus 
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minocycline seem to be very effective in diminishing pro-inflammatory gene 
expression. 
Nitric oxide (NO) is a toxic molecule that is capable of damaging photoreceptors and 
other retinal cells when secreted from microglia. We showed that minocycline 
reduced microglial NO production after LPS challenge and reduced neurotoxicity of 
microglial conditioned medium on photoreceptor cells. Interestingly, adding 
minocycline directly to photoreceptors also reduced microglial mediated cell death. 
Several studies revealed an association between NO production and degenerative 
processes and substances blocking NO production were reported to reduce 
degeneration (Yang et al., 2007a, Hoey et al., 1997, Nagayama et al., 1998, Yang et 
al., 2007b).  
Minocycline could also act directly on photoreceptors to inhibit apoptosis. A protein, 
involved in apoptosis induction, is B-cell lymphoma 2 (Bcl-2) that can interfere with 
pro-apoptotic proteins such as Bax, Bak and Bid and thereby block mitochondrial 
cytochrome-c release and caspase dependent induction of cell death. Likewise, 
minocycline treatment of rd 10 retinitis pigmentosa mice and animals with retinal vein 
occlusion enhanced anti-apoptotic Bcl-2 expression, suppressed pro-apoptotic Bax 
levels and caspase 3/7 activity and thereby exerted neuroprotection (Wang et al., 
2004, Peng et al., 2014, Sun et al., 2013). Additionally, Minocycline reduced 
apoptosis-inducing factor (AIF) mediated cell death in a model of Huntington’s 
disease (Wang et al., 2003, Chen et al., 2000).  
Minocycline could also directly act neuroprotective via its free radical scavenging 
properties. Rat brain homogenate lipid peroxidation 2,2-diphenyl-1-picrylhydrazyl 
(DPPH) radical scavenging assays revealed that minocycline exerts anti-oxidative 
capacity comparable to Vitamin E (Kraus et al., 2005). Other studies report that 
treatment with minocycline enhanced transcription of anti-oxidative nuclear 
respiratory factor 2 (Nrf 2) regulated genes like NAD(P)H dehydrogenase (quinone) 1 
(NQO1) and heme oxygenase 1 (HO-1) (Sakata et al., 2012). It was proposed that 
minocycline’s anti-oxidative action relies on the one hand on its chemical structure 
and on the other hand on its modulatory capacity of certain enzymes, like nitric oxide 
synthase or lipoxygenase (Plane et al., 2010).  
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Beside the so far elucidated options, how minocycline mediates neuroprotection, 
further mechanisms were proposed. It was reported that minocycline has the ability to 
attenuate p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation in 
spinal cord microglia and neurons and thereby act anti-nociceptive in models of 
tissue injury and inflammation-evoked pain (Hua et al., 2005). Similarly, Matsui and 
colleagues reported that both Minocycline and an inhibitor of p38 repress release of 
pro-inflammatory substances like nitric oxide (NO) and prostaglandine E2 (PGE2) in 
spinal cord microglia, which are thought to be implicated in nociceptive signaling 
(Matsui et al., 2010).  
Minocycline could also mediate neuroprotection by blocking Matrix 
metalloproteinases (MMPs). MMPs are involved in the transition of leukocytes across 
barriers, a critical aspect in CNS pathologies with enhanced immune cell infiltration 
such as multiple sclerosis. It was shown that minocycline can block MMP activity, 
resulting in less severe disease outcome in experimental autoimmune 
encephalomyelitis (Brundula et al., 2002). In line with these findings, interfering with 
MMPS by Minocycline was also able to decrease infarct size in models of cerebral 
ischemia (Park et al., 2011, Koistinaho et al., 2005). In the eye, minocycline 
administration reduced neovascularization in a model of alkali burn-induced corneal 
neovascularization, possibly by diminishing MMPs (MMP2/9/13), proinflammatory 
cytokine (IL-1 ȕ, IL-6) production as well as angiogenic factors (VEGF, bFGF) (Xiao 
et al., 2012).  
Taken together, different mechanisms are discussed how minocycline can exert 
neuroprotection but most studies revealed that reduction of microglial reactivity is a 
key event.  
 
5.2.2 Minocycline – future challenges and perspectives  
Minocycline was able to reduce microglial reactivity and prevented light induced 
retinal degeneration, reflected in a preserved outer nuclear layer (Scholz et al., 
2015b). This is in agreement with other studies showing neuroprotection in 
degenerative diseases of the CNS (Garrido-Mesa et al., 2013). The good CNS 
permeability and bioavailability and the fact that minocycline is already in use in 
patients as an antibiotic makes the transfer from bench to bedside way easier. For 
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the usage of minocycline in retinopathies, data from a first clinical trial, testing 
minocycline as medication for diabetic macular edema, are available. Minocycline 
improved visual function, central macular edema and vascular leakage compared to 
historical controls (Cukras et al., 2012). Because of the promising findings from 
preclinical and clinical trials extension of minocycline application to further retinal 
degenerative pathologies with microglial contribution is conceivable. Since some 
retinopathies like AMD also comprise a detrimental growth of blood vessels, it would 
be interesting to test combinatorial therapeutic strategies targeting both microglial 
cells and angiogenesis.  
Possible challenges to transfer minocycline to the clinic include the occurrence of 
side effects such as tissue hyperpigmentation, serious hypersensitivity reactions and 
autoimmune disorders (Kim and Suh, 2009). Hence the application regimen of 
minocycline in pre-clinical studies varies there might also be difficulties to find an 
effective dosage to treat retinopathies in patients. Differences between laboratory 
animals and patients such as variations in the half-life of minocycline need to be 
considered (Noble et al., 2009).  
 
5.3 Conclusion  
There are only limited strategies for treating inherited and complex retinal 
degenerations and to detect microgliosis in the eye.  
This thesis suggests that the brain degeneration biomarker TSPO may also be used 
to detect gliosis in the eye. Treatment with TSPO-ligand, XBD173 reduced the 
neurotoxic potential of microglial cells and prevented light-induced retinal 
degeneration. Therefore TSPO is a promising target to control microglial reactivity 
and to treat retinal degeneration.  
In addition findings revealed that minocycline ameliorates light-induced retinal 
damage by counter-regulation of microglial reactivity and direct effects on 
photoreceptors. Taken together the data highlight microglia-directed treatment 
strategies, as a promising therapeutic option for retinal degenerative diseases. 
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Translocator protein (18 kDa) (TSPO) is expressed
in reactive retinal microglia and modulates
microglial inflammation and phagocytosis
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Abstract
Background: The translocator protein (18 kDa) (TSPO) is a mitochondrial protein expressed on reactive glial cells
and a biomarker for gliosis in the brain. TSPO ligands have been shown to reduce neuroinflammation in several
mouse models of neurodegeneration. Here, we analyzed TSPO expression in mouse and human retinal microglia
and studied the effects of the TSPO ligand XBD173 on microglial functions.
Methods: TSPO protein analyses were performed in retinoschisin-deficient mouse retinas and human retinas.
Lipopolysaccharide (LPS)-challenged BV-2 microglial cells were treated with XBD173 and TSPO shRNAs in vitro and
pro-inflammatory markers were determined by qRT-PCR. The migration potential of microglia was determined with
wound healing assays and the proliferation was studied with Fluorescence Activated Cell Sorting (FACS) analysis.
Microglial neurotoxicity was estimated by nitrite measurement and quantification of caspase 3/7 levels in 661 W
photoreceptors cultured in the presence of microglia-conditioned medium. The effects of XBD173 on filopodia
formation and phagocytosis were analyzed in BV-2 cells and human induced pluripotent stem (iPS) cell-derived
microglia (iPSdM). The morphology of microglia was quantified in mouse retinal explants treated with XBD173.
Results: TSPO was strongly up-regulated in microglial cells of the dystrophic mouse retina and also co-localized
with microglia in human retinas. Constitutive TSPO expression was high in the early postnatal Day 3 mouse retina
and declined to low levels in the adult tissue. TSPO mRNA and protein were also strongly induced in LPS-challenged
BV-2 microglia while the TSPO ligand XBD173 efficiently suppressed transcription of the pro-inflammatory marker genes
chemokine (C-C motif) ligand 2 (CCL2), interleukin 6 (IL6) and inducible nitric oxide (NO)-synthase (iNOS). Moreover,
treatment with XBD173 significantly reduced the migratory capacity and proliferation of microglia, their level of NO
secretion and their neurotoxic activity on 661 W photoreceptor cells. Furthermore, XBD173 treatment of murine and
human microglial cells promoted the formation of filopodia and increased their phagocytic capacity to ingest latex beads
or photoreceptor debris. Finally, treatment with XBD173 reversed the amoeboid alerted phenotype of microglial cells in
explanted organotypic mouse retinal cultures after challenge with LPS.
Conclusions: These findings suggest that TSPO is highly expressed in reactive retinal microglia and a promising target to
control microglial reactivity during retinal degeneration.
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Background
The translocator protein (18 kDa) (TSPO), previously
known as the peripheral benzodiazepine receptor, is an
integral part of the outer mitochondrial membrane [1]
where it forms a complex with other mitochondrial pro-
teins, such as the voltage-dependent anion channel
(VDAC) and the adenine nucleotide transporter (ANT)
[2]. TSPO mediates the transport of cholesterol into the
inner mitochondrial membrane, where it serves as a
precursor for steroids and neurosteroids [3]. Hence, the
protein is constitutively expressed in steroidogenic tis-
sues such as the adrenal gland, the gonads and the brain
[4]. In the central nervous system TSPO is present both
in neurons and activated glial cells [5-7]. Endogenous
ligands of TSPO are cholesterol, porphyrins and active
peptide fragments cleaved off from the diazepam binding
inhibitor [8]. Glial up-regulation of TSPO is a major hall-
mark of neurodegenerative diseases [9] and various TSPO
ligands have been developed as molecular markers to detect
gliosis by means of Positron Emission Tomography (PET)
imaging [10].
TSPO ligands are also under investigation as treatment
options for a variety of neurological disorders, including
Alzheimers disease [11], multiple sclerosis [12], neuro-
pathic pain [13], peripheral nerve injury [9] and anxiety
disorders [14]. Classical synthetic TSPO ligands, such
as the benzodiazepine derivative 4-chlorodiazepam
(Ro5-4864) and the isoquinoline carboxamide PK11195,
directly enhance GABAergic neurotransmission [15].
TSPO ligands such as etifoxine and XBD173 (emapunil)
stimulate the synthesis of neurosteroids and may exert
anti-inflammatory and neuroprotective effects [16].
Inherited retinal degenerations are clinically and genetic-
ally heterogeneous diseases characterized by progressive
vision loss [17]. Although the individual mechanisms of
pathogenesis remain to be resolved, microglial activation
is a common hallmark of retinal degeneration [18]. The
retinoschisin-deficient (Rs1h-/Y) mouse is a prototypic
model for inherited retinal dystrophies with strong micro-
glial reactivity [19,20]. Modulation of retinal microglia
with docosahexaenoic acid could dampen microglial
reactivity in Rs1h-/Y mice and thereby reduced retinal
degeneration [21]. TSPO ligands could potentially have a
similar effect and may target the neurodegenerative cas-
cade via their anti-inflammatory and microglia modulating
effects.
In this study, we showed that TSPO expression is
directly connected to retinal microgliosis in a mouse
model of retinal degeneration and in human retinal sec-
tions. Moreover, we demonstrated that the TSPO ligand
XBD173 induces an anti-inflammatory, neuroprotective
and pro-phagocytic phenotype in microglia using cul-
tures of murine and human microglial cell lines as well
as mouse retinal explants.
Methods
Animals
MacGreen [22], Rs1h-/Y [19] and wild-type mice were all
on a pure C57BL/ 6 J background. Animals were main-
tained in an air-conditioned environment on a 12-hour
lightdark schedule at 22°C, and had free access to food
and water. The health of the animals was regularly moni-
tored, and all procedures complied with the German Law
on Animal Protection and the Institute for Laboratory
Animal Research Guide for the Care and Use of Laboratory
Animals, 2011.
Human tissue
Retinal samples of donors were obtained from the Eye
Bank of the Center of Ophthalmology, University of
Cologne, Germany. The donor age ranged between 54
and 72 years. Postmortem time ranged between 5 and
36 h. After dissection of the anterior segment, the
remaining tissue included the posterior pole. The re-
search followed the tenets of the Declaration of Helsinki.
Reagents
E. coli 0111:B4 lipopolysaccharide and aminoglutethi-
mide were purchased from Sigma Aldrich (St. Louis,
MO, USA). XBD173 (emapunil) was obtained by custom
synthesis from APAC Pharmaceuticals (Ellicott City,
MD, USA). XBD173 was dissolved in ethanol.
Cell culture and retinal explants
BV-2 microglia-like cells were cultured in RPMI/5% fetal
calf serum (FCS) supplemented with 2 mM L-Glutamine
and 195 nM β-mercaptoethanol. Isolation and culture of
primary retinal microglia has been described previously
[21]. BV-2 cells were stimulated with 50 ng/ml lipopoly-
saccharide (LPS) and various concentrations of XBD173
or ethanol as vehicle control. 661 W photoreceptor-
like cells were a gift from Prof. Muayyad Al-Ubaidi
(Department of Cell Biology, University of Oklahoma
Health Sciences Center, Oklahoma City, OK, USA) and
the culture conditions have been described elsewhere
[23]. Human microglial cell lines (iPSdM) were gener-
ated from induced pluripotent stem (iPS) cell lines ob-
tained by reprogramming from skin fibroblasts as
previously described [24,25]. These cells proliferate without
addition of growth factors and they were passaged 1:3 twice
a week. The microglial phenotype was confirmed by flow
cytometry (CD11b, CD16/32, CD36, CD45, CX3CR1). Ret-
inas from MacGreen mice were rinsed in DMEM/Hams
F12 medium supplemented with 1% FCS and placed on
25 mm circular Nucleopore filters (VWR, Darmstadt,
Germany) with the photoreceptor side facing the mem-
brane. After 24 h of in vitro culture with vehicle, 1 μg/ml
LPS, 20 μM XBD173 or 1 μg/ml LPS + 20 μM XBD173,
retinas were fixed and imaged in flat-mounts. Ramified and
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amoeboid microglial cells were directly imaged by
green fluorescent protein (GFP) fluorescence using the
Axioskop2 MOT Plus Apotome microscope (Carl Zeiss,
Jena, Germany) and counted.
Scratch wound-healing assay
A total of 400,000 BV-2 microglial cells were grown in
six-well plates as 80% confluent monolayers and were
wounded with a sterile 100 μl pipette tip. Thereafter, the
cells were stimulated with 50 ng/ml LPS, 50 μM
XBD173, 50 ng/ml LPS + 50 μM XBD173, or ethanol as
solvent control. Migration into the open scar was docu-
mented with microphotographs taken at different time
points after wounding using a Nikon ECLIPSE TE2000
inverted microscope (Nikon, Tokyo, Japan). The number
of migrating cells was quantified by counting all cells
within a 0.4 mm2 region in the center of each scratch.
The number of migrated cells was then normalized to
the average cell density to account for changes in prolif-
eration. A minimum of five individual cultures was used
to calculate the mean migratory capacity of each cell
culture condition.
Proliferation assay
For carboxyfluorescein diacetate succinimidyl ester (CFSE)
proliferation assays, BV-2 microglial cells were labeled with
1 μM CFSE (e-Bioscience, San Diego, CA, USA) and
cultured (1.5 × 105 per well) in a six-well plate. After 24 h
of culture with vehicle, 100 ng/ml LPS, 50 μM XBD173 or
100 ng/ml LPS + 50 μM XBD173, cells were stained with a
fixable viability dye (e-Bioscience), to exclude dead cells
from the analysis. The fluorescence intensity of CFSE-
labeled BV-2 cells was analyzed by flow cytometry (FACS
Canto II). Analysis of cell division was performed using
FlowJo software (Treestar Inc., Ashland, OR, USA).
shRNA knock-down of TSPO in BV-2 cells
For knockdown of endogenous TSPO in BV-2 cells,
shRNA vectors were obtained from the RNAi consor-
tium (TRC). Briefly, BV-2 cells were transfected with
2.5 μg vector DNA using TransIT®-LT1 transfection re-
agent (Mirus Bio LLC, Madison, WI, USA) to express
TSPO-specific or scrambled shRNAs. Twenty-four hours
after transfection cells were stimulated with vehicle,
50 ng/ml LPS, 20 μM XBD173 or 50 ng/ml LPS + 20 μM
XBD173 for 12 hours before cells were harvested for
RNA isolation and mRNA expression analysis.
661 W photoreceptor apoptosis assay
To test microglial neurotoxicity, a culture system of 661 W
photoreceptors with microglia-conditioned medium was
established. 661 W photoreceptor cells were incubated for
48 h either in their own medium or with culture superna-
tants from unstimulated, 50 ng/ml LPS, 50 μM XBD173 or
50 ng/ml LPS + 50 μM XBD173 treated microglial cells.
The 661 W cell morphology was assessed by phase contrast
microscopy and apoptotic cell death was determined with
the Caspase-Glo® 3/7 Assay (Promega GmbH, Mannheim,
Germany). Cells were lysed and incubated with a lumino-
genic caspase-3/7 substrate, which contains the tetrapeptide
sequence DEVD. Luminescence was then generated by
addition of recombinant luciferase and was proportional to
the amount of caspase activity present. The luminescent
signal was read on an Infinite F200 pro plate reader (Tecan,
Crailsheim, Germany). A blank reaction was used to meas-
ure background luminescence associated with the cell
culture system and Caspase-Glo® 3/7 Reagent (Promega).
The value for the blank reaction was subtracted from all
experimental values. Negative control reactions were per-
formed to determine the basal caspase activity of 661 W
cells. Relative luciferase units (RLU) reflect the level of
apoptotic cell death in the different 661 W cell cultures.
Nitrite measurement
Nitric oxide concentrations were determined by measur-
ing the amount of nitrite produced by BV-2 microglial
cells into the culture medium using the Griess reagent
system (Promega). A 50 μl cell culture supernatant was
collected and an equal volume of Griess reagent was
added to each well. After incubation for 15 minutes at
room temperature, the absorbance was read at 540 nm
on an Infinite F200 pro plate reader (Tecan). The con-
centration of nitrite for each sample was calculated from
a sodium nitrite standard curve.
Phagocytosis assays
BV-2 microglial cells were pre-treated for 2 h with
compounds before 4 μl latex bead solution (Polystyrene
microparticles, Sigma Aldrich, St. Louis, MO, USA) was
added to the wells. Cells were incubated for 6 h and five
micrographs per well were taken using an AxioVert.A1
inverted microscope (Carl Zeiss). The phagocytic activity
was determined by calculating the number of cells which
phagocytosed 10 or more latex beads compared to all
cells per field. The conditions for human microglial cells
(iPSdM) were the same with the modification that cells
were pre-treated for 24 h, the incubation time with
beads was 24 h and only fully saturated cells were
counted as positive. To study the microglial uptake of
apoptotic photoreceptor cell material, 661 W photo-
receptor cells were starved with serum deprivation,
harvested and fluorescently labeled using CellTracker
CM-DiI (Invitrogen, Carlsbad, CA, USA). For phagocyt-
osis, BV-2 microglial cells were pre-treated for 2 h with
compounds before 400 μl stained apoptotic 661 W solu-
tion was added for further 6 h. iPSdM cells were pre-
treated for 24 h before 400 μl stained apoptotic 661 W
solution was added for further 24 h. Cells were then
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fixed and nuclei were stained with 4,6-diamidino-2-
phenylindole. Fluorescence micrographs were taken and
ImageJ software (National Institutes of Health, Bethesda,
MD, USA) was used to determine the ratio of phagocy-
tosed apoptotic photoreceptor fragments (red signal)
relative to the total microglia cell number (DAPI signal).
Phalloidin staining
BV-2 microglial cells or human microglial cells (iPSdM)
were grown on cover slips in six-well plates and the
indicated compounds were added for 24 h. Thereafter,
the cells were fixed, permeabilized with 0.1% Triton
X-100 and f-actin was fluorescently labeled using 0.1 μg/
ml Phalloidin-TRITC (Sigma). The nuclei were stained
using 4,6-diamidino-2-phenylindole and photomicro-
graphs were taken with an Axioskop2 MOT Plus Apotome
microscope (Carl Zeiss).
Immunohistochemistry
Immunohistochemical analyses were performed on
10 μm retinal sections embedded in optimal cutting
temperature (OCT) compound (Hartenstein, Würzburg,
Germany) or on retinal flat mounts. Samples were fixed
in 4% paraformaldehyde, rinsed and rehydrated with
PBS. Sections were blocked with a dried milk solution
followed by an overnight incubation with primary
antibodies at 4°C. Antibodies included rabbit anti-Iba1
antibody (Wako Chemicals, Neuss, Germany), rabbit
anti-TSPO antibody (Abcam, Cambridge, UK), goat
anti-MAP2 antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), and goat anti-GFAP antibody (Santa
Cruz Biotechnology). After washing, samples were la-
beled with a secondary antibody conjugated to Alexa488
(green) or Alexa594 (red) (Jackson Immuno-Research,
West Grove, PA, USA) and counter-stained with DAPI.
Sections and flat-mounts were mounted in DAKO fluor-
escent mounting medium (Dako Deutschland GmbH,
Hamburg, Germany) and viewed with an Axioskop2
MOT Plus Apotome microscope (Carl Zeiss).
Western blot analysis
Mouse retinal tissue was homogenized in cold RIPA buf-
fer (20 mM Na-phosphate buffer, 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100 and protease inhibitors) using a
TissueLyser LT (Qiagen, Hilden, Germany). Insoluble
debris was removed by centrifugation for 15 minutes at
16,000 g. LPS-treated and control BV-2 microglia were
directly lysed in RIPA buffer. Protein concentrations
were determined by Bradford assay (Roti-quant, Roth,
Karlsruhe, Germany). A total of 10 μg of microglial or
30 μg of total-retina proteins were separated by SDS-
PAGE on 15% gels with PageRuler pre-stained protein
ladder (Thermo Scientific, Waltham, MA, USA). Pro-
teins were then transferred to 0.45 μm nitrocellulose
membranes (Biorad, Munich, Germany). After blocking
in TBS-T containing 5% nonfat dry milk, membranes
were incubated with primary antibodies against TSPO
(ab109497, Abcam,) or Actin (sc-1616, Santa Cruz
Biotechnology). Blots were then incubated with sec-
ondary goat anti-rabbit IgG-HRP or rabbit anti-goat
IgG-HRP antibodies (sc-2004, sc-2768, Santa Cruz
Biotechnology). Enhanced chemiluminescence signals
were then visualized and imaged with the MultiImage
II system (Alpha Innotech, Santa Clara, CA, USA).
RNA isolation and reverse transcription
Total RNA was extracted from total retina, BV-2 micro-
glial cells or isolated retinal microglia according to the
manufacturers instructions using the RNeasy Mini Kit
(Qiagen). Purity and integrity of the RNA was assessed
on the Agilent 2100 Bioanalyzer with the RNA 6000
Nano LabChip® reagent set (Agilent Technologies, Santa
Clara, CA, USA). The RNA was quantified spectro-
photometrically and then stored at −80°C. First-strand
cDNA synthesis was performed with the RevertAid™ H
Minus First Strand cDNA Synthesis Kit (Fermentas,
Schwerte, Germany).
Quantitative real-time RT-PCR
Amplifications of 50 ng cDNA were performed with
an ABI7900HT machine (Applied Biosystems, Carlsbad,
CA, USA) in 10 μl reaction mixtures containing 1 ×
TaqMan Universal PCR Master Mix (Applied Biosys-
tems), 200 nM of primers and 0.25 μl of dual-labeled
probe (Roche ProbeLibrary, Roche Applied Science,
Basel, Switzerland). The reaction parameters were as fol-
lows: 2 minutes 50°C hold, 30 minutes 60°C hold and 5
minutes 95°C hold, followed by 45 cycles of 20 s 94°C
melt and 1 minute 60°C anneal/extension. Primer se-
quences and Roche Library Probe numbers were as fol-
lows: CCL2, forward primer 5-catccacgtgttggctca-3,
reverse primer 5-gatcatcttgctggtgaatgagt-3, probe #62;
IL6, forward primer 5-gatggatgctaccaaactggat-3, re-
verse primer 5-ccaggtagctatggtactccaga-3, probe #6;
iNOS, forward primer 5-ctttgccacggacgagac-3, reverse
primer 5- tcattgtactctgagggctga-3, probe #13. Measure-
ments were performed in triplicates and results were an-
alyzed with an ABI sequence detector software version
2.3 using the ΔΔCt method for relative quantification.
Pregnenolone ELISA
BV-2 cells were seeded on 24-well plates in 1 ml/well of
RPMI/5% FCS supplemented with 2 mM L-Glutamine
and 195 nM β-mercaptoethanol. After cells had attached
after 6 h, 50 ng/ml LPS and/or 20 μM XBD173 were
added to each well. After 21 h, cells were washed twice
with HEPES assay buffer (140 mM NaCl, 5 mM KCl,
1.8 mM CaCl2, 1 mM MgSO4, 10 mM glucose, 10 mM
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HEPES/NaOH, pH 7.4) as described previously [26].
Then 1 ml of HEPES assay buffer supplemented with
BSA (0.1%) and Trilostane (25 μM) (Sigma-Aldrich)
was added to each well. Again 50 ng/ml LPS and/or
20 μM XBD173 were added. After 3 h the supernatants
were removed to perform pregnenolone ELISA accord-
ing to the manufacturers recommendations (IBL
International, Hamburg, Germany). In brief, 50 μl
of each sample were pipetted into a rabbit anti-
pregnenolone antibody coated 96-microwell Plate. A
total of 100 μl of pregnenolone-HRP conjugate was
then added. Ready-to-use-calibrators were provided by
IBL international. After 1 h of incubation and washing
150 μl of tetramethylbenzidine/hydrogen peroxide
(TMB) substrate was added. Assays were read with a
Tecan Spectra at 450 nm. Data were analyzed by
Magellan Data Analysis Software (Tecan).
Statistical analyses
Real-time quantitative RT-PCR data were analyzed
with the ΔΔCt method using an unpaired Students
t-test. Assays for nitrite secretion, microglial migration
and pregnenolone ELISAs were analyzed with an
unpaired Students t test. Caspase 3/7 assays and
phagocytosis assays were analyzed with a Mann
Whitney U-test. P <0.05 was considered as statistically
significant.
Results
Induction of TSPO expression in activated microglia of
the retina
To identify genes regulated during activation of microglia,
we have previously performed DNA microarray analysis
of isolated retinal microglial cells from degenerating
retinoschisin-deficient (Rs1h-/Y) and control macrophage/
microglia MacGreen reporter mice [21]. Among the differ-
ently expressed transcripts, a significantly increased mRNA
expression of TSPO was detected in activated retinal
microglia (data not shown). Therefore, we determined the
protein expression of TSPO in the retina and found a weak
expression in the MacGreen reporter mouse, which was
present in ramified microglia of the plexiform layers and
astrocytes of the ganglion cell layer (Figure 1A-C). How-
ever, there was a remarkable increase of TSPO expression
specifically in microglia of MacGreen/Rs1h-/Y retinas
(Figure 1D-F). Notably, there was nearly a full overlap of
TSPO signals with amoeboid microglial cells which mi-
grated to the degenerating inner nuclear layer (Figure 1F).
In the human retina, TSPO expression was also evident in
inner plexiform layer microglial cells as demonstrated
by Iba1 co-immunostaining as well as in astrocytes
(Figure 1G-I). To exclude that TSPO is significantly
expressed in Müller cells or retinal neurons, immunos-
tainings for glial fibrillary acid protein (GFAP) and
microtubule-associated protein 2 (MAP2) were per-
formed. Neither wild-type retinas nor Rs1h-/Y retinas
Figure 1 TSPO expression as a marker for microgliosis in degenerating and aging retinas. In MacGreen mice, representative
photomicrographs show low TSPO expression in retinal microglia (green GFP signal and red TSPO immunofluorescence) and constitutive
expression in astrocytes (red TSPO immunofluorescence) (A-C) but strong up-regulation in retinal microglia from MacGreen/Rs1h-/Y mice (D-F).
The overlap of TSPO and Iba1 immunostaining also indicates co-expression in human retinal microglia (G-I). TSPO immunostaining staining does
not co-localize with the Müller cell marker GFAP (J, K) or the neuronal microtubule marker MAP2 (L, M). ONL, outer nuclear layer; OPL, outer
plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer, GFP, green fluorescent protein; TSPO, translocator
protein (18 kDa); GFAP, glial fibrillary acid protein; MAP2, microtubule-associated protein 2. Scale bar, 50 μm.
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displayed an overlap of TSPO signals with GFAP
(Figure 1J, K) or MAP2 (Figure 1L, M), respectively.
To further verify the steep TSPO expression in react-
ive microglia, mRNA analysis of isolated retinal micro-
glia from MacGreen and MacGreen/Rs1h-/Y retinas was
performed. There was a strong and significant increase of
TSPO mRNA in MacGreen/Rs1h-/Y microglia (12.01 ±
0.82, P <0.01) compared to MacGreen microglia (1.0 ±
1.07) (Figure 2A). TSPO induction was also confirmed on
the protein level when total retinas of MacGreen/Rs1h-/Y
mice compared to MacGreen mice were analyzed
(Figure 2B). We next performed TSPO transcript ana-
lysis in early postnatal development of the mouse
retina. TSPO was present at higher levels in early
retinal development and turned to lower levels in the
adult retina (Figure 2C). We then analyzed whether the
induction of TSPO expression is also present in cul-
tured BV-2 microglia, which were activated by LPS.
Treatment of BV-2 cells with 50 ng/ml LPS elicited a
highly significant increase in TSPO levels (4.11 ± 0.31,
P <0.001) compared to vehicle-treated BV-2 cells
(1.0 ± 0.80) (Figure 2D). The increase of TSPO in LPS-
activated BV-2 microglia was also confirmed on the
protein level using Western blot analysis (Figure 2E).
The selective TSPO ligand XBD173 dampens pro-
inflammatory and neurotoxic microglial activation
We investigated whether stimulation of TSPO with the se-
lective ligand XBD173 influences microglial reactivity. We
first tested the mRNA expression of the chemo-attractant
protein CCL2, the pro-inflammatory cytokine IL6 and
iNOS in LPS-activated microglia upon treatment with three
different doses of XBD173. The TSPO ligand significantly
and dose-dependently suppressed mRNA levels of CCL2
(Figure 3A, P = 0.0014 for 20 μM XBD173 and P = 0.0003
for 50 μM XBD173 versus vehicle control), IL6 (Figure 3B,
P = 0.0004 for 20 μM XBD173 and P = 0.0001 for 50 μM
XBD173 versus vehicle control), and iNOS (Figure 3C,
P = 0.0104 for 20 μM XBD173 and P = 0.0004 for 50 μM
XBD173 versus vehicle control).
To test whether the anti-inflammatory effect of
XBD173 depends on TSPO expression, shRNA mediated
knock-down of TSPO was performed. Transfection of
BV-2 cells with two different TSPO-specific shRNAs
showed a 50 to 60% knock-down of TSPO mRNA levels
compared to a scramble control (data not shown). The
mRNA expression levels of CCL2 (Figure 3D), IL6
(Figure 3E) and iNOS (Figure 3F) were no longer
suppressed by XBD173 treatment when either shRNA1
or shRNA2 that specifically target TSPO were present.
This clearly implicates that the suppressing effect of
XBD173 acts via TSPO in BV-2 cells.
When co-administered together with 50 ng/ml LPS,
50 μM XBD173 also strongly diminished NO-production
from BV-2 microglial cells compared to vehicle-treated cells
(Figure 3G, P <0.0001). We then performed an apoptosis
assay of 661 W photoreceptor cells incubated in the
presence of microglia-conditioned medium. LPS-activated
microglial cells incubated in the presence of 50 μM
XBD173 had a significantly lower pro-apoptotic effect on
photoreceptor cells than microglia cultured with vehicle
(Figure 3H, P <0.0022).
We then analyzed the effect of the TSPO ligand on
microglial migration. Stimulation of BV-2 microglial cells
Figure 2 TSPO mRNA and protein expression in reactive microglia. (A) Strong induction of TSPO mRNA levels in isolated microglial cells
from MacGreen/Rs1h-/Y mice compared to MacGreen mice. (B) TSPO protein induction in total retinas from MacGreen/Rs1h-/Y mice compared to
MacGreen mice. (C) Temporal TSPO mRNA expression profiling shows a high early postnatal expression level and continuous decline to low
levels in adult mouse retinas. (D, E) LPS activation of BV-2 microglial cells leads to the induction of TSPO transcripts (D) and protein (E). Data
show mean ± SD (n = 3/group, measured in triplicates) **P <0.01 MacGreen/Rs1h-/Y versus MacGreen; ***P <0.001 BV-2 + 50 ng/ml LPS versus BV-
2. LPS, lipopolysaccharide; TSPO, translocator protein (18 kDa).
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with 50 μM XBD173 strongly reduced the migration of BV-
2 cells in a wound-healing scratch assay (Figure 4A). This
effect was quantified and significant in non-activated
microglia (Figure 4B, P <0.0008) as well as LPS-
preactivated BV-2 cells (Figure 4B, P <0.0406). We
constantly noticed a reduced cell number in our culture
assays and, therefore, tested a potential anti-mitotic effect
of XBD173. CFSE labeling and FACS analyses clearly dem-
onstrated that XBD173 reduced the proliferation rate of
both unstimulated and LPS-treated BV-2 cells (Figure 4C).
Figure 3 The TSPO agonist XBD173 dampens gene transcription of pro-inflammatory markers and reduces microglial neurotoxicity.
LPS-activated BV-2 microglial cells were cultured in the presence of various concentrations of XBD173 for 24 h and the pro-inflammatory
transcript markers CCL2 (A), IL6 (B), iNOS (C) were determined by real time qRT-PCR. Data show mean ± SD (n = 3/group, measured in triplicates)
*P <0.05, **P <0.01, ***P <0.001 XBD173 + LPS versus LPS-treated cells. (D-F), Knock-down of TSPO with two independent shRNAs abrogates the
suppressing effects of XBD173 on CCL2 (D), IL6 (E) and iNOS (F) gene expression in BV-2 cells. (G), Production of NO as determined by detection
of nitrite from BV-2 microglial cells treated with 50 μM XBD173 in the absence or presence of 50 ng/ml LPS. Data show mean ± SD (n = 9/group)
***P <0.001 XBD173 + LPS versus LPS-treated cells. (H), 661 W photoreceptor cell cultures were treated with conditioned media from BV-2
microglial cells for 48 hours. The supernatant from control-stimulated, 20 μM XBD173-treated, 50 ng/ml LPS-treated, or 20 μM XBD173 + 50 ng/ml
LPS-treated cells was added to 661 W photoreceptor cells and apoptosis-related caspase 3/7 activation was determined. Data show mean ± SD
(n = 6/group) **P <0.01 XBD173 + LPS versus LPS-treated cells. CCL2, (C-C motif) ligand 2; IL6, interleukin-6; iNOS, inducible nitric oxide synthase;
LPS, lipopolysaccharide; NO, nitric oxide.
Figure 4 The TSPO agonist XBD173 reduces microglial migration and proliferation. (A) Scratch assay to mimic wound-healing in cultured
BV-2 microglia treated with vehicle, 50 ng/ml LPS, 50 μM XBD173 or both. Microphotographs from scratched areas were quantified 8 h after
treatment (B). Data show mean ± SEM (n = 5/group) *P <0.05 XBD173 versus control, *P <0.001 XBD173 + LPS versus LPS-treated cells. (C), CFSE-
based proliferation assay of BV-2 microglial cells treated with vehicle, 100 ng/ml LPS, 50 μM XBD173 or 100 ng/ml LPS + 50 μM XBD173. The pro-
liferation rate of BV-2 microglia was analyzed 24 hours after treatment using flow cytometry and a representative graph out of four repetitions is
shown. CFSE, carboxyfluorescein diacetate succinimidyl ester; LPS, lipopolysaccharide; TSPO, translocator protein (18 kDa).
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XBD173 increases filopodia formation and phagocytosis
in murine and human microglia
To investigate further functional consequences of treat-
ment with the TSPO ligand, we tested the effects of
TSPO activation on the morphology and phagocytosis of
murine BV-2 microglia and human microglial cells
(iPSdM) derived from human induced pluripotent stem
cells. Staining of the f-actin cytoskeleton with phalloidin
indicated that XBD173 caused a prominent formation of
filopodia in murine BV-2 cells either in the absence or
presence of LPS (Figure 5A-D). This effect was even
more pronounced in human iPSdM, which showed a
large rim of flattened filopodia (Figure 5E-H).
This striking phenomenon of XBD173-induced filo-
podia formation prompted us to analyze the phagocytic
capacity in detail using latex beads and CM-DiI-stained
apoptotic 661 W photoreceptor material as a more
physiological trigger. BV-2 microglial cells stimulated
with XBD173 showed a significantly higher phagocytosis
rate of latex beads in non-activated cells (Figure 6A, B,
P = 0.0013) as well as LPS-preactivated cells (Figure 6A,
B, P = 0.0029). A similar effect of XBD173 was noticed
with fluorescent apoptotic 661 W photoreceptors in
non-activated (Figure 6C, D, P = 0.0192) and LPS-
incubated BV-2 cells (Figure 6C, D, P = 0.0013). XBD173
had a similar stimulating effect on the phagocytic poten-
tial of human microglial cells with strongly increased
uptake of latex beads (Figure 6E, F, P <0.0001) and CM-
DiI-stained apoptotic 661 W membranes (Figure 6G, H,
P <0.0001).
To test whether the phenomenon of XBD173-induced
phagocytosis is dependent on neurosteroid synthesis, we
first quantified pregnenolone levels in BV-2 cells. Stimu-
lation of BV-2 microglia with either 20 μM XBD173
alone (Figure 7A, P <0.0005) or together with 50 ng/ml
LPS (Figure 7A, P <0.0074) strongly increased pregneno-
lone levels measured in the cell culture supernatant. We
next performed bead phagocytosis assays with BV-2 cells
stimulated with 20 μM XBD173 in the presence or ab-
sence of the CYP11A1 inhibitor aminoglutethimide. As
previously shown in Figure 6, BV-2 cells stimulated with
XBD173 showed a higher phagocytosis potential than
control cells (Figure 7B, P <0.0001). Interestingly, this
effect was completely prevented when the cells were co-
incubated with 20 μM XBD173 and 100 μM aminoglu-
tethimide (Figure 7B). These data suggest that the
phagocytosis promoting effect of XBD173 requires preg-
nenolone synthesis.
XBD173 reduces the number of LPS-alerted amoeboid
microglia in living retinal explants
Finally, we analyzed whether the XBD173-dependent
morphological transformation of microglial cells can
also be observed in the ex vivo retina. Retinas from
MacGreen reporter mice were used to enable easy GFP-
based analysis of microglial ramification. Retinal explants
cultured for 24 h in vitro retained their ramified morph-
ology (Figure 8A) and the microglial network was not
significantly affected by XBD173 alone (Figure 8B). In
contrast, retinal microglia dramatically changed their
morphology in the presence of LPS with a large fraction
of bloated amoeboid cells (Figure 8C). This LPS-induced
morphological transition of microglia was effectively
suppressed by XBD173 (Figure 8D). We then performed
a quantitative analysis of ramified and amoeboid micro-
glial cells in all retinal explants. As already indicated in
Figure 7A-D, the number of amoeboid cells was signifi-
cantly increased in LPS-treated cultures compared
to vehicle-treated explants (Figure 8E, P = 0.0012).
Interestingly, co-incubation of explants with LPS and
XBD173 resulted in a strongly reduced number of
alerted amoeboid microglia cells (Figure 8E, P <0.0001).
Thus, XBD173 was not only able to influence microglial
reactivity in vitro but also significantly affected microglia in
living mouse retinas.
Figure 5 The TSPO ligand XBD173 promotes microglial filopodia formation. (A-D) Representative images of phalloidin-stained murine BV-2
microglial cells treated with 50 μM XBD173 in the absence or presence of 50 ng/ml LPS. (E-H) Representative images of phalloidin-stained human
iPS-derived microglia (iPSdM) treated with 30 μM XBD173 in the absence or presence of 250 ng/ml LPS. LPS, lipopolysaccharide; TSPO,
translocator protein (18 kDa).
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Discussion
Based on its selective expression in activated glial cells
of the brain, TSPO is a marker for brain gliosis and
TSPO ligands have been developed for in vivo imaging
in human and mouse [27,28]. In the present study, we
now show that selective up-regulation of TSPO is closely
associated with the reactivity of microglia during retinal
degeneration. To our knowledge, this is the first report
to identify TSPO as a biomarker of activated microglia
both in mouse and human retinal tissue. Major ques-
tions are why and how TSPO is up-regulated in reactive
retinal microglia. Microgliosis in the retina of a mouse
model of retinoschisin-deficiency starts at postnatal Day
14, peaks at P21 and then declines to lower levels [29].
The peak of microglial reactivity perfectly overlaps with
high induction of TSPO expression levels. In the brain,
TSPO detects activation of both microglia and astrocytes
as a result of injury but also during recovery from injury
[30,31], indicating that the presence of TSPO on acti-
vated glia may be a self-limiting mechanism of activation
and proliferation. Our data of up-regulated TSPO ex-
pression in LPS-stimulated BV-2 microglia revealed that
TLR4 signaling may play a crucial role in TSPO induc-
tion. In line with our experiments, up-regulation of
TSPO in the recovery phase from neuropathic pain was
prevented by pharmacological blockade of TLR4 [13].
We, therefore, hypothesize that retinal damage and the
presence of damage-associated molecular patterns may
trigger TLR4 signaling on microglia and thereby influ-
ence TSPO expression.
Our experiments demonstrate that the selective TSPO
ligand XBD173 efficiently reversed the LPS-triggered
Figure 6 The TSPO ligand XBD173 increases microglial phagocytosis. Phagocytosis was monitored in BV-2 cells incubated with latex beads
(A, B) or CM-DiI-stained apoptotic 661 W photoreceptor material (C, D). Data show mean ± SEM (n = 9/group) **P <0.01 XBD173 + LPS versus
LPS-treated cells, *P <0.05 XBD173 versus vehicle-treated cells. Phagocytosis was monitored in human iPSdM cells incubated with latex beads
(E, F) or CM-DiI-stained apoptotic 661 W photoreceptor material (G, H). Data show mean ± SEM (n = 9/group) ***P <0.01 XBD173 + LPS versus
LPS-treated cell and XBD173 versus vehicle-treated cells. LPS, lipopolysaccharide; TSPO, translocator protein (18 kDa).
Figure 7 The TSPO ligand XBD173 increases pregnenolone levels and CYP11A1 inhibition prevents XBD173-induced phagocytosis. (A)
Pregnenolone levels in cell culture supernatants of BV-2 cells treated with 20 μM XBD173, 50 ng/ml LPS, or 20 μM XBD173 + 50 ng/ml LPS for 24
hours. Data show mean ± SD (n = 3/group) ***P <0.001 XBD173 versus vehicle-treated cells, **P <0.01 XBD173 + LPS versus LPS-treated cells. (B)
Quantification of latex bead phagocytosis of BV-2 cells treated with 20 μM XBD173 or 20 μM XBD173 + 100 μM aminoglutethimide for 24 hours.
Data show mean ± SEM (n = 30/group) ***P <0.0001 XBD173 versus control cells. LPS, lipopolysaccharide; TSPO, translocator protein (18 kDa).
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production of the pro-inflammatory mediators CCL2,
IL6 and iNOS. The TSPO ligand and mitochondrial
effector PK11195 effectively inhibited LPS-induced
microglial expression of COX-2 and TNF-alpha via
modulation of Ca2+-mediated signaling pathways [32].
The same compound reduced the expression of pro-
inflammatory cytokines and neuronal apoptosis in
quinolinic-acid-treated rat brain [33]. These findings
together with our data on the global influence of
XBD173 on gene expression revealed that targeting
TSPO has a broad influence on inflammatory signaling
in microglia. As we have shown in microglial cell
culture, one potential mechanism of the effects of
XBD173 could be the synthesis of pregnenolone, as
has been previously shown for astrocytes [34]. These
findings support the concept that microglia locally
synthesize the anti-inflammatory neurosteroid precursor
pregnenolone after activation of TSPO by respective
ligands.
Our studies revealed that TSPO significantly influenced
the f-actin cytoskeleton and fostered the formation of
filopodia along with prominent effects on microglial migra-
tion and phagocytosis. A high phagocytic activity with a
low migratory capacity is a typical hallmark of homeostatic
microglia which constantly survey their environment with
long protrusions [35]. Over the last years it has also become
clear that microglial phagocytosis of apoptotic cells is
largely anti-inflammatory [36]. Thus, we hypothesize that
induction of TSPO signaling may shift alerted microglia to
a more homeostatic and less inflammatory state. In line
with this, TSPO ligands have been shown to influence
chemotaxis and phagocytosis in peripheral blood cells
[37-39]. TSPO overexpression also increased the prolifera-
tion and migratory capacity of rat C6 glioma cells whereas
treatment with the TSPO ligand PK11195 had a strong
anti-proliferative effect and exerted pro-apoptotic activity
on these cells [40]. Treatment of LPS-challenged microglia
with XBD173 could effectively reduce the number of
amoeboid cells in the explanted mouse retina but did not
significantly increase the fraction of ramified cells. This
clearly indicates that TSPO signaling may serve to control
microglia dynamics during the activation and/or resolution
phase of retinal damage. In the native retina, endogenous
ligands for TSPO may fulfill this function. Several endogen-
ous molecules that bind TSPO have been identified in
steroidogenic tissues, including the protein diazepam
binding inhibitor (DBI) [41]. DBI can be cleaved into sev-
eral active peptide fragments such as octadecaneuropeptide
(ODN) and trikontatetraneuropeptide (TTN) which are
released from astrocytes [10]. TTN then stimulates neuro-
synthesis in C6 glioma cells by acting on TSPO [8]. Thus,
we hypothesize that either retinal astrocytes or Müller cells
may express DBI and secrete active peptides to control
microglial activity via targeting of TSPO.
Conclusions
We have shown that TSPO is highly expressed in react-
ive retinal microglia and BV-2 cells stimulated with
LPS. The selective TSPO ligand XBD173 efficiently
dampened pro-inflammatory gene expression in BV-2
microglial cells and reduced their neurotoxic potential
on 661 W photoreceptor cells. XBD173 treatment of
BV-2 cells and human iPS-derived microglial cells also
promoted filopodia formation and phagocytic uptake.
In the explanted mouse retina, XBD173 treatment
blocked the LPS-dependent accumulation of amoeboid
microglial cells. In conclusion, our data implicate that
TSPO expression is connected to retinal microglia re-
activity and that selective TSPO ligands may be a
promising therapeutic approach to dampen microglio-
sis during retinal degeneration.
Figure 8 The TSPO ligand XBD173 reduces the number of alerted amoeboid retinal microglia ex vivo. (A-D) Representative GFP images
of the retinal microglia network in explanted mouse retinas treated for 24 hours with vehicle (A), 20 μM XBD173 (B), 1 μg/ml LPS + vehicle (C)
and 1 μg/ml LPS + 20 μM XBD173 (D). (E) Quantification of ramified and amoeboid microglial cells in 10 independent image areas of two
individual flat mounts (mean ± SEM). **P <0.01 for amoeboid cells in LPS versus control explants; ***P <0.0001, for amoeboid cells in XBD173 +
LPS versus LPS-treated explants. GFP, green fluorescent protein; LPS, lipopolysaccharide; TSPO, translocator protein (18 kDa).
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Targeting translocator protein (18 kDa)
(TSPO) dampens pro-inflammatory
microglia reactivity in the retina and
protects from degeneration
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Abstract
Background: Reactive microglia are commonly seen in retinal degenerative diseases, and neurotoxic microglia
responses can contribute to photoreceptor cell death. We and others have previously shown that translocator
protein (18 kDa) (TSPO) is highly induced in retinal degenerations and that the selective TSPO ligand XBD173
(AC-5216, emapunil) exerts strong anti-inflammatory effects on microglia in vitro and ex vivo. Here, we investigated
whether targeting TSPO with XBD173 has immuno-modulatory and neuroprotective functions in two mouse
models of acute retinal degeneration using bright white light exposure.
Methods: BALB/cJ and Cx3cr1GFP/+ mice received intraperitoneal injections of 10 mg/kg XBD173 or vehicle for five
consecutive days, starting 1 day prior to exposure to either 15,000 lux white light for 1 h or 50,000 lux focal light for
10 min, respectively. The effects of XBD173 treatment on microglia and Müller cell reactivity were analyzed by
immuno-stainings of retinal sections and flat mounts, fluorescence-activated cell sorting (FACS) analysis, and mRNA
expression of microglia markers using quantitative real-time PCR (qRT-PCR). Optical coherence tomography (OCT),
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stainings, and morphometric analyses were
used to quantify the extent of retinal degeneration and photoreceptor apoptosis.
Results: Four days after the mice were challenged with bright white light, a large number of amoeboid-shaped
alerted microglia appeared in the degenerating outer retina, which was nearly completely prevented by treatment
with XBD173. This treatment also down-regulated the expression of TSPO protein in microglia but did not change
the TSPO levels in the retinal pigment epithelium (RPE). RT-PCR analysis showed that the microglia/macrophage
markers Cd68 and activated microglia/macrophage whey acidic protein (Amwap) as well as the pro-inflammatory
genes Ccl2 and Il6 were reduced after XBD173 treatment. Light-induced degeneration of the outer retina was nearly
fully blocked by XBD173 treatment. We further confirmed these findings in an independent mouse model of focal
light damage. Retinas of animals receiving XBD173 therapy displayed significantly more ramified non-reactive
microglia and more viable arrestin-positive cone photoreceptors than vehicle controls.
Conclusions: Targeting TSPO with XBD173 effectively counter-regulates microgliosis and ameliorates light-induced
retinal damage, highlighting a new pharmacological concept for the treatment of retinal degenerations.
Keywords: Translocator protein (18 kDa) (TSPO), Microglia, Photoreceptors, Retinal degeneration, Light damage,
Age-related macular degeneration
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Background
Microglial cells are the resident tissue macrophages of the
central nervous system (CNS), including the retina. In the
healthy retina, they are located in the plexiform layers
from where they permanently scan the retinal environ-
ment with their motile protrusions [1]. Several receptors
that are specific for the binding of chemokines, cytokines,
complement factors, antibodies, or damage-associated
molecular patterns enable these cells to recognize and im-
mediately respond to pathological changes of their envir-
onment [2–4]. Beside their homeostatic function in the
healthy retina, microglia reactivity and age-related changes
of microglia physiology contribute to degenerative path-
ologies of the retina and the entire CNS [3, 5–14]. To-
gether with monocytes and macrophages, microglial cells
are major players in chronic immune processes including
parainflammation [15]. Reactive microglia are detectable
in the damaged photoreceptor layers of patients with de-
generative retinal diseases such as retinitis pigmentosa
and age-related macular degeneration (AMD) [6]. Micro-
glia not only phagocytose dead cells but also take up living
rods in a mouse model for retinitis pigmentosa [10].
Therefore, microglial activation cannot be just regarded as
a bystander effect but rather actively contributes to photo-
receptor cell death during retinal degeneration.
In attempts to better characterize retinal microglia re-
activity and find novel markers, we and others have pre-
viously identified very high expression of translocator
protein (18 kDa) in reactive retinal microglia [16, 17].
Translocator protein (TSPO), previously known as the
peripheral benzodiazepine receptor, likely mediates the
transport of cholesterol into the inner mitochondrial
membrane, where it serves as a precursor for steroids
and neurosteroids [18]. The protein is constitutively
expressed in steroidogenic tissues and up-regulated in ac-
tivated glial cells [19–21]. Glial up-regulation of TSPO is a
major hallmark of neurodegenerative diseases [22], and
various TSPO ligands have been developed as molecular
markers to detect gliosis by means of PET imaging [23].
Specific TSPO ligands are also under investigation as
treatment options for neurological disorders including
Alzheimer’s disease [24], multiple sclerosis [25], neuro-
pathic pain [26], peripheral nerve injury [22], and anx-
iety disorders [27]. Classical synthetic TSPO ligands
such as the benzodiazepine derivative 4′-chlorodiazepam
(Ro5-4864) and the isoquinoline carboxamide PK11195
directly enhance GABAergic neurotransmission [28]. In
contrast, structurally different synthetic TSPO ligands
such as etifoxine (Stresam) and XBD173 (AC-5216, ema-
punil) also stimulate the synthesis of neurosteroids and
exert potent anti-inflammatory and neuroprotective ef-
fects [29]. XBD173 is a very selective and high-affinity
phenylpurine ligand for TSPO whereas the benzoxazine
etifoxine additionally binds GABAA receptors [30]. Since
XBD173 has a high and specific affinity for TSPO with a
more beneficial side-effect profile than benzodiazepine
derivatives, a precise and potentially long-term applica-
tion to limit neuroinflammation seems feasible.
In a previous report, we have comprehensively charac-
terized the anti-inflammatory effects of the TSPO ligand
XBD173 using murine and human microglial cells as
well as cultured mouse retinal explants [16]. XBD173
strongly suppressed pro-inflammatory gene expression
in LPS-challenged microglia and diminished their neuro-
toxic potential on photoreceptor cell cultures, indicating
that targeting TSPO with XBD173 is a promising ap-
proach to control microglial reactivity [16]. In this study,
we addressed the questions whether XBD173 influences
microglial reactivity in vitro and protects from acute
white light-induced retinal degeneration in two different
mouse models. We selected white light exposure as it is
an environmental risk factor and mimics several features
of human retinal degenerative diseases in rodents [31–33].
This model is also very useful for a quantitative correl-
ation of microglial responses with processes of retinal
degeneration [34–36].
Methods
Reagents
XBD173 (emapunil) was obtained by custom synthesis
from APAC Pharmaceuticals, Ellicott City, MD21042.
XBD173 was dissolved in DMSO.
RNA isolation and reverse transcription
Total RNA was extracted from murine retinas using the
NucleoSpin® RNA Mini Kit (Macherey-Nagel, Dueren,
Germany). RNA was quantified spectrophotometrically
with a NanoDrop 2000 (Thermo Scientific). First-strand
cDNA synthesis was carried out with the Revert Aid H
Minus First-strand cDNA Synthesis Kit (Fermentas,
K1632).
Quantitative RT-PCR
cDNA (25 ng) were amplified in 10 μl reaction mixture
consisting of 5 μl Fast Start Universal Probe Master (Rox)
(Roche), 2 μl of primers (10 μM), 0.375 μl purified water,
and 0.125 μl of dual-labeled UPL probe (Roche Applied
Science, Basel, Switzerland) with an Applied Biosystems
7900 HT Fast Real-Time PCR system (Applied Biosystems,
Carlsbad, CA, USA). The following reaction parameters
were used: 10 min 95 °C hold, followed by 40 cycles of 15 s
95 °C melt, and 1 min 60 °C anneal/extension. Primer se-
quences and UPL probe numbers were as follows: Cd68,
forward primer 5′-ctctctaaggctacaggctgct-3′, reverse primer
5′-tcacggttgcaagagaaaca-3′, probe #27; Amwap, forward
primer 5′-tttgatcactgtggggatga-3′, reverse primer 5′-acacttt
ctggtgaaggcttg-3′, probe #1; Tspo, forward primer 5′-actgta
ttcagccatggggta-3′, reverse primer 5′-accatagcgtcctctgtgaa
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a-3′, probe #33; Il6, forward primer 5′-gatggatgctaccaaactg-
gat-3′, reverse primer 5′-ccaggtagctatggtactccaga-3′, probe
#6; iNos, forward primer 5′-ctttgccacggacgagac-3′, reverse
primer 5′-tcattgtactctgagggctga-3′, probe #13; Ccl2, for-
ward primer 5′-catccacgtgttggctca-3′, reverse primer 5′-gat
catcttgctggtgaatgagt-3′, probe #62; Casp8, forward primer
5′-tgaacaatgagatccccaaat-3′, reverse primer 5′-caaaaatttca
agcaggctca-3′, probe #11; and Atp5b, forward primer 5′-gg
cacaatgcaggaaagg-3′, reverse primer 5′-tcagcaggcacatagata
gcc-3′, probe #77. Measurements were performed in tripli-
cates. Atp5b expression was used as reference gene, and re-
sults were analyzed with the ABI sequence detector
software version 2.4 using the ΔΔCt method for relative
quantification.
Animals
Experiments were performed with 10–14-week-old albino
BALB/cJ mice and Cx3cr1GFP/+ mice on C57BL/6J back-
ground of both sexes. Animals were housed in an air-
conditioned environment with 12-h light-dark schedule
and had free access to water and food. All experimental
procedures complied with the German law on animal pro-
tection and the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research. The animal protocols
used in this study were reviewed and approved by the gov-
ernmental body responsible for animal welfare in the state
of Nordrhein-Westfalen (Landesamt für Natur, Umwelt
und Verbraucherschutz Nordrhein-Westfalen, Germany)
(reference number 84-02.04.2015-A039) and by the Ani-
mal Welfare and Ethical Review Board of Queen’s Univer-
sity Belfast under the regulation of the UK Home Office
Animal (Scientific Procedures) Act 1986.
XBD173 administration
The mice received intraperitoneal injections of XBD173
at a dose of 10 mg/kg body weight, dissolved in DMSO
or DMSO vehicle control twice daily for the first 2 days,
starting 1 day before the light exposure and once daily
for the remaining 3 days.
Light exposure regimens
BALB/cJ and Cx3cr1GFP/+ mice were dark-adapted for 16 h
before light exposure. After pupil dilatation with 1 %
phenylephrine and 2.5 % tropicamide under dim red light,
the mice were exposed to bright white light with an inten-
sity of 15,000 lux for 1 h or focal white light with an inten-
sity of 50,000 lux delivered by an otoscope (1218AA, Karl
Storz, Tuttlingen, Germany) for 10 min, respectively. After
light exposure, the animals were housed in dark-reared
conditions overnight and then maintained under normal
light conditions for the remaining experimental period.
Immunohistochemistry
Eyes were harvested for immunohistochemical analysis
4 days after light exposure. After fixation with 4 % parafor-
maldehyde, eyes were embedded in optimal cutting
temperature compound or dissected for retinal flat mount
analysis. Sixteen-micrometer sections were rehydrated with
phosphate-buffered saline (PBS) and blocked with 1 % dried
milk solution containing 0.01 % Triton X-100. Flat mounts
were incubated with 5 % Tween and 5 % Triton X-100 in
PBS overnight, and non-specific binding was blocked by in-
cubation with dried milk solution. Subsequently, retinal
sections and flat mounts were incubated with primary anti-
bodies at 4 °C overnight. Primary antibodies targeting the
following proteins were used: rabbit anti-Iba1 antibody
(dilution 1:500; Wako Chemicals, Neuss, Germany), rabbit
anti-TSPO antibody (dilution 1:250; Abcam, Cambridge,
UK), rabbit anti-glial fibrillary acidic protein (dilution 1:200;
G9269, Sigma, USA), mouse anti-glutamine synthetase
(dilution 1:200; MAB302, Millipore, Darmstadt, Germany),
and rabbit anti-cone arrestin (Millipore, Darmstadt,
Germany). After a washing step, the sections and flat
mounts were incubated with a secondary antibody either
conjugated to Alexa488 (green; dilution 1:1000) or
Alexa594 (red; dilution 1:800) (Jackson Immuno-Research,
West Grove, PA, USA) for 1 h. After counterstaining with
4′,6-Diamidin-2-phenylindol (DAPI) in some instances,
the samples were mounted in DAKO fluorescent mount-
ing medium (Dako Deutschland GmbH, Hamburg,
Germany) and analyzed with an Axioskop2 MOT Plus
Apotome microscope (Carl Zeiss) or an Eclipse TE200-U
confocal microscope (Nikon).
Optical coherence tomography
Animals were anesthetized by intraperitoneal injection of
Rompun (10 mg/kg body weight)-Ketavet (100 mg/kg
body weight), and their pupils were dilated with phenyl-
ephrine HCl (0.25 %)-tropicamide (0.05 %) before image
acquisition. Spectral domain optical coherence tomog-
raphy (SD-OCT) was performed on both eyes with a Spec-
tralis™ HRA+OCT device (Heidelberg Engineering) to
investigate structural changes in the retina after light
exposure and XBD173 administration. Thickness measure-
ments were performed using the Heidelberg Eye Explorer
Software using a circular ring scan (circle diameters 3 and
6 mm), centered on the optic nerve head, which represents
the average retinal thickness (μm) in a certain field.
TUNEL assay and morphometric analyses
Retinal sections were labeled with an in situ cell death
detection kit, fluorescein (Roche), to detect the amount
of apoptotic cells 4 days after light exposure. For a better
overview, the sections were also counterstained with
DAPI for 10 min. After a washing procedure, sections
were mounted in DAKO fluorescent mounting medium
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(Dako Deutschland GmbH, Hamburg, Germany) and
analyzed with an Axioskop2 MOT Plus Apotome micro-
scope (Carl Zeiss). Quantitative morphometric analyses
were performed by counting the number of rows of
photoreceptor nuclei along the nasal/temporal axis.
Flow cytometry
Mouse retinas were dissected 4 days after light exposure
and dissociated using the Neuronal Tissue Dissociation Kit-
Postnatal Neurons (MACS, Miltenyi, Bergisch Gladbach,
Germany). To identify microglia cells and macrophages,
the single-cell suspension was stained with anti-mouse/hu-
man CD11b-APC antibody (MACS, Miltenyi, Bergisch
Gladbach, Germany) at a dilution of 1:10 for 15 min in the
dark at 4 °C. After a washing step, cells were fixed with
FluoroFix Buffer (Biolegend, San Diego, CA, USA) in the
dark for 30 min at room temperature. Afterwards, the cells
were washed and resuspended in PBS solution (pH 7.2,
0.5 % containing bovine serum albumin (BSA), and
2 mM EDTA) until flow cytometric analyses with a
fluorescence-activated cell sorting (FACS) Canto II (Becton
Dickinson, Heidelberg, Germany). The number of CD11b+
cells was determined using FlowJo software (Treestar,
Ashland, USA).
Statistical analysis
The differences between control mice and animals after
light exposure that either received sham injections or
XBD173 injections were analyzed using a one-way ANOVA
and Dunnett’s multiple comparison test. p < 0.05 was con-
sidered statistically significant.
Results
The TSPO ligand XBD173 prevents microglia reactivity
and gliosis in murine retinas exposed to acute white light
We have previously identified that Tspo mRNA and pro-
tein are highly induced in genetic models of retinal degen-
eration and that its specific ligand XBD173 has potent
anti-inflammatory activity on microglia in vitro [16]. Based
on these data, we hypothesized that XBD173 could also
modulate microglial responses in the damaged retina in
vivo. We have chosen acute light-induced degeneration as
it is a fast and reproducible mouse model that mimics sev-
eral features of human retinal degenerative diseases in-
cluding innate immune activation and selective cell death
of photoreceptor cells [33].
Dark-adapted BALB/cJ mice were exposed to white light
with an intensity of 15,000 lux for 1 h. The animals re-
ceived daily intraperitoneal injections of 10 mg/kg XBD173
or vehicle, starting 1 day before the light exposure for five
consecutive days (Fig. 1a). Four days after light exposure,
the effects of XBD173 treatment on microgliosis were an-
alyzed by staining of retinal sections and flat mounts. In
healthy controls, immunolabeling of retinal sections with
the marker IBA1 showed ramified microglia exclusively in
the plexiform layers and inner retina (Fig. 1b). Light ex-
posure and vehicle administration induced strong micro-
glia reactivity resulting in the migration and appearance of
amoeboid-shaped microglia in the degenerating photo-
receptor layer and the subretinal area (Fig. 1c). This severe
thinning of the outer retina and accumulation of microglia
in and around the outer nuclear layer was not detectable
in mice treated with XBD173 (Fig. 1d). We next analyzed
changes in the microglial network in retinal flat mounts
stained with Iba1. In contrast to controls, where microglial
cells are highly ramified in the outer plexiform layer
(OPL) (Fig. 1e), light-exposed retinas showed clear signs
of microglia reactivity in the OPL (Fig. 1f), which was
reverted in conditions of XBD173 therapy (Fig. 1g). Fur-
thermore, the appearance of many amoeboid-shaped
microglia in the subretinal area triggered by light exposure
was strongly reduced in the XBD173 treatment group
(Fig. 1h–j). This finding that XBD173 very likely prevented
migration of many microglia from the inner to the outer
retina was corroborated by a quantitative analysis count-
ing the number of microglial cells in the outer nuclear
layer (ONL) and subretinal area (Fig. 1k, l). We then de-
termined the number of CD11b-positive cells in the retina
using flow cytometry. These data also showed that
XBD173 administration strongly reduced the percentage
of CD11b-positive cells in the light-exposed retina com-
pared to vehicle controls (Fig. 1m–p).
We then wanted to better characterize the reactive glio-
sis and its relation to the expression of TSPO itself. Expos-
ure to light in the vehicle control triggered strong
expression of TSPO that was mainly confined to outer ret-
inal microglia and some astrocytes in the ganglion cell
layer (Fig. 2a, b). This cellular expression pattern is in
agreement with previous immunohistochemical data from
genetic mouse models of retinal degeneration [16, 37] and
highlights the induced expression of TSPO in microglia
upon activation. Administration of XBD173 strongly di-
minished TSPO expression (Fig. 2c), indicating a much less
reactive microgliosis and confirming our stainings with
Iba1 (Fig. 1). Interestingly, we also identified specific ex-
pression of TSPO in the retinal pigment epithelium (RPE)
network that was visualized by co-staining with phalloidin
(Fig. 2d). However, this RPE-specific expression pattern of
TSPO was not obviously influenced by light exposure or
XBD173 therapy (Fig. 2e, f), indicating a constitutive role of
TSPO in the RPE that is unrelated to gliosis. We then ana-
lyzed the expression of glutamine synthetase (GS), a consti-
tutively expressed Müller cell protein and glial fibrillary
acid protein (GFAP), a marker für Müller cell and astrocyte
reactivity. GS staining was not significantly changed by light
exposure and XBD173 treatment (Fig. 2g–i, m), whereas
XBD173 significantly reduced the light-dependent induc-
tion of GFAP expression (Fig. 2j–l, n). These findings
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Fig. 1 XBD173 treatment of light-exposed mice prevents microglia reactivity. a Light exposure regimen and mode of XBD173 administration.
Representative photomicrographs show retinal sections (b–d) and flat mounts (e–j) stained with IBA1 (green) and DAPI (blue). In control retinas,
microglial cells were located in the OPL, IPL, and GCL (b, e, h). Light-exposed retinas injected with vehicle control showed a massive thinning of
the ONL and many amoeboid-shaped, reactive microglia in the ONL and the subretinal space (c, f, i). Compared to vehicle controls, the ONL of
XBD173-treated retinas appeared markedly preserved and less amoeboid microglia were detectable in the ONL and the subretinal space (d, g, j).
The total number of Iba1-positive microglial cells in the ONL (k) and the subretinal area (l) after light damage was significantly reduced in the
XBD173 therapy group. Data show mean ± SEM (control n = 3, light exposure and vehicle treatment n = 6, light exposure and XBD173 treatment
n = 12 sections). The percentage of CD11b-positive cells in the retina as determined by flow cytometry was strongly reduced by XBD173
treatment in representative FACS plots (m–o) and quantitative analyses of n = 3–4 retinas (p). ONL outer nuclear layer, OPL outer plexiform
layer, INL inner nuclear layer, IPL inner plexiform layer, GCL ganglion cell layer. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar 50 μm
Scholz et al. Journal of Neuroinflammation  (2015) 12:201 Page 5 of 12
Fig. 2 XBD173 treatment of light-exposed mice down-regulates TSPO in microglia and prevents gliosis. Representative photomicrographs of retinal
sections and flat mounts from mice 4 days after light exposure. Control retinas show weak TSPO labeling (a), and strong up-regulation of TSPO
expression confined to microglia was present upon light exposure and vehicle treatment (b). XBD173-treated mice displayed only constitutive
expression of TSPO in the RPE, but no strong signal in the retina was found (c). Number of analyzed photomicrographs: control n = 5 sections
from two individual mice, light exposure and vehicle treatment n = 7 sections from five individual mice, light exposure and XBD173 treatment
n = 11 sections from five individual mice. The expression of TSPO in the RPE was relatively unaffected in the different conditions as shown in
flat mount images stained with anti-TSPO antibody and phalloidin (d–f). Glutamine synthetase (GS), a constitutive Müller cell protein, and glial
fibrillary acidic protein (GFAP) as markers for gliosis were analyzed (g–n). GS expression did not differ in the various treatment groups (g–i, m)
whereas GFAP expression was changed significantly (j–l, n). Data show mean ± SEM (control n = 5 sections from five individual mice, light exposure and
vehicle treatment n = 5 sections from three individual mice, light exposure and XBD173 treatment n = 5 sections from four individual mice). **p < 0.01.
ONL outer nuclear layer, OPL outer plexiform layer, INL inner nuclear layer, IPL inner plexiform layer, GCL ganglion cell layer. Scale bar 50 μm
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indicate that gliosis triggered by light damage can be pre-
vented by targeting TSPO.
XBD173 reduces pro-inflammatory gene expression in
retinal degeneration
In addition to these cellular analyses of retinal microglia,
we investigated whether mRNA levels of pro-inflammatory
transcripts were influenced by XBD173 administration in
vivo. CD68, activated microglia/macrophage whey acidic
protein (AMWAP), and TSPO itself are molecules that
are connected with microglia proliferation and reactiv-
ity [16, 38, 39]. Four days after light exposure, all three
genes were induced in the retina, with especially high
levels of Amwap (Fig. 3a–c). In light-exposed mice treated
with XBD173, the expression of Cd68 (Fig. 3a, p = 0.0342),
Amwap (Fig. 3b, p = 0.0182), and Tspo (Fig. 3c, p = 0.0338)
were significantly suppressed. Furthermore, transcripts
that reflect the activation of key microglial pathways in-
cluding chemotaxis, pro-inflammatory cytokines, and rad-
ical production were analyzed. mRNA levels of the
chemotactic molecule Ccl2 and the cytokine Il6 were
strongly up-regulated in the retinas of sham-injected
light-exposed mice, and XBD173 administration dimin-
ished their expression (Fig. 3d, e). Notably, the expression
of iNos was not significantly altered by light exposure or
XBD173 treatment (Fig. 3f) potentially indicating different
time kinetics of chemokine/cytokine levels and oxygen
radical responses. These data suggest that XBD173 has
potent microglia-related immuno-modulatory effects in
vivo in the mouse retina.
XBD173 treatment prevents light-induced retinal
degeneration
We next asked whether targeting TSPO with XBD173 also
improves the outcome of disease progression. We first per-
formed in vivo optical coherence tomography (OCT) to
detect the retinal damage after light exposure and under
conditions of XBD173 treatment. The OCT images
showed clear changes especially in ONL reflectance in the
retinas of sham-treated light-exposed mice, indicating a se-
vere degeneration of the photoreceptor layer (Fig. 4a, b). In
contrast, XBD173-treated animals displayed nearly normal
retinal layers similar to that of healthy controls (Fig. 4c).
Volume scans revealed a significant thinning of the retinal
tissue, especially in the central area around the optic nerve
head after light exposure, which was much less pro-
nounced in the XBD173-treated groups (Fig. 4d–f). Quan-
tification of the retinal thickness in all analyzed animals
demonstrates a significant reduction in the 3- and 6-mm
central areas, respectively, after light exposure (p < 0.0001),
Fig. 3 XBD173 treatment dampens microglia-related pro-inflammatory marker expression after light exposure. To determine the mRNA expression
of inflammation-associated genes in the retina, qRT-PCR analysis was performed 4 days after light exposure. a–c The microglia markers Cd68 and
Amwap were up-regulated after light exposure, and TSPO levels were also increased. In contrast, the retinas from XBD173-treated mice expressed
significantly less Cd68, Amwap, and Tspo transcripts after light exposure. d, e XBD173 treatment reduced the expression of Ccl2 and Il6 that were
elevated by light exposure. f iNOS expression was not altered. Data show mean ± SEM out of three independent experiments (control n = 4–8,
light exposure plus vehicle treatment n = 8–15, light exposure plus XBD173 treatment n = 8–15 per group, measured in duplicates) with *p < 0.05;
**p < 0.01; ***p < 0.001
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that could be rescued by administration of XBD173
(p < 0.0001) (Fig. 4g, h).
To confirm these findings on the histological level,
panorama images of retinal sections proceeding through
the optic nerve head obtained 4 days after light exposure
were stained with DAPI (Fig. 5a–c). The photoreceptor
layer showed a clear thinning in sham-injected mice ex-
posed to light, which was not evident in mice after
XBD173 administration (Fig. 5a–c). In accordance with
these data, the number of terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL)-positive cells as
indicators of cell death was also increased with light and
strongly reduced by XBD173 injection (Fig. 5d, e). Further
quantitative morphometric analyses along the nasal/tem-
poral axis revealed that light exposure especially reduced
the central retinal thickness and that this decline was sig-
nificantly less in the XBD173-treated group of mice
(Fig. 5g). Moreover, molecular analyses using quantitative
real-time PCR (qRT-PCR) of total retinal RNA detected a
clear counter-regulatory effect of XBD173 on caspase 8
mRNA levels (Fig. 5h, p = 0.0007). These data together
clearly point towards a strong neuroprotective effect of
XBD173 in conditions of light damage.
XBD173 prevents focal light-induced retinal damage
We were finally interested to validate our findings in an
independent model using focal light-induced retinal dam-
age. Cx3cr1GFP/+ reporter mouse eyes, which facilitate
label-free microglia visualization, were exposed to 50,000
lux cold light delivered by an otoscope for 10 min in the
Fig. 4 XBD173 preserves retinal thickness in light-exposed mice. SD-OCT was performed 4 days after light exposure to analyze changes in retinal
structures. a–c Light-exposed mice show an altered reflectance in the ONL, which was not present in XBD173-treated mice. d–f Representative
heat maps show the average retinal thickness of control and light-exposed mice after vehicle or XBD173 treatment, respectively. Light-exposed
mice show a significant thinning of the retina, in the central (g) and more peripheral area (h), which was preserved by XBD173 treatment. g, h
One data point represents the average thickness of the central retina, calculated from four different areas around the optic nerve head in circle
diameters of 3 mm (g) and 6 mm (h), respectively. Data show mean ± SEM out of two independent experiments (control n = 6, light exposure
plus vehicle treatment n = 10, light exposure plus XBD173 treatment n = 10/group) with ***p < 0.001
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same experimental design as described above for complete
light exposure (Fig. 6a). Fundus imaging showed a clear
focal light-induced retinal damage with a central area of
atrophy (Fig. 6b). Confocal imaging of GFP-positive ONL
microglia within the retinal lesion area of sham-treated
mice clearly indicated a reactive phenotype compared
to controls and XBD173-injected animals, respectively
(Fig. 6c–e). As short cellular processes and enlargement of
soma are characteristic for microglial activation, we quanti-
fied this morphological change using a grid system by
counting the points of all cells that crossed the grid as de-
scribed previously [40]. This analysis showed a significant
reduction of grid cross points in focal light-exposed retinas,
and this was fully reverted in the XBD173-treated group of
animals (Fig. 6f).
In the last set of experiments, we determined the num-
ber of cone photoreceptors in the focal light damage
model using confocal microscopy of retinal flat mounts
that were stained with anti-cone arrestin antibodies. The
areas of focal light damage showed a much weaker arrestin
staining compared to controls and compared to the retinas
of XBD173-treated animals, respectively (Fig. 6g–i). The
quantitative analysis of 6–8 independent retinas revealed a
more than 8-fold reduction in the number of cone
Fig. 5 XBD173 protects the light-exposed retina from cell death. a–c Representative panorama sections of the retina were stained with DAPI to
further characterize structural changes. Light exposure caused severe degeneration particularly of the ONL. XBD173 administration reduced
degeneration, represented by a clearly thicker photoreceptor layer, scale bar 200 μM. d–f Representative photomicrographs of TUNEL-stained
retinal sections show the amount of apoptotic cells 4 days after light exposure. Light exposure caused a strong increase of apoptotic cells, especially in
the ONL. Only very few TUNEL-positive cells were visible after XBD173 administration. Scale bar 50 μm (g). For quantification of retinal thickness, anterior
and posterior areas were divided into ten sections with the optic nerve as reference and rows of photoreceptor nuclei were counted. Data
show mean ± SEM (control n = 4, light exposure plus vehicle treatment n = 8, light exposure plus XBD173 treatment n = 10/group) with *p < 0.05;
**p < 0.01; ***p < 0.001 light exposed + vehicle versus control (red color) and light exposed + XBD173 versus light exposed + vehicle (blue color).
h mRNA analyses revealed a significantly lower expression of caspase 8 in light-exposed XBD173-treated mice compared to controls and vehicle-injected
retinas. Data show mean ± SEM out of two independent experiments (control n= 4, light exposure plus vehicle treatment n= 8, light exposure plus
XBD173 treatment n= 8/group, measured in triplicates) with **p< 0.01; ***p< 0.001
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photoreceptors upon light damage and a 4.8-fold increase
in the XBD173 therapy group, indicating a prominent ef-
fect on photoreceptor survival (Fig. 6j).
Discussion
Due to its high expression in activated glia, TSPO is a
marker for brain gliosis and TSPO ligands are commonly
used for in vivo imaging in humans and mice [41, 42]. We
have previously identified high TSPO levels in retinal
microglia of murine models of inherited retinal degener-
ation [16, 37]. In the present study, we now show that
TSPO is also strongly induced in retinal microglia after
light exposure and that the TSPO ligand XBD173 has po-
tent microglia-modulatory and neuroprotective functions
in the retina in vivo. To our knowledge, this is the first re-
port of TSPO-directed pharmacological targeting of the
diseased retina.
To mimic exposure to bright daylight, which is a well-
known environmental risk factor for retinal degenerations,
we exposed the mice to 15,000 lux UV-free white light for
1 h in the first set of experiments and to 50,000 lux focal
cold white light for 10 min in the validation studies. White
light has an emission spectrum relatively similar to that of
daylight, and it is less artificial than the light of a particular
wavelength [43, 44]. Furthermore, white light contains a
significant fraction of short-wavelength blue light (403 nm)
which is thought to have a higher damaging potential
than the light of longer wavelength including green
light (490–580 nm), which was used in some studies to
mimic retinal degeneration [45]. The higher damaging
potential of blue light is due to a process called photo-
reversal, the regeneration of rhodopsin from bleaching
intermediates that results in a higher number of photon
absorption in a certain time span [46].
Very early microglial activation was observed already
1 day after light challenge in both models (data not shown),
indicating that microglia sense subtle disturbances in the
light-damaged retina before overt cell death occurs. TSPO
Fig. 6 XBD173 treatment prevents microglia reactivity and rescues cone photoreceptors in focal light-induced damage. a Light exposure regimen
and mode of XBD173 administration. b Representative fundus image showing the focal light lesion 4 days after Cx3cr1GFP/+ mice were exposed
to 50,000 lux for 10 min. c–e Representative confocal images of GFP-positive retinal microglia in flat mounts from control mice (c) and lesion
areas of light-exposed mice (d, e). The average size of microglial cells was assessed using the grid cross point system (f). Data show mean ± SEM
(n= 40–180 cells per group) with ***p< 0.001. g–i Retinal flat mounts were processed for cone arrestin staining and examined by confocal microscopy.
Representative confocal images of cone arrestin-positive cells in flat mounts from control mice (g) and lesion areas of light-exposed mice (h, i). j Average
density of cone photoreceptor cells. Data show mean ± SEM (n= 6–8 retinas per group) with *p< 0.05; ***p< 0.001. Scale bar 50 μm
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expression was present in these reactive microglia, and our
analyses towards the phenotype and behavior of microglia
together with previous in vitro data [16] suggest that
XBD173 exerts its neuroprotective function at least par-
tially via modulation of microglia. Likewise, another spe-
cific TSPO ligand, etifoxine, also potently diminished
inflammatory pathology and thereby attenuated the clinical
score of experimental autoimmune encephalomyelitis, an
experimental mouse model for multiple sclerosis [25]. The
tight correlation of microglia reactivity with TSPO expres-
sion was also identified in the genetic mouse model of my-
osin VII deficiency that mimics both features of retinal
dystrophies and glaucoma [47]. Therefore, TSPO induction
in retinal microglia may be an early and reliable marker for
changes in the microglia phenotype in different types of
retinal degenerative diseases [37].
Our mRNA expression data of XBD173-treated retinas
showed not only decreased transcript levels of Cd68,
Amwap, and Tspo but also reduced Ccl2 and Il6 expres-
sion. The CCL2/CCR2 axis is crucial in subretinal macro-
phage and microglia accumulation in retinal degeneration
models and human AMD, and these findings implicate that
CCL2/CCR2 inhibition may be a novel tool to limit inflam-
mation and neurodegeneration in the retina [48, 49]. Simi-
larly, human reactive microglia express IL6, which in turn
prevents retinal regeneration and promotes subretinal im-
mune cell survival [50, 51]. Thus, the XBD173/TSPO axis
seems to target two key pathways of chronic microglia re-
activity in the retina.
As we have shown previously in microglial cell cultures
[16], one potential mechanism of the anti-inflammatory
effects of XBD173 could be the local synthesis of pregnen-
olone, as has been also demonstrated for brain astrocytes
[52]. Pregnenolone can be further metabolized to proges-
terone and allopregnanolone that are both potent neuro-
protective and anti-inflammatory molecules [53–55].
When orally applied to rd1 mice with inherited retinal de-
generation, progesterone potently reduced oxidative stress
levels, diminished gliosis, and provided a temporal im-
provement in photoreceptor function [56].
We have demonstrated constitutive mitochondrial TSPO
expression in the RPE that was unaffected by light exposure
or XBD173 therapy. Therefore, TSPO in RPE mitochondria
could potentially fulfill a housekeeping function. Of note,
increased damage of mitochondrial DNA specifically in the
RPE has been recently implicated as a risk factor for AMD
and mutations of electron transport chain components
could potentially limit energy production [57]. Thus, in
addition to its anti-inflammatory effects on microglia,
TSPO may sustain mitochondrial homeostasis and integrity
by regulating the oxygen consumption rate. However, this
function and the previously identified physiological roles of
TSPO remain to be characterized with novel cell-type spe-
cific knockout mouse models [58, 59].
Conclusions
We have shown that modulation of microglia with the syn-
thetic TSPO ligand XBD173 preserved the retinal structure
by counter-regulation of microglial pro-inflammatory re-
sponses during light exposure. Our data suggest that tar-
geting TSPO in the retina may be a novel promising
approach for anti-inflammatory and neuroprotective ther-
apies in retinal degenerative disorders.
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Minocycline counter-regulates pro-
inflammatory microglia responses in the
retina and protects from degeneration
Rebecca Scholz1, Markus Sobotka1, Albert Caramoy1, Thomas Stempfl2, Christoph Moehle2 and Thomas Langmann1*
Abstract
Background: Microglia reactivity is a hallmark of retinal degenerations and overwhelming microglial responses
contribute to photoreceptor death. Minocycline, a semi-synthetic tetracycline analog, has potent anti-inflammatory
and neuroprotective effects. Here, we investigated how minocycline affects microglia in vitro and studied its
immuno-modulatory properties in a mouse model of acute retinal degeneration using bright white light exposure.
Methods: LPS-treated BV-2 microglia were stimulated with 50 μg/ml minocycline for 6 or 24 h, respectively.
Pro-inflammatory gene transcription was determined by real-time RT-PCR and nitric oxide (NO) secretion was
assessed using the Griess reagent. Caspase 3/7 levels were determined in 661W photoreceptors cultured with
microglia-conditioned medium in the absence or presence of minocycline supplementation. BALB/cJ mice received
daily intraperitoneal injections of 45 mg/kg minocycline, starting 1 day before exposure to 15.000 lux white light for
1 hour. The effect of minocycline treatment on microglial reactivity was analyzed by immunohistochemical stainings of
retinal sections and flat-mounts, and messenger RNA (mRNA) expression of microglia markers was determined using
real-time RT-PCR and RNA-sequencing. Optical coherence tomography (OCT) and terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) stainings were used to measure the extent of retinal degeneration
and photoreceptor apoptosis.
Results: Stimulation of LPS-activated BV-2 microglia with minocycline significantly diminished the transcription
of the pro-inflammatory markers CCL2, IL6, and inducible nitric oxide synthase (iNOS). Minocycline also reduced the
production of NO and dampened microglial neurotoxicity on 661W photoreceptors. Furthermore, minocycline had
direct protective effects on 661W photoreceptors by decreasing caspase 3/7 activity. In mice challenged with white
light, injections of minocycline strongly decreased the number of amoeboid alerted microglia in the outer retina and
down-regulated the expression of the microglial activation marker translocator protein (18 kDa) (TSPO), CD68, and
activated microglia/macrophage whey acidic protein (AMWAP) already 1 day after light exposure. Furthermore, RNA-seq
analyses revealed the potential of minocycline to globally counter-regulate pro-inflammatory gene transcription in the
light-damaged retina. The severe thinning of the outer retina and the strong induction of photoreceptor apoptosis
induced by light challenge were nearly completely prevented by minocycline treatment as indicated by a preserved
retinal structure and a low number of apoptotic cells.
Conclusions: Minocycline potently counter-regulates microgliosis and light-induced retinal damage, indicating
a promising concept for the treatment of retinal pathologies.
Keywords: Minocycline, Microglia, Photoreceptors, Retinal degeneration, Light damage, Age-related macular
degeneration
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Background
Age-related macular degeneration (AMD) is a leading
cause of severe visual impairment in the elderly, and the
number of affected persons steadily increases as a conse-
quence of demographic changes [1]. Late stage AMD can
be classified in a dry and a wet form, representing atrophic
and neovascular processes, respectively. Wet AMD can be
treated with intravitreal injections of anti-vascular endo-
thelial growth factor (VEGF) medication, while no estab-
lished treatment options exist for the dry form [2]. The
pathogenesis of AMD is characterized by the early pres-
ence of drusen, damage of the retinal pigment epithelium
(RPE) and photoreceptor layer primarily affecting the
macular region and a chronic inflammatory response in
the retina leading to the expression of pro-inflammatory
and pro-angiogenic factors [2]. This immunological re-
sponse in the retina can be regarded as para-inflammation
and involves the reactivity of microglial cells [3–5].
Microglial cells are the tissue macrophages of the cen-
tral nervous system (CNS), including the retina. In the
healthy adult retina, they are located in the plexiform
layers from where they permanently scan the retinal en-
vironment with their motile protrusions [6]. The expres-
sion of several receptors that are specific for the binding
of chemokines, cytokines, complement factors, anti-
bodies, or damage-associated molecular patterns enables
these cells to recognize and immediately respond to
pathological changes of their environment [7–9]. Besides
their supportive function in the healthy retina, microglia
reactivity and age-related changes of microglia physi-
ology contribute to degenerative pathologies of the ret-
ina and the entire CNS [3, 4, 8, 10–17]. A large number
of amoeboid shaped reactive microglia are detectable in
the degenerating photoreceptor layer of AMD and retin-
itis pigmentosa retinas [4]. These cells contain phagocy-
tosed rhodopsin-positive particles [4], and a recent
report demonstrated that microglia do not only phago-
cytose dead cells but also take up living rods in a mouse
model for retinitis pigmentosa [13]. Therefore, microglial
activation cannot be just regarded as a bystander effect
but rather actively contributes to photoreceptor cell
death during retinal degeneration.
Because of these findings, substances that modulate
microglial reactivity such as minocycline are good candi-
dates to prevent inflammation and dampen degenerative
processes in the retina. Minocycline is a second-generation
semi-synthetic tetracycline analog, which is used against
Gram-positive and Gram-negative bacteria for over 30 years.
Besides its bacteriostatic capacity, minocycline exerts anti-
inflammatory, anti-apoptotic, and neuroprotective effects in
experimental models of Parkinson’s disease [18], multiple
sclerosis [19–22], neuropathic pain [16], Alzheimer’s
disease [23, 24], and in a genetic mouse model of retinitis
pigmentosa [25].
In this study, we addressed the questions how minocy-
cline modulates microglial reactivity in vitro and whether
it protects from acute white light-induced retinal degener-
ation in the mouse. We selected white light exposure as it
is an environmental risk factor that mimics several fea-
tures of AMD in rodents including degeneration of photo-
receptors and the retinal pigment epithelium [26–28].
This model is also very useful for a temporal correlation
of microglial responses with processes of retinal degener-
ation and RPE dysfunction [29–31].
Methods
Reagents
Minocycline hydrochloride (M9511), Escherichia coli
0111:B4 lipopolysaccharide (LPS), and Z-Leu-Leu-Leu-al
(MG-132) were purchased from Sigma-Aldrich (St. Louis,
MO, USA).
Cell culture
BV-2 microglia were cultured in RPMI1640 with 5 %
fetal calf serum (FCS) supplemented with 2 mM L-
glutamine, 1 % penicillin/streptomycin, and 195 nM
β-mercaptoethanol at 37 °C in a humidified atmosphere
of 5 % CO2, as described previously [32, 33]. BV-2 cells
were pre-incubated for 30 min with 50 μg/ml minocycline
or NaCl as vehicle control. Afterwards, the cells were
stimulated with 50 ng/ml LPS, 50 μg/ml minocycline, or
50 ng/ml LPS plus 50 μg/ml minocycline for 24 h. After
stimulation, cells or supernatant were harvested for fur-
ther analysis. 661W photoreceptor-like cells were a kind
gift from Prof. Muayyad Al-Ubaidi (Department of Cell
Biology, University of Oklahoma Health Sciences Center,
Oklahoma City, OK, USA). 661W photoreceptor cells
were cultured with Dulbecco’s modified Eagle’s medium
(DMEM), high glucose with L-glutamine, supplemented
with 10 % FCS and 1 % penicillin/streptomycin. Cultures
were maintained in a sterile humidified environment at
37 °C and 5 % CO2 as described elsewhere [34].
RNA isolation and reverse transcription
Total RNA was extracted from cultured BV-2 micro-
glia or murine retinas using the NucleoSpin® RNA
Mini Kit (Macherey-Nagel, Dueren, Germany). RNA
was quantified spectrophotometrically with a NanoDrop
2000 (Thermo Scientific). First-strand complemen-
tary DNA (cDNA) synthesis was carried out with the
Revert Aid H Minus First-strand cDNA Synthesis Kit
(Fermentas, K1632).
Real-time RT-PCR
cDNA (25 ng) were amplified in a 10-μl reaction mixture
consisting of 5 μl Fast Start Universal Probe Master (Rox)
(Roche), 2 μl of primers (10 μM), 0.375 μl purified water,
and 0.125 μl of dual-labeled Universal ProbeLibrary (UPL)
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probe (Roche Applied Science, Basel, Switzerland) with an
Applied Biosystems 7900 HT Fast Real-time PCR system
(Applied Biosystems, Carlsbad, CA, USA). The following
reaction parameters were used: 10 min 95 °C hold,
followed by 40 cycles of 15 s 95 °C melt, and 1 min
60 °C anneal/extension. Primer sequences and UPL
probe numbers were as follows: CD68, forward primer 5′-
ctctctaaggctacaggctgct-3′, reverse primer 5′-tcacggttgcaag
agaaaca-3′, probe #27; activated microglia/macrophage
whey acidic protein (AMWAP), forward primer 5′-tttgatc
actgtggggatga-3′, reverse primer 5′-acactttctggtgaaggcttg-
3′, probe #1; translocator protein (TSPO), forward primer
5′-actgtattcagccatggggta-3′, reverse primer 5′-accatagcgt
cctctgtgaaa-3′, probe #33; IL6, forward primer 5′-gatgg
atgctaccaaactggat-3′, reverse primer 5′-ccaggtagctatggta
ctccaga-3′, probe #6; inducible nitric oxide synthase
(iNOS), forward primer 5′-ctttgccacggacgagac-3′, reverse
primer 5′-tcattgtactctgagggctga-3′, probe #13; CCL2, for-
ward primer 5′-catccacgtgttggctca-3′, reverse primer 5′-
gatcatcttgctggtgaatgagt-3′, probe #62; CASP8, forward
primer 5′-tgaacaatgagatccccaaat-3′, reverse primer 5′-
caaaaatttcaagcaggctca-3′, probe #11; and ATP5B, forward
primer 5′-ggcacaatgcaggaaagg-3′, reverse primer 5′-tcagc
aggcacatagatagcc-3′, probe #77. Measurements were
performed in triplicates. ATP5B expression was used
as reference gene and results were analyzed with the
ABI sequence detector software version 2.4 using the
ΔΔCt method for relative quantification.
RNA-sequencing and bioinformatic data analysis
Library preparation and RNA-seq were carried out as
described in the Illumina TruSeq Stranded mRNA Sam-
ple Preparation Guide, the Illumina HiSeq 1000 System
User Guide (Illumina, Inc., San Diego, CA, USA), and
the KAPA Library Quantification Kit—Illumina/ABI
Prism User Guide (Kapa Biosystems, Inc., Woburn, MA,
USA). In brief, 300 ng of total RNA was used for purify-
ing the poly-A containing messenger RNA (mRNA)
molecules using poly-T oligo-attached magnetic beads.
Following purification, the mRNA was fragmented to an
average insert size of 200–400 bases using divalent cat-
ions under elevated temperature (94 °C for 4 min). The
cleaved RNA fragments were copied into first-strand
cDNA using reverse transcriptase and random primers.
Strand specificity was achieved by replacing dTTP with
dUTP in the Second Strand Marking Mix (SMM),
followed by second-strand cDNA synthesis using DNA
Polymerase I and RNase H. The incorporation of dUTP
in second-strand synthesis quenches the second strand
during amplification, because the polymerase used in the
assay is not incorporated past this nucleotide. The
addition of Actinomycin D to First Stand Synthesis Act
D mix (FSA) prevents spurious DNA-dependent synthe-
sis, while allowing RNA-dependent synthesis, improving
strand specificity. These cDNA fragments then had the
addition of a single “A” base and subsequent ligation of
the adapter. The products were purified and enriched
with PCR to create the final cDNA library. The libraries
were quantified using the KAPA SYBR FAST ABI Prism
Library Quantification Kit. Equimolar amounts of each
library were used for cluster generation on the cBot
(TruSeq SR Cluster Kit v3). The sequencing run was
performed on a HiSeq 1000 instrument using the
indexed, 50 cycles single read (SR) protocol and the
TruSeq SBS v3 Kit. Image analysis and base calling
resulted in .bcl files, which were converted into .fastq
files by the CASAVA1.8.2 software. Library preparation
and RNA-seq were performed at the service facility
“KFB—Center of Excellence for Fluorescent Bioanaly-
tics” (Regensburg, Germany).
The RNA express workflow on Illumina BaseSpace
was used to determine differential gene expression in
two biological replicates of control retinas, light-exposed
retinas, and light-exposed retinas treated with minocy-
cline, respectively. In brief, alignment of RNA-seq reads
to the mouse UCSC mm10 genome and mapping to
genes was performed with STAR aligner [35]. Differen-
tial gene expression between the two biological repli-
cates each was calculated with DESeq2 [36]. The cutoff
of genes considered to be differentially expressed was a
log2 fold change of ≥2 or ≤−2.
Integrative analysis of genome-wide expression activ-
ities was performed with the Gene Expression Dynamics
Inspector (GEDI), a Matlab (Mathworks, Natick, MA)
freeware program which uses self-organizing maps
(SOMs) to translate high-dimensional data into a 2D
mosaic [37]. Each tile of the mosaic represents an indi-
vidual SOM cluster and is color-coded to represent high
or low expression of the cluster’s genes, thus identifying
the underlying pattern.
The RNA-seq raw data and normalized DESeq2
counts of this study are publicly available at the National
Center for Biotechnology Information Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) as series
record GSE71025.
Nitrite measurement
Nitric oxide concentrations were determined by meas-
urement of nitrite released into BV-2 culture super-
natants using the Griess reagent system (Promega).
Fifty-microliter cell culture supernatants from differ-
entially stimulated BV-2 cells were incubated with
100 μl Griess reagent in each well of a translucent
96-well plate. After incubation for 30 min at room
temperature, absorbance was measured at 540 nm
on an Infinite F200 Pro plate reader (Tecan). Nitrite
concentrations were calculated on the basis of a so-
dium nitrite reference curve.
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661 W photoreceptor apoptosis assay
To investigate microglial neurotoxicity and to assess
whether minocycline also has direct effect on photore-
ceptors, 661W cells were incubated for 48 h with culture
supernatants from differentially stimulated BV-2 cells or
culture supernatants supplemented with minocycline.
Apoptotic cell death was determined using the Caspase-
Glo® 3/7 Assay (Promega). Cells were lysed and incu-
bated with a luminogenic caspase-3/7 substrate, which
contains the tetrapeptide sequence DEVD. After incuba-
tion at room temperature for 1 h, the generated lumi-
nescence was measured on an Infinite F200 Pro plate
reader (Tecan). A blank reaction without cells was used
to determine background luminescence associated with
the cell culture system and Caspase-Glo® 3/7 reagent.
The values of the blank reactions were subtracted from
all experimental values. Negative control reactions were
performed to determine the basal caspase activity of
661 W cells. Relative luciferase units (RLU) reflect the
level of apoptotic cell death.
Animals
All experiments were performed with 10–14-weeks-old
albino BALB/cJ mice of both sexes. Animals were
housed in an air-conditioned environment with 12-h
light-dark schedule and had free access to water and
food. All experimental procedures complied with the
German law on animal protection and the ARVO
Statement for the Use of Animals in Ophthalmic and
Vision Research. The animal protocols used in this
study were reviewed and approved by the governmental
body responsible for animal welfare in the state of
Nordrhein-Westfalen (Landesamt für Natur, Umwelt und
Verbraucherschutz Nordrhein-Westfalen, Germany) (refer-
ence number 84-02.04.2015-A039).
Minocycline administration
The mice received intraperitoneal injections of minocy-
cline at a dose of 45 mg/kg or NaCl as solvent control
where indicated twice daily for the first two days, start-
ing one day before the light exposure and once daily for
the remaining days.
Light exposure regimen
BALB/cJ mice were dark-adapted for 16 h before light
exposure. After pupil dilatation with 1 % Phenylephrin
and 2.5 % Tropicamid under dim red light, the mice
were exposed to bright white light with an intensity
of 15.000 lx for 1 h. After light exposure, the animals
were housed in dark-reared conditions overnight and
then maintained under normal light conditions for
the remaining experimental period.
Immunohistochemistry
Eyes were harvested for immunohistochemical analysis
4 days after light exposure. After fixation with 4 % para-
formaldehyde, eyes were embedded in optimal cutting
temperature (OCT) compound or dissected for retinal
flat mount analysis. Sixteen-micrometer sections were
rehydrated with PBS and blocked with dried milk solu-
tion. Flat mounts were incubated with 5 % Tween, 5 %
Triton-X100 in PBS overnight and non-specific binding
was blocked by incubation with dried milk solution.
Subsequently, retinal sections and flat mounts were
incubated with primary antibodies at 4 °C overnight.
Primary antibodies targeting the following molecules
were used: rabbit anti-Iba1 antibody (Wako Chemicals,
Neuss, Germany), rabbit anti-TSPO antibody (Abcam,
Cambridge, UK), and rabbit anti-Glial Fibrillary Acidic
Protein (G9269, Sigma). After a washing step, the sections
and flat mounts were incubated with a secondary antibody
either conjugated to Alexa488 (green) or Alexa594
(red) (Jackson Immuno-Research, West Grove, PA, USA)
for 1 h. After counterstaining with 4',6-diamidino-2-
phenylindole (DAPI), the samples were mounted in
DAKO fluorescent mounting medium (Dako Deutschland
GmbH, Hamburg, Germany) and analyzed with an Axios-
kop2 MOT Plus Apotome microscope (Carl Zeiss).
Optical coherence tomography (OCT)
Animals were anesthetized by intraperitoneal injection
of Rompun (10 mg/kg body weight)-Ketavet (100 mg/kg
body weight), and their pupils were dilated with Phenyl-
ephrine HCl (0.25 %)-Tropicamide (0.05 %) before image
acquisition. Spectral-domain OCT (SD-OCT) was per-
formed on both eyes with a Spectralis™ HRA +OCT de-
vice (Heidelberg Engineering) to investigate structural
changes in the retina after light exposure and minocy-
cline administration. Thickness measurements were per-
formed with a circular ring scan (circle diameter 1, 3, 6
ETDRS), centered on the optic nerve head, which repre-
sents the average retinal thickness [μm] in a certain field.
Central retinal thickness was calculated from four fields
around the optic nerve head using the Heidelberg Eye
Explorer Software.
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay
Retinal sections were labeled with an in situ cell death
detection kit, Fluorescein (Roche) to detect the amount
of apoptotic cells 4 days after light exposure. For a better
overview, the sections were also counterstained with
DAPI for 10 min. After a washing procedure, sections
were mounted in DAKO fluorescent mounting medium
(Dako Deutschland GmbH, Hamburg, Germany) and
analyzed with an Axioskop2 MOT Plus Apotome micro-
scope (Carl Zeiss).
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Statistical analysis
Nitrite secretion, caspase 3/7 activities, and real-time
RT-PCR data from BV-2 cells were analyzed with one-way
ANOVA and Bonferroni’s multiple comparison tests.
Real-time RT-PCR data of murine retinas and OCT
measurements of retinal thickness were analyzed using a
one-way ANOVA and Dunnett’s multiple comparison
tests. p < 0.05 was considered statistically significant.
Results
Minocycline dampens the pro-inflammatory response
and neurotoxic potential of microglia and promotes
photoreceptor survival in vitro
We first investigated whether minocycline treatment
affects reactivity and neurotoxicity of BV-2 microglial
cells. Gene expression of the chemoattractant protein
CCL2, the pro-inflammatory cytokine IL6, and iNOS,
which catalyzes the generation of toxic nitric oxide
(NO), were analyzed in LPS-activated BV-2 cells that
were treated with minocycline for 6 and 24 h, respect-
ively. Minocycline significantly dampened LPS-induced
gene expression of CCL2 (Fig. 1a, p < 0.0001 for LPS ver-
sus minocycline + LPS treatment), IL6 (Fig. 1b, p = 0.002
for LPS versus minocycline + LPS treatment), and iNOS
(Fig. 1c, p < 0.0001 for LPS versus minocycline + LPS
treatment) in a short-term setting of 6-h incubation.
Minocycline also decreased mRNA expression of these
three genes after a 24-h treatment period (Fig. 1d–f ),
but the level of significance was only reached for iNOS
(Fig. 1f, p < 0.0001 for LPS versus minocycline + LPS
treatment). These findings indicate that minocycline
action on microglia is a relatively rapid process and very
likely interferes with immediate/early mechanisms of
pro-inflammatory activation.
Since iNOS levels were also significantly inhibited by
minocycline in the longer incubation experiment, we de-
termined the amount of nitric oxide produced by BV-2
cells after stimulation with LPS, minocycline, and both
compounds together after 24 h. LPS-treated microglial
cells stimulated with minocycline released significantly
less nitric oxide compared to cells that were stimulated
with LPS alone (Fig. 2a, p < 0.0001), indicating that
minocycline may reduce microglial neurotoxicity.
Using an apoptosis assay of 661W photoreceptor-like
cells treated with microglia-conditioned medium with or
without additional minocycline supplementation, we tested
whether minocycline can reduce microglial neurotoxicity
and possibly exert direct beneficial effects on photoreceptor
survival. The supernatant from LPS-stimulated microglia
significantly increased caspase 3/7 activity in 661 W cells as
a biomarker of cell death (Fig. 2b, p < 0.0001 for LPS versus
control treatment). In contrast, conditioned medium from
LPS-treated BV-2 cells that were co-stimulated with mino-
cycline induced significantly lower caspase 3/7 levels in
661 W cells (Fig. 2b, left part, p < 0.0001 for LPS versus
minocycline + LPS supernatant treatment). Furthermore,
treatment of 661W photoreceptors with supernatant from
LPS-treated BV-2 cells that was supplemented with
Fig. 1 Minocycline dampens pro-inflammatory gene transcription in microglia. BV-2 microglial cells were pre-treated with 50 μg/ml minocycline
or NaCl as a vehicle control for 30 min. The cells were then further stimulated with either 50 μg/ml minocycline, 50 ng/ml LPS, or a combination
of both. Six hours (a–c) and 24 h (d–f) later transcript levels of the pro-inflammatory marker genes CCL2 (a, d), IL6 (b, e), and iNOS (c, f) were
determined by quantitative real-time PCR. Data show mean ± SEM out of three independent experiments (n = 5/group, measured in triplicates)
with *p < 0.05, **p < 0.01, ***p < 0.001
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minocycline also reduced caspase 3/7 levels (Fig. 2b, right
part, p < 0.001 for LPS versus LPS supernatant +minocy-
cline supplement). Thus, minocycline reduced the levels of
secreted neurotoxic and pro-apoptotic molecules from
microglia but also exerted direct survival-promoting effects
on photoreceptors that were challenged with reactive
microglia-supernatants.
Minocycline prevents microglia reactivity in retinas
exposed to acute white light
To test the effects of minocycline on microglial re-
sponses in the damaged retina in vivo, we selected the
murine model of acute light-induced degeneration. This
model mimics several features of AMD including im-
mune activation and apoptosis of photoreceptor cells.
After 16 h of dark adaptation, BALB/cJ mice were ex-
posed to white light with an intensity of 15.000 lux for
1 h. The mice received daily intraperitoneal injections of
45 mg/kg minocycline, starting 1 day before the light
exposure for five consecutive days. The first 2 days, the
mice received two injections per day and then once daily
for the remaining 3 days (Fig. 3, top, schematic drawing).
Four days after light exposure, the effect of minocycline
administration was analyzed by staining of retinal sec-
tions and flat mounts with markers for reactive gliosis.
In control animals, retinal immunolabeling with the
marker Iba1 showed ramified microglia in the plexiform
layers as expected (Fig. 3a). Light exposure caused a
severe thinning of the outer nuclear layer and many
amoeboid shaped microglia appeared in the degenerating
photoreceptor layer and the subretinal area (Fig. 3b).
This prominent degeneration of photoreceptors and
accumulation of microglia in the outer retina was not
detectable in retinas of mice treated with minocycline
(Fig. 3c). To better analyze the microglial network and
localization, retinal flat mounts were stained with Iba1.
In contrast to healthy controls, where microglial cells
are absent in the outer retina, retinal flat mounts from
light-exposed mice showed high numbers of amoeboid
shaped microglia in the subretinal area (Fig. 3d, e).
Treatment with minocycline clearly prevented migration
of many microglia to the subretinal area, and the cells in
this region had a more ramified morphology (Fig. 3f ).
To better characterize the reactive phenotype of glia
cells, the expression of the activation markers TSPO for
microglia and glial fibrillary acid protein (GFAP) for
Müller cells and astrocytes were analyzed. Exposure to
light initiated a strong increase in TSPO expression, es-
pecially confined to outer retinal microglia (Fig. 3h). In
contrast, administration of minocycline strongly re-
duced TSPO expression, indicating a less reactive
microglia phenotype (Fig. 3i). Expression of GFAP in
Müller cells and astrocytes of retinas exposed to light
was also increased compared to controls (Fig. 3j, k),
whereas minocycline-treated animals displayed only weak
GFAP staining (Fig. 3l). These findings indicate that the
reactive gliosis elicited by acute light damage can be
significantly suppressed by minocycline treatment.
Minocycline counter-regulates pro-inflammatory gene
expression in retinal degeneration
In addition to these in situ analyses of retinas, we investi-
gated whether mRNA levels of microglia-related pro-
inflammatory marker genes were influenced by minocycline
Fig. 2 Minocycline stimulation dampens microglial NO production and reduces their neurotoxic potential on 661W photoreceptors. BV-2 cells
were pre-treated with 50 μg/ml minocycline or NaCl for 30 min. The cells were then further stimulated with either 50 μg/ml minocycline, 50 ng/ml
LPS, or a combination of both. a Twenty-four hours later, the nitric oxide production was determined by Griess reaction which detects the amount of
nitrite in the cell culture supernatant. Data show mean ± SEM (n = 3/group, measured in triplicates). b To determine the neurotoxic potential
of microglia, the cell culture supernatant of the differentially treated microglial cells was transferred to 661W photoreceptor cells. Furthermore,
cell culture supernatant of untreated and LPS-stimulated BV-2 cells supplemented with minocycline was transferred to 661W photoreceptor
cells to test whether minocycline may have a direct neuroprotective effect. After 48 h of incubation with microglia conditioned-medium,
apoptotic cell death was analyzed by caspase 3/7 activity measurements. Data show mean ± SEM (n = 3/group, measured in duplicates) with
*p < 0.05, **p < 0.01, ***p < 0.001
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administration in vivo. CD68, AMWAP, and TSPO are
markers that are associated with microglia proliferation and
reactivity [38–41]. Four days after light exposure all three
markers were clearly up-regulated in the retina, with
especially high induction levels of CD68 and AMWAP
(Fig. 4a–c). In mice treated with minocycline, the expres-
sion of CD68 (Fig. 4a, p = 0.0002) and AMWAP (Fig. 4b,
p = 0.007) were significantly suppressed and mRNA levels
of TSPO were reduced (Fig. 4c, p = 0.057). Furthermore,
transcripts that reflect the activation of key microglial
pathways including chemotaxis, pro-inflammatory cyto-
kines, and radical production were analyzed. In retinas of
light exposed mice that were treated with minocycline,
mRNA levels of the chemotactic molecule CCL2 were
Fig. 3 Treatment of light-exposed mice with minocycline blocks microglia reactivity and Müller cell gliosis. Of both sexes, 10- to 14-week-old
BALB/c mice were dark-adapted for 16 h. After pupil dilatation, the mice were exposed to bright white light with an intensity of 15.000 lux for
1 hour. The mice received intraperitoneal injections of minocycline at a dose of 45 mg/kg body weight twice daily for the first 2 days, starting
1 day before the light exposure and once daily for the remaining 3 days. Four days after the light exposure OCT, immunohistochemical stainings,
real-time RT-PCR analysis, and RNA sequencing were performed to determine the in vivo effects of minocycline treatment (schematic drawing).
Representative photomicrographs show retinal sections (a–c) and flat mounts (d–f) stained with Iba1 (green), TSPO (red) (g–i), and GFAP (red) (j–l).
In control retinas, microglial cells were located in the OPL, IPL, and GCL (a, d); low levels of TSPO were only observable in the GCL (g); and signs
for Müller cell gliosis were not detectable (j). b, e, h, and k Photomicrographs of light-exposed mice showed a massive thinning of the ONL
and an increased number of amoeboid shaped, reactive microglia in the ONL, and the subretinal space (b, e). h A strong up-regulation of TSPO
expression was detectable in microglia. k Up-regulation of GFAP indicates Müller cell gliosis. c, f, i, and l Representative photomicrographs of
minocycline-treated mice 4 days after light exposure. Compared to untreated controls, the ONL of minocycline-treated mice appeared markedly
preserved and less microglia were detectable in the ONL and the subretinal space (c, f). i Microglial cells were negative for TSPO expression.
l GFAP expression was only detectable in astrocytes, indicating a lack of reactive Müller cells. TSPO translocator protein, GFAP glial fibrillary acid
protein, ONL outer nuclear layer, OPL outer plexiform layer, INL inner nuclear layer, IPL inner plexiform layer, GCL ganglion cell layer. Scale bar 50 μm
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significantly decreased compared to untreated animals
(Fig. 4d, p < 0.0001). The expression of IL6 was also ele-
vated after exposure to light and returned to baseline in
the minocycline administration group (Fig. 4e). In contrast
to our in vitro data, no significant differences in iNOS
expression were detectable after light exposure or minocy-
cline treatment after the 4-day period (Fig. 4f). This
suggests that minocycline also exerts microglia-related
anti-inflammatory effects in vivo in the retina.
Minocycline dampens early microglia responses to acute
white light
Analysis 4 days after light exposure revealed that mino-
cycline reduced the number of activated microglial cells
and impaired their pro-inflammatory gene transcription.
We next studied whether minocycline also affects early
microglia responses at time points that lack overt cell
death as trigger for migration and reactivity. Furthermore,
we included a vehicle-treated control group in these ex-
periments to exclude potentially protective stress-related
effects. One day after light exposure retinal sections from
control, vehicle- or minocycline-treated mice were stained
with Iba1. Ramified microglia were present in the plexi-
form layers and the ganglion cell layer of control animals
(Fig. 5a). In contrast, retinas from light-exposed and
vehicle-treated mice revealed many amoeboid shaped
microglia in the outer nuclear layer (ONL), which did not
show structural changes at this early time point after light
challenge (Fig. 5b). Minocycline treatment completely
prevented this early microglia migration into the
ONL (Fig. 5c).
We next also analyzed the mRNA expression of
microglia-associated markers in a time kinetic experi-
ment. Light exposure enhanced the expression of the
CD68, AMWAP, and TSPO in vehicle-treated mice
already 1 day after exposure to white light (Fig. 5d–f ).
Minocycline administration dampened the expression of
these genes at every analyzed time point and reached
statistical significance for CD68 (Fig. 5d, vehicle versus
control p < 0.0001, vehicle versus minocycline p = 0.0001
1 day after light exposure) and TSPO (Fig. 5f, vehicle
versus control p = < 0.0001, vehicle versus minocycline
p = 0.0018 1 day after light exposure, and vehicle versus
minocycline p = 0.0113 2 days after light exposure). The
migration marker CCL2 was strongly up-regulated in
light-exposed vehicle controls, reaching statistical signifi-
cance 1 day after light exposure (control versus vehicle
p = 0.0046). Minocycline-treated mice expressed lower
CCL2 at every analyzed time point. Furthermore, mino-
cycline also significantly reduced the expression of IL6,
Fig. 4 Minocycline treatment dampens microglia-related pro-inflammatory marker expression after light exposure. To determine the mRNA expression
of inflammation associated genes in the retina, qRT-PCR analysis were performed 4 days after light exposure. a–c The microglia activation markers CD68
and AMWAP were significantly up-regulated after light exposure, and TSPO levels were also increased. In contrast, retinas from minocycline-treated mice
expressed significantly less CD68 and AMWAP transcripts and also reduced mRNA levels of TSPO. d Minocycline treatment reduced the expression of
CCL2 that was significantly elevated by light exposure. e IL6 was enhanced by light exposure, which was reversed in the minocycline administration
group. f iNOS expression was not significantly altered. Data show mean ± SEM (control n= 4, light exposure n = 4, light exposure and minocycline
treatment n = 5/group, measured in triplicates) with *p < 0.05, **p < 0.01, ***p < 0.001
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which was strongly upregulated in the vehicle-treated
group (Fig. 5h, control versus vehicle p = 0.0082, vehicle
versus minocycline p = 0.0371 1 day after light expos-
ure). In contrast to our previous analysis after 4 days
(Fig. 4f ), iNOS was induced 1 day after light exposure in
vehicle controls and was significantly reduced in the
minocycline administration group (Fig. 5i, control versus
vehicle p < 0.0001, vehicle versus minocycline p = 0.0004
1 day after light exposure).
In a small pilot experiment, we further explored
whether microglia may be even earlier alarmed in the
light damage condition. Indeed, ramified microglia
projected their long protrusions reaching through the
ONL already 4 h after light exposure (Additional file 1:
Figure S1A, B). mRNA analysis in these retinas
clearly showed increased expression of CCL2, IL6,
and CD68 in the absence of changes in caspase 8
levels (Additional file 1: Figure S1C–F). Therefore,
we conclude that microglial activation is an early
event after light exposure that is not only triggered
by dead cells and that minocycline is very effective
in attenuating this process.
Fig. 5 Minocycline suppresses early microglial activation after exposure to bright white light. Representative photomicrographs show retinal
sections (a–c) stained with Iba1 (green) of control, vehicle- or minocycline-treated mice 1 day after light exposure. In healthy controls, microglial
cells are only located in the plexiform layers and GCL (a). Images of light-exposed vehicle-treated mice show amoeboid microglia located in the
ONL, whereas retinal structures appear unaffected 1 day after light exposure (b). Compared to vehicle-treated mice, amoeboid, reactive microglia
are absent in the ONL of mice treated with minocycline (c). ONL outer nuclear layer, OPL outer plexiform layer, INL inner nuclear layer, IPL inner
plexiform layer, GCL ganglion cell layer. Scale bar 50 μm. Data show representative photomicrographs (control n = 6, light exposure and vehicle
treatment n = 3, light exposure and minocycline treatment n = 3/group). Retinal mRNA expression of microglia and inflammation-associated genes
were determined by real-time RT-PCR at 1, 2, or 4 days after light exposure (d–i). Compared to controls, the microglial-associated markers CD68,
AMWAP, and TSPO were markedly increased in vehicle-treated mice peaking 1 day after light exposure. Expression levels in minocycline-treated
mice were lower at every analyzed time point (d–f). CCL2 was induced in light-exposed vehicle-treated mice, which was suppressed in the
minocycline-treated group (g). Minocycline treatment also significantly reduced the expression of IL6 and iNOS, which was strongly upregulated in
the vehicle-treated group (h, i). Data show mean ± SEM (control n = 6, light exposure and vehicle treatment n = 3, light exposure and minocycline
treatment n = 3/group, measured in triplicates) with *p < 0.05, **p < 0.01, ***p < 0.001
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Minocycline exerts global anti-inflammatory effects on
the retinal transcriptome
We then asked whether minocycline treatment has a
global effect on gene expression in the light exposure
model of retinal degeneration. RNA-sequencing analysis
with two biological replicates was performed on total
retinal RNA isolated from control mice, from animals
after light exposure, and from light-exposed animals that
received minocycline. We first used the Gene Expression
Dynamics Inspector (GEDI) to determine the global pat-
terns of gene expression in the three different condi-
tions. GEDI is based on self-organizing maps to identify
genome-wide transcriptome activity via “gestalt” recog-
nition [37]. GEDI is sample-oriented rather than gene-
oriented, which allows the identification of genome-wide
patterns. Each mosaic tile in the GEDI map represents a
gene cluster that is expressed at similar levels, with blue
color indicating a low level and red corresponding to
high expression. The three GEDI maps show a highly
dynamic regulation of gene expression in light-exposed
and minocycline-treated retinas compared to control
(Fig. 6a). Light exposure initiated the formation of a
prominent red cluster band that was nearly reversed by
minocycline treatment (Fig. 6a). In the next step, we per-
formed DESeq2 analysis to determine differential gene
expression between the groups using a log2 fold change
cutoff of ≥2. The MA-plots demonstrate that light ex-
posure caused a significant induction of 217 genes with
no down-regulated transcripts (Fig. 6b). In contrast, the
light-exposed versus light-exposed plus minocycline
treatment analysis identified 113 down-regulated and 38
up-regulated transcripts (Fig. 6c). A closer look at the
differentially expressed genes showed that most of the
transcripts induced under light damage conditions be-
long to immune-related biological pathways including
markers directly related to microglia reactivity such as
macrophage scavenger receptor 1 (MSR1), AMWAP
(alias WFDC17), CD68, and complement factor C3
(Additional file 2: Table S1). The vast majority of tran-
scripts down-regulated by minocycline treatment was
induced by light exposure alone, and hence, their ex-
pression was reversed (Additional file 3: Table S2). These
results demonstrate that both light damage and minocy-
cline have a major impact on the global pattern of gene
expression in the retina and that minocycline adminis-
tration effectively counterbalances most of the pro-
inflammatory signaling events in the degenerating retina.
Minocycline treatment protects the retina from
light-induced degeneration
We finally asked whether targeting retinal microglia with
minocycline also improves the outcome of disease pro-
gression. We first performed in vivo optical coherence
tomography (OCT) of mice to detect structural changes
of the retina after light exposure and under conditions of
minocycline treatment. The OCT images showed clear
changes in ONL reflectance in retinas of light-exposed an-
imals, indicating a strong degeneration of the photorecep-
tor layer (Fig. 7a, b). In contrast, minocycline-treated mice
displayed a normal hyperreflective photoreceptor layer
similar to that of controls (Fig. 7c). Volume scans revealed
Fig. 6 Light exposure and minocycline exert global effects on the
retinal transcriptome. a Gene Expression Dynamics Inspector (GEDI)
analysis of the complete RNA-seq dataset (Gene Expression Omnibus
Series Nr. GSE71025) from control retinas and light-exposed retinas
in the absence or presence of minocycline. Biological duplicates
were analyzed for each condition and the pseudo-color scale indi-
cates high (red) or low (blue) expression levels. b, c DESeq2 analysis
to determine differential gene expression between the indicated
groups using a log2 fold change cutoff of ≥2 and ≤−2. The MA-plots
demonstrate that light exposure caused a global induction of 217
genes (b), whereas light exposure plus minocycline administration
reversed this effect with many counter-regulated transcripts (c)
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a severe thinning of the retina, especially in the central
area around the optic nerve head after light exposure,
which was not observed in the minocycline-treated groups
(Fig. 7d–f ). Quantification of the retinal thickness in
all analyzed animals demonstrate a significant reduction
in the central area after light exposure (p < 0.0001),
which could be rescued by treatment with minocycline
(p < 0.0001) (Fig. 7g). To confirm these findings, pano-
rama images of retinal sections proceeding through the
optic nerve head were stained with DAPI. The photo-
receptor layer showed a clear thinning in the group of
mice exposed to light, which was not evident in mice after
minocycline treatment (Fig. 7h–j, Fig. 3a–c). TUNEL
stainings and mRNA analyses of caspase 8 levels also
revealed that light exposure significantly induced cell
death in mouse retinas, which was prevented in
minocycline-treated animals (Fig. 7k–n). These data
clearly point toward a strong neuroprotective effect of
minocycline in conditions of acute light damage.
Discussion
Several studies revealed that minocycline exerts anti-
microbial, anti-inflammatory, anti-apoptotic, and neuro-
protective properties in different animal models of
neuronal degenerative diseases, including Parkinson’s dis-
ease, multiple sclerosis, Alzheimer’s disease, Huntington’s
disease, amyotrophic lateral sclerosis, and retinitis pig-
mentosa [16, 18–20, 23, 25, 42–44]. Here, we report for
Fig. 7 Minocycline prevents light-induced retinal degeneration. a–g SD-OCT was performed 4 days after light exposure to analyze changes in retinal
structures. a–c Light-exposed mice show an altered reflectance in the ONL, which was not present in minocycline-treated mice. d–f Representative
heat maps show the average retinal thickness of control, light-exposed minocycline-treated and untreated mice. Light-exposed mice show a significant
thinning of the retina, especially in the central area, which was preserved by minocycline treatment. g One data point represents the average thickness
of the central retina [μm], calculated from four different areas around the optic nerve head. Data show mean ± SEM (control n = 16 eyes, light exposure
n = 30 eyes, light exposure and minocycline treatment n = 32 eyes). h–j Representative panorama sections of the retina were stained with DAPI to
further characterize structural changes in the retina. Light exposure caused severe degeneration particularly of the ONL. Minocycline administration
reduced degeneration, represented by a clearly thicker photoreceptor layer, scale bar, 200 μM. k–m Representative photomicrographs of
TUNEL-stained retinal sections show the amount of apoptotic cells 4 days after light exposure. Light exposure caused a strong increase of
apoptotic cells, especially in the ONL. Less TUNEL-positive cells were visible after minocycline administration. n RNA analyses revealed a
significantly higher expression of caspase 8 in light-exposed retinas, compared to retinas of minocycline-treated mice, indicating a higher amount of
apoptotic cells. Scale bar, 50 μm. Data show mean ± SEM (control n = 4 retinas, light exposure n = 4 retinas, light exposure and minocycline treatment
n = 5 retinas, measured in triplicates) *p < 0.05, **p < 0.01, ***p < 0.001
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the first time that minocycline administration preserves
the retinal structure in a white light-induced degeneration
model, which mimics several features of dry AMD and
monogenic retinal dystrophies. The main questions
discussed in this study were if and how minocycline
stimulation modulates the neurotoxic potential of micro-
glia and whether minocycline administration could be
a suitable immuno-modulatory strategy to treat retinal
degeneration.
Our in vitro studies in LPS-activated BV-2 microglia
demonstrated that minocycline was capable to diminish
gene expression of the pro-inflammatory markers CCL2,
IL6, and iNOS in a rapid temporal response. This is con-
sistent with earlier reports with microglia isolated from
rat retinas where minocycline dampened mRNA expres-
sion and secretion of IL1β, TNFα, and iNOS [45]. In line
with this, Henry et al. reported that minocycline reduced
mRNA levels of TLR 2, MHC-II, IL1β, and IL6 in BV-2
cells [46]. These results together with our data suggest
that minocycline is highly effective in reducing pro-
inflammatory gene transcription in microglia.
The production of toxic nitric oxide by phagocytes
plays an important role in degenerative processes [47–49].
Here, we demonstrated that minocycline effectively damp-
ened nitric oxide production of LPS-stimulated microglia.
Furthermore, minocycline reduced the general neurotoxic
potential of reactive microglia on 661W photoreceptor
cells. Supernatants from microglia that were stimulated
with both LPS and minocycline were less toxic to photore-
ceptors than those of cells that were treated with LPS
only. Investigations in RAW264.7 macrophages and spinal
cord microglia also confirmed that minocycline blocks the
production of toxic nitric oxide [50, 51]. Hence, others
have found an association of reduced iNOS levels and NO
itself with delayed neurodegeneration [19, 47, 52]. In
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
mouse model of Parkinson’s disease, minocycline re-
duced MPP+ induced glial iNOS expression, which
was most likely due to an inhibition of p38 MAPK
phosphorylation [19].
Besides the reduction of NO production, several other
mechanisms of action are discussed for the beneficial ef-
fects of minocycline. Indeed, we here also showed that
minocycline administration directly protected photore-
ceptors from microglia mediated death. In a model of
Huntington’s disease, minocycline delayed disease pro-
gression and mortality by inhibition of caspase-1 and
caspase-3 up-regulation, enzymes which play an import-
ant role in the induction of necrosis and apoptosis [43].
Studies in R6/2 mice confirmed that minocycline can
inhibit both caspase-independent (apoptosis inducing
factor) and caspase-dependent (Smac/Diablo and cyto-
chrome c) mitochondrial cell death pathways [53]. How-
ever, despite its ability to reduce pro-inflammatory markers
in a mouse model for age-related neuron loss, minocycline
failed to inhibit apoptosis and neuron loss [54].
A further mechanism how minocycline exerts its
protective functions is the inhibition of matrix metallo-
proteases (MMPs). MMPs are a family of zinc- and
calcium-dependent proteolytic enzymes that are respon-
sible for the degradation of structural proteins in the
extracellular matrix and their activation is associated
with neurological disorders. Thus, blockage of MMPs by
minocycline decreased the cerebral infarct size in a
mouse model of focal cerebral ischemia. This effect was
most likely due to the inhibition of CCL2, TNFα, and
indoleamine 2,3-dioxygenase (IDO) expression [55, 56].
Our OCT images and immunohistochemical analysis
showed that the treatment with minocycline preserved
retinal structure and reduced the amount of apoptotic
cells after exposure to bright white light. The protection
of photoreceptors was associated with a reduced number
of reactive, amoeboid-shaped, TSPO-positive microglia
in the outer retina. Accordingly, our mRNA analyses of
retinas revealed suppression of microglial activation
markers including AMWAP and CD68 after administra-
tion of minocycline [38–40]. Analysis at different time
points after light exposure revealed that microglial activa-
tion is an early event that precedes photoreceptor death.
Moreover, our RNA-sequencing data revealed a global
transcriptomic effect of minocycline with a complete clus-
ter of light-damage-induced pro-inflammatory genes that
was counter-regulated by minocycline. Of note, the RNA-
seq dataset also detected up-regulation of structural ret-
inal genes such as keratins and adhesion molecules by
minocycline. These results strongly indicate that modula-
tion of microglia reactivity is a key mechanism in minocy-
cline’s mode of action in the retina. This notion is
supported by studies demonstrating that inhibition of
microglia with minocycline protects from neuronal degen-
erative diseases including Alzheimer disease or Parkinson
disease [16, 18]. In the eye, minocycline could also re-
duce microglial activation and improve neuronal func-
tion [13, 25, 57, 58]. In a model of green light
exposure, preservation of retinal structure and ERG
amplitudes by minocycline was associated with re-
duced numbers of CD11b+ cells in the outer retina
[58]. To mimic exposure to bright daylight, which is
discussed as a contributing factor for retinal degener-
ations, we used 15.000 lux UV-free white light in our
studies. White light has an emission spectrum similar
to that of daylight, and it is less artificial than light of a
particular wavelength [59, 60]. Furthermore, white light
contains also short wavelength blue light (403 nm) which
is thought to have a higher damaging potential than light
of longer wavelength including green light (490–580 nm),
which was used in earlier studies [58]. The higher
damaging potential of blue light is due to a process
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called photo-reversal, the regeneration of rhodopsin
from bleaching intermediates that results in a higher
number of photon absorption in a certain time span.
Because of different light exposure settings in our study
and the work of Zhang et al. [58], different underlying
damage mechanisms cannot be ruled out [28, 59, 61, 62].
In the rd10 mouse model for retinitis pigmentosa,
minocycline inhibited microglial activation and down-
regulated the expression of pro-inflammatory molecules
including TNFα, COX1, and COX2. Moreover, pro-
apoptotic molecules such as BAX and Caspase 3 were
suppressed by minocycline, and the retinal structure and
function were preserved [25]. Of note, minocycline could
also diminish photoreceptor death in rds mice by a
microglia-independent mechanism as depletion of micro-
glia by clodronate prevented their recruitment but failed
to inhibit photoreceptor apoptosis [63].
Conclusions
We have shown that microglia activity is an early event in
retinal degeneration induced by bright white light. Mino-
cycline administration preserved the retinal structure by a
global counter-regulation of microglial pro-inflammatory
responses and direct effects on photoreceptors during
light exposure. Our data suggest that treatment strategies
that modulate microglial reactivity and support photo-
receptor survival provide a potential therapeutic option
for retinal degenerative diseases.
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in the plexiform layers and GCL (A). Images of light exposed mice show
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outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer;
GCL, ganglion cell layer. Scale bar 50 μm. Data show representative
photomicrographs (control n = 5, light exposure n = 4). Retinal mRNA
expression of microglia-associated genes and caspase 8 were determined
by real-time RT-PCR (C-F). Data show mean ± SEM (control n = 5 retinas, light
exposure n = 4 retinas measured in triplicates) with *p < 0.05. (JPG 684 kb)
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Additional File 1: Supplementary Figure 1 - Early microglial activation after exposure to bright 
white light. 
 
 
 
 
 
 
 
 
 
 
 
 
Additional file 1: 
Figure S1. Early 
microglial activation 
after exposureto bright white light. Representative photomicrographs show retinalsections (A–B) 
stained with Iba1 (green) of control mice and animals 4 hafter light exposure. In healthy controls, 
microglial cells are only locatedin the plexiform layers and GCL (A). Images of light exposed mice 
show microglia with protrusions in the ONL (B). ONL, outer nuclear layer; OPL, outer plexiform layer; 
INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar 50 μm. Data 
show representative photomicrographs (control n = 5, light exposure n = 4). Retinal mRNA expression 
of microglia-associated genes and caspase 8 were determined by real-time RT-PCR (C-F). Data show 
mean ± SEM (control n = 5 retinas, lightexposure n = 4 retinas measured in triplicates) with *p < 0.05. 
(JPG 684 kb
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Additional File 2: Supplementary Table 1 - Differentially expressed transcripts comparing light 
exposure versus control 
 
Nr Gene Mean count log2 FC 
1 Msr1 281 4.74 
2 Ms4a6d 213 3.96 
3 Clec7a 464 3.94 
4 Steap4 195 4.6 
5 Slc15a3 125 3.52 
6 Timp1 63.9 3.34 
7 Cd68 597 3.54 
8 C3ar1 279 4.09 
9 Ctse 67.1 3.18 
10 Hal 70.7 3.37 
11 Mmp12 26.3 3.12 
12 Cd84 166 3.68 
13 Emr1 421 3.72 
14 Mki67 102 3.47 
15 Lcn2 434 2.83 
16 Lcp1 262 3.45 
17 Tlr13 120 2.7 
18 Tyrobp 741 3.6 
19 Apobec1 202 2.77 
20 Siglec1 130 3.11 
21 Cybb 116 3.36 
22 Top2a 53.7 3.03 
23 Fcer1g 229 3.41 
24 Ly9 69 2.77 
25 Cd300a 70.5 2.52 
26 C3 224 3.7 
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27 Cd22 59.1 2.99 
28 Wfdc17 41.6 2.64 
29 Nlrc5 76.9 2.21 
30 Trem2 398 3.5 
31 Cxcr4 126 3.45 
32 Gatm 576 2.97 
33 1300002K09R
ik 
46.9 2.61 
34 Csf2rb2 50.2 2.04 
35 Wdfy4 52.2 2.45 
36 Laptm5 501 3.27 
37 Myo1f 113 3.26 
38 Klhl6 56 2.8 
39 Cebpa 119 3.03 
40 C1qc 949 3.82 
41 Glipr1 36.6 2.83 
42 Plin2 457 2.96 
43 Arl11 60.1 2.63 
44 Cx3cr1 309 2.98 
45 Cdk1 28.9 2.48 
46 AF251705 86.7 2.98 
47 Arhgap25 44.8 2.45 
48 Cd53 371 3.24 
49 Nckap1l 295 2.63 
50 Irf8 113 2.4 
51 Tlr7 155 3.58 
52 Ms4a6b 67.3 2.84 
53 P2ry13 55.9 2.83 
54 Arhgap30 94.5 2.81 
55 Unc93b1 238 2.86 
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56 Gusb 552 2.49 
57 Ctsd 27500 2.76 
58 Tnfrsf1b 136 3.23 
59 Syk 77.9 2.87 
60 Itgb2 165 3.12 
61 Bcl3 46.4 2.69 
62 Vav1 79.7 2.6 
63 Tbxas1 38.6 2.47 
64 Apoc1 70.9 2.4 
65 Fcgr2b 103 2.62 
66 Fcgr3 201 3.35 
67 Itgam 251 2.77 
68 Parvg 83.1 2.23 
69 Sash3 30 2.17 
70 Oasl2 184 2.91 
71 Ms4a7 64.9 2.83 
72 Hexb 2340 2.65 
73 Irf5 61.9 2.25 
74 Rrm2 16.5 2.08 
75 Hpgds 118 2.92 
76 Tnfaip8l2 34.9 2.33 
77 Rac2 74.8 2.92 
78 Dock2 81.5 2.44 
79 Ctsz 1710 2.76 
80 Gpr34 218 2.3 
81 Pik3cg 43.5 2.1 
82 Anpep 92.6 3.37 
83 Havcr2 170 2.62 
84 Btk 37.2 2.35 
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85 Galnt6 36.9 2.32 
86 Ptprc 108 2.66 
87 P2ry6 34.3 2.61 
88 Xdh 132 2.61 
89 Spp1 8340 2.43 
90 Casp1 22.4 2.32 
91 Cd33 75.8 2.31 
92 Rasal3 38 2.1 
93 Serpina3n 504 3.59 
94 Ly86 178 2.3 
95 Crym 1460 2 
96 Lyn 102 2.54 
97 Fyb 84.8 2.64 
98 Grn 2150 2.28 
99 Htr2b 34.4 2.14 
100 Arpc1b 189 2.44 
101 Lilrb4 120 3.66 
102 Cd180 96.5 3.52 
103 C1qb 1050 3.51 
104 Abcc3 135 3.43 
105 C1qa 1380 3.42 
106 Plau 271 3.25 
107 Stab1 517 3.12 
108 Colec12 305 3.11 
109 Capg 98.8 2.93 
110 Plin4 184 2.87 
111 Ifi44 102 2.86 
112 B2m 1460 2.83 
113 Blnk 62.8 2.82 
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114 Cyth4 133 2.82 
115 Lgals3 418 2.82 
116 Rnase4 292 2.82 
117 Lgals9 167 2.79 
118 Serping1 191 2.79 
119 Gp49a 60.5 2.75 
120 Ncf1 161 2.75 
121 Pld4 137 2.7 
122 Ifi27l2a 74.6 2.67 
123 Bst2 177 2.65 
124 Fam46c 102 2.62 
125 Csf1r 808 2.61 
126 Fcgr1 71.6 2.61 
127 Igsf6 28.7 2.61 
128 Dab2 109 2.56 
129 4632428N05R
ik 
223 2.53 
130 Psmb8 112 2.53 
131 Serpina3f 23.6 2.53 
132 Ifi202b 88 2.52 
133 Tifab 34.4 2.52 
134 Anxa3 90.4 2.5 
135 Sepp1 844 2.47 
136 Lgals3bp 406 2.46 
137 Spsb1 109 2.46 
138 Mt2 2540 2.45 
139 Ctla2b 52.6 2.44 
140 Hmha1 146 2.41 
141 Ctss 1140 2.4 
142 Olfml3 329 2.4 
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143 Lcp2 33.1 2.39 
144 Ifi44l 47.8 2.38 
145 Ifit1 78.3 2.38 
146 Serpine2 306 2.38 
147 Lgals1 618 2.37 
148 Pycard 21.8 2.37 
149 Arhgdib 110 2.36 
150 Tlr4 39.2 2.35 
151 Hpse 146 2.34 
152 Hvcn1 92.2 2.34 
153 Mpeg1 2500 2.33 
154 Cyba 208 2.32 
155 P2rx7 48.4 2.31 
156 Sla 64.2 2.29 
157 Naip2 41.6 2.28 
158 Psmb9 83.8 2.28 
159 Irgm1 130 2.27 
160 Lyz2 2880 2.27 
161 H2-Q4 197 2.24 
162 Itpripl2 99.8 2.24 
163 Nupr1 122 2.24 
164 Oas1b 26.4 2.23 
165 Sfpi1 49.8 2.23 
166 Chi3l1 506 2.22 
167 Lipa 422 2.22 
168 Slfn2 37.8 2.22 
169 Tubb6 49.4 2.22 
170 Clec5a 25.9 2.21 
171 Grap 32.2 2.21 
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172 Plcg2 61 2.21 
173 Ptplad2 42 2.21 
174 AI607873 44.5 2.2 
175 Litaf 215 2.19 
176 Gna15 24.8 2.18 
177 Plscr2 64.6 2.18 
178 Serpine1 66.9 2.18 
179 Apbb1ip 37.6 2.16 
180 Fabp5 154 2.16 
181 Hk3 61.5 2.16 
182 S100a6 236 2.16 
183 Serpina3m 25.6 2.16 
184 Evi2a 42.4 2.15 
185 Gbp3 155 2.15 
186 Rassf2 102 2.15 
187 Csf3r 80.6 2.13 
188 H2-T23 161 2.13 
189 Adap2 59.5 2.12 
190 Fcgr4 30.7 2.12 
191 Kcnk6 34 2.12 
192 Slc7a7 58.8 2.12 
193 Clec2d 107 2.11 
194 Cst7 22.2 2.11 
195 Fcrls 28.6 2.11 
196 Apoe 10200 2.1 
197 Trim30a 71.8 2.1 
198 Slc11a1 56.1 2.08 
199 Adcy7 153 2.05 
200 Anxa4 145 2.05 
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201 Gbp1 163 2.05 
202 Gbp2 150 2.05 
203 H2-T24 59.9 2.05 
204 Eif2ak2 166 2.04 
205 Tgfbr2 163 2.04 
206 Tnfrsf1a 177 2.04 
207 Axl 448 2.03 
208 Isg15 53.6 2.03 
209 Amz1 31.4 2.02 
210 5430435G22R
ik 
85.9 2.01 
211 Ifitm3 169 2.01 
212 Rsad2 58.7 2.01 
213 Cmklr1 30.9 2 
214 Ucp2 638 2.34 
215 Emp1 107 2.23 
216 Emilin2 23.6 2.06 
217 Parp14 163 2.02 
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Additional File 3: Supplementary Table 2 - Differentially expressed transcripts comparing light 
exposure versus light exposed plus minocyline treatment 
 
Nr Gene Mean count log2 FC 
1 Dsp 176 3.66 
2 Krt12 1080 3.57 
3 Aldh3a1 467 3.33 
4 Krt5 651 3.32 
5 Tmprss11a 45.1 3.08 
6 Dsc3 35.8 3.06 
7 Fbln1 182 3.04 
8 Calml3 131 2.99 
9 Myh11 695 2.93 
10 Lypd2 70 2.92 
11 Dsg1a 36.2 2.9 
12 Aqp3 46.3 2.89 
13 Prb1 93.9 2.84 
14 Tyr 305 2.8 
15 Dcn 441 2.75 
16 Lypd3 27.2 2.72 
17 Edn3 213 2.71 
18 Sdc1 85.3 2.68 
19 Tacstd2 32.7 2.6 
20 Krt6a 101 2.58 
21 Anxa8 30.2 2.54 
22 Slurp1 33.2 2.44 
23 Krt6b 52.8 2.41 
24 Trim29 34.4 2.37 
25 Fam129a 348 2.32 
26 1600029D21Rik 38.4 2.25 
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27 Cldn4 20.6 2.25 
28 Gja1 733 2.24 
29 Tagln 476 2.23 
30 Fam83a 25.2 2.22 
31 Islr 184 2.21 
32 Gjb2 18.8 2.19 
33 Prpmp5 73.2 2.16 
34 Muc4 71.6 2.12 
35 Mlana 151 2.11 
36 Lum 72.6 2.09 
37 Tspan10 149 2.04 
38 Bace2 143 2.01 
39 Arpc1b 239 -2.01 
40 Htr2b 40.9 -2.02 
41 Naip5 37 -2.02 
42 Fyb 107 -2.03 
43 Grn 2620 -2.03 
44 Lyn 129 -2.04 
45 Crym 1750 -2.05 
46 Ly86 216 -2.06 
47 Serpina3n 697 -2.06 
48 Cd33 92 -2.07 
49 Rasal3 46.2 -2.07 
50 Casp1 28.3 -2.08 
51 Spp1 10200 -2.08 
52 Xdh 165 -2.08 
53 P2ry6 42.8 -2.09 
54 Ptprc 133 -2.09 
55 Anpep 118 -2.1 
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56 Btk 45.8 -2.1 
57 Galnt6 45.5 -2.1 
58 Havcr2 206 -2.1 
59 Gpr34 266 -2.11 
60 Pik3cg 52.2 -2.11 
61 Ctsz 2150 -2.12 
62 Pbk 14.3 -2.13 
63 Dock2 99.2 -2.14 
64 Rac2 93 -2.14 
65 Hpgds 148 -2.15 
66 Tnfaip8l2 42.3 -2.15 
67 Fcgr1 86.8 -2.17 
68 Hexb 2890 -2.17 
69 Irf5 75.1 -2.17 
70 Ms4a7 80.2 -2.17 
71 Rrm2 19.9 -2.17 
72 Oasl2 235 -2.18 
73 Fcgr3 250 -2.19 
74 Itgam 310 -2.19 
75 Parvg 101 -2.19 
76 Pik3ap1 56.4 -2.19 
77 Sash3 36.4 -2.19 
78 Fcgr2b 126 -2.21 
79 Apoc1 85.4 -2.22 
80 Tbxas1 47.6 -2.22 
81 Vav1 98.5 -2.22 
82 Bcl3 59.4 -2.25 
83 Itgb2 205 -2.25 
84 Syk 96.4 -2.26 
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85 Tnfrsf1b 175 -2.26 
86 Ctsd 34100 -2.27 
87 Gusb 668 -2.28 
88 Unc93b1 297 -2.28 
89 Arhgap30 117 -2.29 
90 Gp49a 73.6 -2.29 
91 P2ry13 69.8 -2.29 
92 Ms4a6b 83.3 -2.3 
93 Tlr7 192 -2.32 
94 Cd53 462 -2.35 
95 Irf8 135 -2.35 
96 Nckap1l 356 -2.35 
97 AF251705 107 -2.36 
98 Arhgap25 54.1 -2.36 
99 Cdk1 35.6 -2.37 
100 Cx3cr1 378 -2.37 
101 Kif4 390 -2.39 
102 Arl11 72.7 -2.4 
103 Csf2rb 88 -2.4 
104 Plin2 567 -2.41 
105 C1qc 1180 -2.43 
106 Glipr1 45.3 -2.43 
107 Cebpa 148 -2.44 
108 Gm8221 36.4 -2.44 
109 Klhl6 68.6 -2.45 
110 Myo1f 141 -2.45 
111 Laptm5 618 -2.48 
112 Wdfy4 62 -2.49 
113 Csf2rb2 57.7 -2.51 
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114 1300002K09Rik 56.2 -2.52 
115 Cxcr4 157 -2.53 
116 Gatm 702 -2.53 
117 Trem2 487 -2.54 
118 Cd22 71 -2.56 
119 Nlrc5 90.4 -2.56 
120 Wfdc17 50.1 -2.56 
121 Fam46c 121 -2.58 
122 C3 274 -2.6 
123 Cd300a 84.2 -2.63 
124 Fcer1g 283 -2.7 
125 Ly9 82.7 -2.7 
126 Top2a 66.3 -2.72 
127 Cybb 144 -2.75 
128 Siglec1 158 -2.78 
129 Apobec1 242 -2.8 
130 Tyrobp 913 -2.81 
131 Tlr13 142 -2.82 
132 Stab1 627 -2.89 
133 Lcp1 319 -2.9 
134 Abcc3 165 -2.91 
135 Lcn2 519 -2.92 
136 Emr1 512 -2.97 
137 Mki67 126 -2.97 
138 Cd84 203 -2.99 
139 Mmp12 33.1 -3 
140 Hal 86.1 -3.03 
141 Ctse 81.4 -3.04 
142 C3ar1 341 -3.05 
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143 Cd68 728 -3.06 
144 Timp1 79.8 -3.07 
145 Ms4a6c 218 -3.13 
146 Slc15a3 153 -3.23 
147 Lilrb4 146 -3.25 
148 Steap4 249 -3.3 
149 Clec7a 563 -3.32 
150 Ms4a6d 259 -3.42 
151 Msr1 342 -3.92 
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